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ABBREVIATIONS AND DEFINITIONS 
ABI ankle-brachial index 
AFS amputation-free survival 
ADP arteria dorsalis pedis 
AMI acute myocardial infarction 
ATA arteria tibialis anterior 
ATP arteria tibialis posterior 
BMI body mass index 
CAD coronary artery disease 
CI confidence interval 
CLI critical limb ischaemia 
CLTI chronic limb-threatening ischaemia 
cm centimetre  
CRP c-reactive protein, an inflammatory marker
CTA computed tomography angiogram 
DM diabetes mellitus 
DFU diabetic foot ulcer 
DSA digital subtraction angiography 
EBR evidence-based revascularisation 
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HR hazard ratio 
IDF International diabetes federation 
IQR interquartile range 
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LEAD lower extremity arterial disease 
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MACE major adverse cardiovascular event 
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PAD peripheral arterial disease 
PLAN  patient risk estimation, limb staging, anatomic pattern of 
disease 
PTA percutaneous transluminal angioplasty 
PVR pulse volume recording 
RR risk ratio 
STSG split-thickness skin graft 
SSGSV single-segment great saphenous vein 
tcpO2 transcutaneous oxygen pressure 
TASC Trans-Atlantic intersociety consensus 
TAP target artery pathway 
TAP thoracodorsal artery perforator 
TIA transient ischaemic attack 
TMT transmetatarsal 
TP toe pressure  
UK United Kingdom 
US United States 
UT University of Texas 
WHO World Health Organisation 
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ABSTRACT 
Background: Diabetes increases the risk of major amputation 7.6-fold compared to the 
nondiabetic population in Finland. The risk of amputation is highest in patients with 
ischaemia and an infection. While efforts are being made for the better prevention and 
early identification of ulcers, understanding ischaemic ulcers and their treatment, even 
the most complicated ones, is still necessary. 
Aim: We aimed to study lower extremity arterial disease (LEAD) and its risk factors in a 
cohort of type 2 diabetic patients, in addition to investigating the long-term outcome of 
patients with ischaemic diabetic foot tissue defects according to the mode of treatment. 
Patients and methods: 130 type 2 diabetic patients, arbitrarily selected from the register 
of the Helsinki Diabetes Association, were examined at baseline in 1983–1985 and 93 
available patients at follow-up an average of 11 years later. Ankle-brachial index (ABI) 
and serum and urine tests were taken at baseline and ABI again at follow-up (Study I). 
Data on all free tissue transfer (FTT) operations for diabetic and ischaemic tissue defects 
of the lower extremities from the beginning of operations in Helsinki in 1989 to 2003 
were collected mainly from medical records (Studies II and III). Ninety-nine consecutive 
patients admitted for angiography due to a suspicion of an ischaemic ulcer were 
examined and interviewed in 1999 (Study IV). Long-term outcome was analysed mainly 
based on follow-up data from medical records and, in Study I, based on a new 
measurement of (ABI). 
Main results: At baseline, LEAD in type 2 diabetic patients was associated with age, the 
duration of diabetes, smoking and the urinary albumin excretion rate. The development 
of new LEAD 11 years later, after the death of the most morbid group of patients, was 
associated with low density lipoprotein (LDL) and high density lipoprotein (HDL) 
cholesterol levels. (Study I.) 
After combined FTT and vascular reconstruction, the postoperative period was 
uneventful only in 22% of the patients. The one- and five-year limb salvage rates were 
73% and 66%, survival rates 91% and 63%, and amputation-free survival rates 70% and 
41%, respectively. Fifty-two percent of the patients were able to ambulate with the 
preserved leg at two years. Minor ulcer recurrence was observed in 54% of the patients 
with primary skin healing. (Study II.) 
In diabetic patients, the amputation-free survival (AFS) rates at one, five and ten years 
were 90%, 79% and 63%, respectively, among those not requiring revascularisation; 
66%, 25% and 18%, respectively, among those who underwent revascularisation; and 
50%, 42% and 17%, respectively, among those with uncorrectable ischaemia. Major 
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amputation was associated with smoking, heel ulceration, nephropathy and an ulcer 
diameter of over 10 cm. (Study III.) 
Of the patients with ischaemic ulcers, 75% underwent revascularisation, whereas the 
remaining 25% received conservative treatment. Of patients who underwent 
revascularisation, 7 had type 1 diabetes and 33 type 2 diabetes, and 31 were non-
diabetic. The one-, five- and ten-year AFS rates in the whole cohort were 59%, 31% and 
11%, respectively. In multivariate analysis, amputation during the first year of follow-up 
was significantly associated with unreconstructable ischaemia, uraemia and elevated 
CRP (c-reactive protein). (Study IV.) 
Conclusions: A low ABI predicts cardiovascular mortality in diabetic patients with no 
other signs of cardiovascular disease. Smoking, urine albumin excretion rate, LDL 
cholesterol and HDL cholesterol are modifiable factors that should be addressed in order 
to decrease the risk of LEAD. 
After FTT excellent AFS at five years can be expected in diabetic patients with a native 
artery open to the foot. Even in the absence of options for revascularisation, moderate 
AFS can be achieved with careful individual assessment. A large ulcer size and location 
in the heel were associated with amputation after FTT – in diabetic patients also smoking 
and uraemia. 
In patients with ischaemic ulcers, the amputation rate was high during the first two years 
of follow-up, and mortality was high during the whole follow-up period; the 10-year AFS 
was 11%. Amputation during the first year was independently associated with elevated 
CRP, uraemia and uncorrectable ischaemia. Ulcer healing was similar in nondiabetic 
(65%) and type 2 diabetic patients (67%) with revascularisation. 
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1 INTRODUCTION 
A foot ulcer is a serious complication of diabetes. Major amputations in diabetic patients 
are in 85% of the cases preceded by ulceration (Larsson et al. 2008, Reiber et al. 1998, 
Singh et al. 2005). Diabetes increases the risk of major amputation 7.6-fold compared to 
the nondiabetic population in Finland (Ikonen et al. 2010). Ulcers also decrease the 
mobility of patients, restrict their social life, require resources for ulcer care and cause 
hospitalisations. Moreover, diabetic foot ulcers are independently associated with 
mortality (Martins-Mendes et al. 2014). In diabetic patients, three important aetiological 
factors of chronic ulcers are ischaemia, neuropathy and infection. Neuropathy is present 
in roughly 90% of ulcers and ischaemia in 50% (Prompers et al. 2007) .The risk of 
amputation increases in patients with ischaemia and an infection, and it is very high in 
patients with both of these conditions (Prompers et al. 2008).  
The prevention of ulcers is possible in many ways. Optimal glucose balance, the 
avoidance of atherosclerosis risk factors, as well as foot care and educating patients and 
professionals may prevent the majority of ulcers and ward off the deterioration and non-
healing of upcoming ulcers. A careful foot examination is an important part of a routine 
check on diabetic individuals, as is education on foot care and the prevention of foot 
problems. 
When a tissue lesion exists, the identification and timely treatment of ischaemia is of 
utmost importance for the outcome of diabetic foot ulcers. The diagnosis of peripheral 
arterial occlusive disease in diabetic patients is challenging due to the often sclerotic 
medial layer of the artery that results in falsely high ankle pressures. Hence, routine toe 
pressure measurements and low-threshold imaging studies are recommended. Due to 
neuropathy, patients may not feel pain, and the tissue lesion is often already extensive 
when a patient seeks help. In neuroischaemic ulcers, the correction of ischaemia with 
srevascularissation is mandatory to achieve wound healing. When a tissue lesion affects 
the joints, tendons and even bone, extensivesischaemia plastic surgery is needed to 
cover the tissue lesion in addition to correcting the ischaemia by means of 
revascularisation.  
At present, the number of diabetic patients is growing, while prevention as well as early 
intervention remain only halfway towards being fully implemented. Understanding 
ischaemic ulcers and their treatment, even the most complicated ones, is necessary. The 
objective of the present thesis was to study peripheral arterial disease and foot ulcers 
in diabetic patients and, further, the treatment of extensive diabetic foot ulcers. 
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2 REVIEW OF THE LITERATURE 
2.1 DIABETES MELLITUS (DM) 
2.1.1 DEFINITION 
The term diabetes mellitus (DM) covers a state of chronic hyperglycaemia induced by a 
deficiency in insulin production or by a decreased sensitivity to insulin caused by 
multiple aetiologies. The global criteria for the diagnosis of diabetes were published and 
updated by the World Health Organisation in 1965, 1980, 1985, 1999 and 2006 in 
collaboration with the International Diabetes Association. (WHO 2006). In 2011 the 
WHO recommended glycated haemoglobin as an additive test, and the International 
diabetes federation (IDF) global guideline from 2012 named any one of the following as 
a diagnostic test: fasting plasma glucose, oral glucose tolerance test, glycated 
haemoglobin or random plasma glucose (WHO 2011, IDF 2012). In Finland, a national 
guideline, the Current Care Guidelines on Diabetes, first published in 2007, follows the 
international guidelines (Type 2 diabetes Current Care Guidelines 2018, Insulin 
deficiency diabetes. Current Care Guidelines 2018). 
A recent guideline by the WHO names a diversity of diabetes types. The classical main 
types, type 1 and type 2, are still valid (WHO 2019). In the past, the terms insulin-
dependent diabetes (IDDM) or juvenile-onset diabetes for type 1 diabetes, and non-
insulin-dependent diabetes (NIDDM) or adult-onset diabetes for type 2 diabetes, were 
used. Subtypes of these two forms have been replaced by a hybrid form of diabetes 
containing characteristics of both two main types. Type 1 and type 2 diabetes have 
classically been differentiated by the age at diagnosis and the need for insulin. However, 
instead of a strict division to these two main types, a continuum from insulin resistance 
to insulin deficiency corresponds with the current view where the disease may shift from 
one type to another. Therefore, unclassified diabetes has been newly introduced into 
the classification. Other main categories are specific types of diabetes, including 
monogenic diabetes types, and diabetes first detected during pregnancy (WHO 2019). 
The American Diabetes Association cites gestational diabetes and a specific type of 
diabetes due to other causes in addition to type 1 and type 2 diabetes (American 
Diabetes Association 2019). 
2.1.2 AETIOLOGY 
The two main types of diabetes both have a genetic predisposition, which is more 
pronounced in type 2 diabetes. While an identical twin of a patient with type 1 diabetes 
has a 30%–50% risk of the disease, the risk for a twin of type 2 diabetic is over 50% 
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(Olmos et al. 1988, Kerner et al. 2014). However, environmental factors are a requisite 
for the expression of the disease. Moreover, type 1 and type 2 diabetes display 
heterogenic aetiologies, many of which are unknown at present (Flannick et al. 2016, 
American Diabetes Association 2019, WHO 2019). 
Type 1 diabetes occurs when an autoimmune process destroys the beta cells of the 
pancreas. Very active research is under way regarding the aetiology of type 1 diabetes. 
Autoantibodies to islet cells, insulin, Glutamic Acid Decarboxylase (GAD) and to
thyroxine phosphatase are detectable at the time of diagnosis in over 85% of patients 
with type 1 diabetes. Linkage to certain human leucocyte antigen (HLA) genotypes is 
frequent as well. (American Diabetes Association 2019.) A strong role of environmental 
factor seems evident. Enterovirus infection is at least one of the candidates (Blanter et 
al. 2019).  
Type 2 diabetes is often linked to metabolic syndrome, obesity and reduced mobility. 
Genetics are important, but the exact mechanisms remain poorly defined. It seems that 
the genetic network is very complicated, and type 2 diabetes in particular has 
connections with various monogenic diabetes types that have recently been recognised 
due to new methods available in genetic research. 
2.1.3 EPIDEMIOLOGY 
The incidence of type 2 diabetes is increasing throughout the world. 
The highest numbers of diabetics live in China (98 million), India (65 million) and the 
United States (US) (24 million) due to the vast populations. However, the highest 
prevalence of diabetes is observed in some Middle Eastern countries as well as on the 
Western Pacific Islands, where the comparative prevalence (corrected by age) of 
diabetes lies between 23% and 37%. The estimated global comparative prevalence in 
2019 was 9.3%. (IDF 2019.)  
The national prevalence of diabetes in Finland is 9.2% (95% CI (confidence interval) 6.7–
11.5), and the comparative prevalence is 5.6% (95% CI 4.0–7.4) (IDF 2019). Based on the 
statistics of the Social Insurance Institution of Finland (KELA), 320 000 persons 
purchased diabetes medications in 2011. According to the IDF data, the number of 
diabetic persons is 350 000. As undiagnosed diabetes is frequent and not all diabetics 
need medication, the estimated number is over 500 000 diabetic patients (Finnish 
Institute for Health and Welfare 2020).   
In Finland, 75% of diabetic patients have type 2 diabetes (Type 2 diabetes. Current Care 
Guidelines 2018), whereas 90%–95% of the American diabetic population have type 2 
diabetes (American Diabetes Association 2019). In contrast, type 1 diabetes is diagnosed 
in 15% of diabetic patients in Finland and in 5%–10% in the US (Insulin deficiency 
diabetes. Current Care Guidelines 2018, American Diabetes Association  2019).  
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Finland has the highest incidence of type 1 diabetes in the world (IDF 2019). The mean 
incidence of type 1 diabetes in Finland was 62.5 (95% CI, 60.2–64.4) per 100 000 person-
years between 2006 and 2011 in children younger than 15 years of age (Harjutsalo et al. 
2013). The IDF estimate of type 1 diabetes incidence among children under 15 years of 
age was 62.3/100 000 for 2015 (IDF 2015). 
The prevalence of diabetes is remarkable in older age groups. In a population-based 
survey in Wales, the overall prevalence of diabetes was 3.4% in 2004. As regards the 
older population, the prevalence was 7.7% in men and 5.6% in women between 55 and 
64 years of age, 13.6% in men and 9.6% in women between 65 and 74 years, 13.9% in 
men and 9.8% in women between 75 and 84 years, and 17.9% and 12.1% in men and 
women, respectively, over 85 years of age (Morgan et al. 2010). 
2.1.4 DIABETIC COMPLICATIONS 
Diabetes mellitus leads to microvascular and macrovascular complications, which 
significantly reduce the quality of life and cause huge costs. The microvascular 
complications comprise nephropathy, retinopathy and neuropathy, while the 
macrovascular complications include atherosclerotic diseases, such as coronary artery 
disease, cerebrovascular disease and peripheral arterial disease. These complications 
also predispose diabetic patients to chronic ulcerations or may affect the prevention and 
treatment of ulcers  
In high-income countries, the incidence of macrovascular complications is decreasing 
due to better cardiovascular risk factor and blood glucose control, an earlier detection 
of diabetes, better organisation of care and better self-management. As the decrease 
has been steeper than in the population without diabetes, the excess risks of such 
complications for diabetic patients are no longer so striking. An analysis based on the 
Swedish national registry observed a 26% excess in all-cause mortality among diabetic 
population when compared to the nondiabetic population in 1998–2011 (Tancredi et al. 
2015).  
In older patients, the relative risk of macrovascular complications has decreased 
compared to the younger age groups. It has been speculated that the complications will 
be diversified in the future as people with diabetes live longer in the absence of 
macrovascular complications. Deaths due to cancers, renal disease, mental and physical 
disability as well as the cardiovascular complications peripheral vascular disease and 
heart failure may become more common. (Gregg et al. 2016.) The decrease in 
microvascular complications has been less notable. In the US, nephropathy, and 
probably retinopathy, decreased by half the rate of macrovascular complications (Gregg 
et al. 2016).  
The incidence and prevalence of complications is different in type 1 and type 2diabetes. 
The numbers are influenced by age, age at diabetes onset and disease duration. The 
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type 1 diabetic population in general is younger, the diagnosis is made at a notably 
younger age, and the disease duration is longer than in the type 2 diabetic population. 
Recently, however, the number of young-onset type 2 diabetes patients has been 
increasing. A comparison of type 1 and type 2 diabetic patients of the same age of onset 
reveals that the prognosis of type 2 diabetics seems less favourable. Macrovascular 
complications and mortality have been found to be higher in type 2 compared to type 1 
diabetes after an over 20-year follow-up (Constantino et al. 2013). The rates of some 
type 1 diabetes complications (mortality, renal failure and neuropathy) are declining. 
However, others (coronary artery diasease, overt nephropathy and proliferative 
retinopathy) show less favourable changes by 30 years (Pambianco et al. 2006) 
2.1.4.1 NEPHROPATHY 
Microalbuminuria is an easily measurable early sign of diabetic nephropathy. 
Microalbuminuria is observed in 20%–30% of type 1 diabetic patients 15 years after the 
onset of diabetes (Hovind et al. 2004). One in five of type 2 diabetic patients has 
microalbuminuria at onset and one in three after ten years (Adler et al. 2003). The 
prevention of the progression of microalbuminuria to macroalbuminuria and elevated 
creatinine values, in both type 1 and type 2 diabetes, includes good glucose and blood 
pressure control and the elimination of other risk factors.  
End-stage renal disease (ESRD) represents the most severe stage of renal insufficiency. 
The kidneys excrete excess fluids and harmful substances insufficiently. This leads to the 
need of dialysis treatment. Based on existing studies from different countries, 12%–66% 
of patients with ESRD have diabetic nephropathy (Gregg et al. 2016).  
In Finland, after a diagnosis of type 2 diabetes, the 10-year cumulative risk of developing 
ESRD has been found to be 0.29% and 20-year risk 0.74% (Finne et al. 2019). After a 
diagnosis of type 1 diabetes, the cumulative incidence of ESRD has been reported to be 
2.2% at 20 years and 7.8% at 30 years. ESRD was rare within the first 15 years after the 
diagnosis of type 1 diabetes, but the incidence increased thereafter. The risk of ESRD 
was lowest in those with the onset of DM (diabetes mellitus) occurring before the age 
of 5 years. (Helve et al. 2018.) In Finland, type 2 diabetes is the most frequent diagnosis 
in patients undergoing haemodialysis. However, type 1 diabetes just surpassed type 2 
diabetes as the most frequent diagnosis in the background of the initiation of active 
treatment for ESRD. Type 1 diabetes was the most frequent diagnosis in those who 
receive peritoneal dialysis (Finnish Registry for Kidney Diseases 2017). 
Renal transplantation can normalise the renal function. Type 1 diabetes is the third most 
frequent diagnosis among patients receiving a renal transplant. Among renal transplant 
recipients, type 2 diabetes is a relatively rare diagnosis (Finnish Registry for Kidney 
Diseases 2017). 
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The mortality rate is high among diabetic patients with ESRD. In Finnish type 2 diabetic 
patients, the ten- and 20-year cumulative risk of death was 34% and 64%, respectively. 
ESRD increased the risk of death 4.2-fold (Finne et al. 2019). In a large health 
maintenance organisation in the US, 46% of uraemic patients died and only 18% were 
initiated on dialysis. Diabetic patients were overrepresented among those who died, as 
were patients with congestive heart failure, coronary artery disease or anaemia. (Keith 
et al. 2004.) In another study on patients with type 2 diabetes, the prevalence of 
microalbuminuria ten years after diagnosis was 25%, of macroalbuminuria 5.3% and of 
permanently elevated creatinine levels or renal replacement 0.8%. Notably, for a patient 
with macroalbuminuria, death was more probable than developing more severe 
nephropathy. The annual mortality rate was 3.5% in patients with macroalbuminuria 
and 12% in patients with elevated creatinine levels or renal replacement therapy. (Adler 
et al. 2003.)  
2.1.4.2 RETINOPATHY 
Retinopathy affects patients with DFU (diabetic foot ulcer) in at least in two ways. Visual 
impairment hinders self-surveillance of the feet. Retinopathy is associated with an 
increased risk of LEAD in type 1 diabetics (Pongrac Barlovic et al. 2018). According to the 
current understanding, the pathologies underlying diabetic retinopathy are damage to 
the neural retina and the capillary vascular bed of the retina. The clinical manifestations 
are proliferative retinopathy and macular oedema. Retinopathy can be prevented or 
delayed with a good control of glucose and lipid balance, as well as blood pressure. The 
clinical disease can be treated with laser and vitreous anti-vascular endothelial growth 
factor (VEGF) medication injections (Shah and Gardner 2017). Screening and early 
treatment were shown to reduce visual impairment in a population-based study with 
both type 1 and type 2 diabetic patients (Hautala et al. 2014). Without proper treatment, 
diabetic retinopathy may lead to visual loss (Shah and Gardner 2017).  Approximately 
one third of diabetic patients develop retinopathy. The prevalence of retinopathy 
among individuals with a diagnosis of diabetes varies from 10% in Norway to 61% in 
Southern Africa; in many countries, including Finland, these data are not available (IDF 
2012). In an Australian study, the prevalence of retinopathy was 21.9% among those 
with known type 2 diabetes and 6.2% among those with newly diagnosed type 2 
diabetes (Tapp et al. 2003). 
The incidence of retinopathy is probably declining, based on the few existing studies, 
which are not yet specific for retinopathy. In a study from the US, self-reported visual 
impairment decreased from 27% to 19% between 1997 and 2012 (Gregg et al. 2014). In 
Finland, the incidence of retinopathy requiring laser treatment is declining (Kytö et al. 
2011).   
In type 1 diabetes, retinopathy rarely occurs during the first five years after diagnosis or 
before adolescence (Insulin deficiency diabetes. Current Care Guidelines 2018). In a 
17 
 
cohort of type 1 diabetic patients, the 20-year cumulative incidence of severe 
retinopathy was 18% (Kytö et al. 2011). 
 
2.1.4.3 NEUROPATHY 
 
In addition to foot problems, neuropathy increases morbidity in diabetic patients in the 
form of pain, as well as gastrointestinal and urinary tract problems, and it is associated 
with increased mortality (Ziegler et al. 2014). Patients and health care personnel alike 
are often unaware of the presence of polyneuropathy (Ziegler et al. 2015). 
Two aetiologic factors have been named for diabetic polyneuropathy (DPN): the number 
of nerve fibres is diminished and the microvasculature of the nerves is injured. On the 
background are metabolic abnormalities (Tesfaye and Selvarajah 2012). Age, the 
duration of diabetes, the height of the patient and uric acid have been associated with 
neuropathy (Tapp et al. 2003, Young et al. 1993). Peripheral neuropathy is also 
associated with peripheral arterial disease (Ziegler et al. 2015, Ylitalo et al. 2011). In one 
study, ENMG-confirmed neuropathy was observed in 73% of 30 diabetics with at least 
one significant stenosis or occlusion in the iliac, femoral or popliteal artery (Kim et al. 
2014). 
Many subtypes of neuropathy and an almost endless list of diagnostic methods, scores 
and symptoms pose challenges as regards comparisons between epidemiologic studies. 
According to a review article, diabetic sensory polyneuropathy (DSPN) affects less than 
20% of the diabetic population identified by screening. The prevalence was 13%–23% in 
a hospital-based material of type 1 diabetics and 18%–75% among type 2 diabetics. In a 
population-based and primary care cohort, the prevalence of DSPN was 8%–63% among 
type 1 diabetic patients and 13%–51% among type 2 diabetic patients. The prevalence 
based on nerve conduction velocities was higher: 29%–75%. (Ziegler et al. 2014.)  
In studies with more accurate testing of DNP, the prevalence has been higher among 
type 2 than type 1 diabetic patients, and the prevalence increased with age. In a cohort 
of 80 type 1 and 544 type 2 diabetic patients, neuropathy was tested by means of 
vibration and temperature perception, as well as monofilament testing. Thirty-six 
percent of the type 1 diabetic patients (mean age 59 years) and 56% of the type 2 
diabetic patients (mean age 69 years) had neuropathy. Of these, 5% and 8% had severe, 
and 30% and 30% possible neuropathy, respectively (Ziegler et al 2015). In another 
study, where neuropathy was assessed by pin prick and ankle reflex testing, in addition 
to temperature and vibration perception testing, DNP was observed in 5% of diabetic 
patients aged 20–29 years and in 44% of those aged 70–79 years (Young et al. 1993). In 
an Australian population-based study, 13.1% of participants with previously known 
diabetes and 7.1% of newly diagnosed diabetic patients had peripheral neuropathy, 
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assessed by means of temperature perception, monofilament, pin prick, vibration 
perception, and blood pressure drop testing combined with a symptom inquiry. The 
mean age of patients with neuropathy was 73 years and of non-neuropathic patients 62 
years (Tapp et al. 2003).  
The incidence of DNP increases with the time from the diagnosis of diabetes. In newly 
diagnosed type 2 diabetic patients with no neuropathy at baseline, the annual incidence 
of neuropathy has been reported to be approximately 2%, whereas in patients with a 
longer history of diabetes, the reported annual incidence has been approximately 6%–
8% in different studies. The yearly incidence of neuropathy among type 1 diabetics 
seems to vary between 1% and 4% but may be close to 0 or progressing much more 
rapidly, strongly depending on the glycaemic control and the duration of DM (Ziegler et 
al. 2014). 
2.1.4.4 NEUROPATHY AND ULCERS 
Diabetic peripheral neuropathy (DPN) makes the foot vulnerable for ulcers in many 
ways. The loss of sensation causes pressure, friction and sharp trauma to remain 
unnoticed. Motor neuropathy leads to a limited mobility of the joints, affects the 
proprioseptics and coordination and can alter the gait and, gradually, the anatomy of 
the foot. Autonomic neuropathy tends to diminish sweating, causing dry feet with easily 
cracking skin. It also alters the regulation of blood flow and possibly induces 
microvascular dysfunction as well. (Lepäntalo et al. 2011.) In a European multicentre 
study, 86% of the patients with diabetic foot ulcers had peripheral neuropathy. 
Neuropathy was diagnosed if two of the following tests were positive: monofilament 
testing, tactile testing with cotton wool, sharp and blunt testing, and vibration testing 
(Prompers et al. 2007). 
2.1.4.5 MACROANGIOPATHY 
Macroangiopathy is a process where the intimal layer of the artery wall thickens, the 
epithelium is damaged, and deposits, mostly consisting of lipids, develop in the intima. 
With time, these deposits or plaques often calcify. The arteries become obstructed or 
occluded, and plaque ruptures can occur (Leszczynska et al. 2018). The most well-known 
manifestations of macroangiopathy are probably peripheral arterial disease, coronary 
artery disease and cerebrovascular disease. Their coexistence varies between the 
reports (Figure 1). In a population-based register study, the most common first 
macrovascular manifestations in diabetic patients were peripheral arterial disease and 
heart failure (Shah et al. 2015). At the time of diagnosis, 23.5% of diabetic patients had 
at least one macrovascular comorbidity (Palladino et al. 2020). In a cohort containing 
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the entire diabetic population in the Basque Country, the diseases based on the hospital 
discharge register showed a prevalence of 11.5% for ischaemic heart disease, 7% for 
stroke and 2.5% for peripheral vascular disease (Alonso-Moran et al. 2014). According 
to a systematic review of diabetic patients who underwent revascularisation, the 
prevalence of coronary artery disease was 38%–59% and that of cerebrovascular disease 
18%–23% (Hinchliffe et al. 2016).  
The risk of myocardial infarction has been found to be 1.5 times higher in the diabetic 
than the non-diabetic population (Shah et al. 2015). In 1999, roughly one third of 
diabetic individuals in the US reported any heart disease or stroke. During 1997–2009, 
no clear decline was seen in the prevalence of self-reported heart disease. However, the 
incidence of acute myocardial infarction declined by 69% between 1990 and 2010, based 
on US register data. (Gregg et al. 2014.) 
The incidence of stroke declined by 53% between 1990 and 2010, based on US register 
data (Gregg et al. 2014). The hospital-discharge-register-based prevalence of stroke was 
7% among the type 2 diabetic population in the Basque Country in 2010–2011 (Alonso-
Moran et al. 2014). The risk factors of macroangiopathy include diabetes mellitus, 
smoking, hyperlipidaemia and hypertension. In the United Kingdom (UK), the risk of a 
person aged 40 years with no previous cardiovascular disease of developing any 
cardiovascular disease by the age of 80 was 67% for diabetic men, 58% for diabetic 
women, 44% for nondiabetic men and 31% for nondiabetic women (Shah et al. 2015).  
As is well known, a non-optimal glucose balance increases the rate of microvascular 
complications. The connection between glycaemic control and macrovascular disease 
has been more arduous to reveal. Indeed, strict glycaemic control at the onset of type 2 
diabetes reduces macrovascular complications, whereas a good control later, also 
considering symptomatic disease, may have little effect on the macrovascular 
complications (Lovre et al. 2015). For every 1% increase in HbA1C, there is a 25% 
increase in the risk of CVD in diabetic patients (Selvin et al. 2004, Muntner et al. 2005). 
Furthermore, the DCCT study showed that, in type I DM patients, the risk of 
macrovascular complications increased along with HbA1 levels (Bebu et al. 2017). 
Diabetes as a risk factor, especially combined with a previous cardiovascular event, 
increased the risk of new cardiovascular events, fatal and nonfatal. A noteworthy fact is 
that peripheral arterial disease is a strong predictor of cardiovascular disease in diabetic 
patients – stronger than cardiac or cerebral events; an accumulation of uncontrolled risk 
factors in patients with LEAD may offer an explanation (Krempf et al. 2010). Diabetes 
predicts cardiovascular mortality in patients with both symptomatic and asymptomatic 
LEAD (Sigvant et al. 2016). 
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Figure 1. Presentation of cardiovascular complications in two different non-
population-based study cohorts. Both diabetic and non-diabetic patients were 
included. A) German REACH. (Reproduced with permission from Zeymer et al. 2008). 
B) Canadian REACH (Reproduced with permission from Smolderen et al. 2010.)
2.2 LOWER EXTREMITY ARTERIAL DISEASE (LEAD) 
Classical symptoms of atherosclerotic obstructions and occlusions in the lower extremity 
arteries are claudication and critical limb ischaemia, comprising rest pain and ischaemic 
ulcers or gangrene. However, even a multilevel occlusion often lacks symptoms, 
especially in diabetic patients. Indeed, in diabetic patientss with peripheral sensory 
neuropathy, the symptoms are typically absent, and the first symptom may be an ulcer 
or gangrene (Lepäntalo et al. 2011). Diabetic patients  have a 2- to 4-fold risk of LEAD 
compared to non-diabetics (Beckman et al. 2016). With the intensive treatment of risk 
factors, the rate of peripheral arterial disease has been declining along with other 
macrovascular complications (Stratton et al. 2000, Carter et al. 2007, Selvin et al. 2004). 
2.2.1 CLINICAL MANIFESTATIONS 
2.2.1.1 ASYMPTOMATIC LEAD 
Asymptomatic disease can be detected by noninvasive measures, such as the ABI. 
However, in diabetic patients, studies based on ABI measurement may underestimate 
the prevalence of LEAD because in 30%–50% of the cases, ankle pressure is falsely 
elevated due to medial sclerosis (Lepäntalo et al. 2011, Faglia et al. 2009, Acin et al. 
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2014, Prompers et al. 2007). According to one estimate, two thirds of all patients with 
LEAD are asymptomatic (Aboyans et al. 2018). In Germany, 26% of diabetic and 13% of 
non-diabetic individuals aged over 65 years (median age 74 years) and visiting primary 
care for any cause had an ABI of < 0.9 (Lange et al. 2004). In Sweden, 29% of 68-year-old 
men with diabetes and 12% of those without diabetes had an ABI of < 0.9 (Ögren et al. 
2005). Notably, patients with asymptomatic LEAD have an increased risk of 
cardiovascular complications, stroke, acute myocardial infarction and death (Sigvant et 
al. 2016). 
2.2.1.2 CLAUDICATION 
Claudication is ischaemic pain that starts when the muscles of the lower extremity are 
exercised, typically when walking. The pain is relieved by stopping exercise. The 
symptom is caused by insufficient blood flow to meet the increased demand of 
exercising muscles. In the Swedish general population, the prevalence was 7.1% in men 
and 6.6% in women with a median age of 71 years (Sigvant et al. 2007). 
In diabetic patients, neuropathy may abolish the sensation of pain. However, diabetic 
patientss had a more than two-fold risk of claudication in a US study, in which prevalence 
of claudication in the general population was 0.9%–1.9% in men and 0.4%–1.1% in 
women, depending on age (45–84 years) (Murabito et al. 1997). Of diabetic patients, 
5.1% had claudication, whereas the proportion of claudicants among non-diabetic 
patients was 2.1% in another study (Lange et al. 2004). 
2.2.1.3 CRITICAL LIMB ISCHAEMIA /CHRONIC LIMB-THREATENING ISCHAEMIA 
The term critical limb ischaemia was defined in 1982 to describe lower limb ischaemia 
that places the limb under the threat of amputation unless a revascularisation is 
performed (Jamieson 1982). The definitions have later varied (Table 1). Recently, the 
term chronic limb-threatening ischaemia (CLTI) has been adopted (Conte et al. 2019). A 
new category of “subcritical” ischaemia was proposed by Wolfe et al. in 1997 and later 
supported by the European Society for Vascular Surgery (Wolfe et al. 1997, Becker et al. 
2011). Limbs threatened with amputation may need different efforts than limbs with 
delayed healing and non-healing of ulcers (Becker et al. 2011). Indeed, the WIfI 
classification presents 4 grades for ischaemia (Mills et al. 2014). It is estimated that the 
incidence of CLTI in the general population is 500–1 000/ 1 million inhabitants per year 
(Norgren et al. 2007).  
Approximately half of the patients with DFU attending specialist clinics have ischaemia. 
In the Eurodiale study, LEAD was found by means of ABI measurements in 22%–73% of 
the patients with a diabetic foot ulcer, depending on the centre, and a total of 49% of 
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these patients had an ABI of < 0.9 and/or non-palpable arteria tibialis posterior (ATP) 
and arteria dorsalis pedis ( ADP) pulses, while 12% had an ABI of < 0.5 (Schaper 2012). 
In a Swedish study, 49% of the diabetic foot ulcers were neuroischaemic, based on an 
ankle pressure of < 80mmHg, a toe pressure of < 45 mmHg, or Wagner grades 4 and 5 
whenever pressures were not obtained (Gershater et al. 2009). In a surgical series from 
a Helsinki University Hospital clinic, 50% of the patients undergoing infrainguinal bypass 
due to an ischaemic tissue lesion had diabetes mellitus (Söderström et al. 2008).  
Table 1. Definition of CLI and CLTI (chronic limb-threatening ischaemia) 
Jamieson 1982 Lower limb ischaemia that threatens the limb with 
amputation unless a revascularisation is performed. 
Second European Consensus 
Document on Chronic CLI 1991 
Ankle pressure below 50 mmHg or toe pressure below 
30 mmHg. 
 TASC I (Dormandy and 
Rutherford 2000) 
Ankle pressure < 50–70 mmHg or toe pressure < 30–
50 mmHg or reduced supine forefoot TcpO2 < 30–50 
mmHg. 
TASC II (Norgren et al. 2007) Objectively proven arterial occlusive disease. 
IWGDF and ESVS 
recommendations (Cao et 
al.2011) 
Ulcer healing is severely impaired if ABI <0.6. Values > 0.6 
should not be trusted. Nevertheless, toe pressure and 
tcpO2 < 30mmHg would indicate severely impaired 
healing whereas toe pressure > 55 mmHg and tcpO2 > 
50 mmHg would be favourable regarding healing. 
Guidance by IWGDF on diabetic 
foot ulcer and peripheral arterial 
disease (Brownrigg et al. 2016) 
The presence of ABI 0.9–1.3, toe brachial index ≥ 0.75, 
and the presence of triphasic pedal Doppler arterial 
waveforms largely exclude LEAD. Imaging studies and 
subsequent revascularisation should be considered if toe 
pressure is < 30 mmHg or TcPO2 < 25 mmHg, and if the 
ulcer is not healing in 6 weeks. 
CLTI (Conte et al. 2019) Presence of LEAD in combination with rest pain, 
gangrene, or a lower limb ulceration with > 2 weeks’ 
duration. The role of accurate clinical classification is 
emphasised. WIfI classification is recommended. 
ESVS European Society for Vascular Surgery, TASC Transatlantic Intersociety Consensus, 
IWGDF International Working Group for Diabetic Foot, LEAD lower extremity arterial disease, 
CLI (critical limb ischaemia), CLTI (chronic limb-threatening ischaemia) 
2.2.1.4 DISTRIBUTION OF LEAD IN DIABETIC PATIENTS 
In diabetic patients with foot ulcers or gangrene, atherosclerosis typically occludes and 
obstructs arteries below the knee and the arteria profunda femoris. The lesions are 
typically multilevel, often bilateral and are common both in men and women. (Jude et 
al. 2001, Diehm et al. 2006, Graziani et al. 2007, Apelqvist et al. 2011.) In 413 diabetic 
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patients undergoing endovascular treatment for CLTI, 7% had a > 50% stenosis only in 
the popliteal or more proximal arteries and 32% only in the infrapopliteal arteries, while 
60% had both infrapopliteal and more proximal stenosis (Faglia et al. 2009). In a cohort 
of 1,046 diabetic patients with ischaemic foot ulcers, 314 (30%) patients underwent 
percutaneous transluminal angioplasty (PTA) and 190 (18%) vascular reconstruction. In 
46% of the endovascular cases, the crural arteries were treated and 51% of the open-
surgical reconstructions had truncal or lower run-off (Apelqvist et al. 2011). A cohort of 
ischaemic diabetic feet showed occlusion in 25% of the fibular arteries, in 56% of the 
posterior tibial arteries (ATP)s, in 53% of the anterior tibial arteries (ATA)s, and in 12% 
of the tibiofibular trunks (Aerden 2014). 
2.2.2 EPIDEMIOLOGY IN DIABETES 
Great variation in epidemiological data on LEAD in diabetic patients exists regarding the 
study population and the definition of LEAD (Table 2 and Table 3). Large, population-
based register studies mostly rely on diagnosis and symptomatic disease. A recent 
review estimates that the prevalence of LEAD varies between 10% and 40% in general 
diabetic populations (Hinchliffe et al. 2016).  
In a register study consisting of the entire type 2 diabetic population over 35 years of 
age in the Basque Country, the prevalence of peripheral arterial disease was 2.5%. It was 
more prevalent in men (3.95%) than in women (0.97%). (Alonso-Morán et al. 2014.) In 
a population-based survey from Wales, 9% of diabetic patientss (mean age 60–61 years) 
had a diagnosis of diabetic foot or peripheral vascular disease. Notably, 16% of diabetic 
men over 50 years of age had LEAD based on their medical records, but when all patients 
with an ABI of < 0.9 were included, the prevalence was 30% (Hirsch et al. 2001). In an 
Australian population-based study of persons over 25 years of age, 13.6% of individuals 
with known diabetes and 6.9% of newly diagnosed diabetics had LEAD, as defined with 
ABI and a claudication questionnaire. The prevalence increased with the duration of 
diabetes, reaching 31.3% after 20 years’ duration. (Tapp et al. 2003.) In a Scottish 
population-based study, 17% of all diabetic patients (mean age 59 years) had absent 
foot pulses (Leese at al. 2011).  
In an English population-based cohort of 1.9 million individuals, including 34,198 
diabetic patients aged over 30 years with no previous cardiovascular events, 992 (2.9%) 
of the diabetic patients experienced the first presentation of LEAD during a mean 5.5-
year follow-up time, constituting 610/100 000 person years (Shah et al. 2015)  
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Table 2. Prevalence of LEAD in diabetic patients. 
Study patients prevalence method else 
Charles 
et al. 
2011 
1 533 screened DM 
patients from GP 
7.3%-9.1%/ 
6-year-fup 
ABI intensive/ routine 
treatment groups 
NS difference, 
mean age 60 yrs 
Lange et 
al. 2004 
6 880 all/1743 DM 
consecutive GP 
multicentre 
26.3% DM/ 
15.3% 
nonDM 
ABI < 0.9 ≥ 65y, mean 72.5 
yrs, ABI, physical 
examination, 
interview 
Lange et 
al. 2004 
6 880/1743 DM 
consecutive GP 
multicentre 
5.1%DM/2.1
% nonDM 
claudication ≥ 65 y, mean 
72.5 yrs, ABI, 
physical 
examination, 
interview 
Shah et 
al. 2015 
3.7 million cohort, 
400 000 any diabetes 
11.5% ABI, patient-
reported history 
of arterial 
intervention or 
claudication 
Lifeline screening 
survey, not (but 
near) population-
based, mean age 
66.5 years 
Alonso-
Moran 
et al. 
2014 
149 000 type 2 DM 
subjects 
2.5% register-based 
diagnosis 
over 35-yr-old  
population of the 
Basque Country 
Jensen 
et al. 
2006 
20 300 local 
population Norway, 
500 DM  
1.2% DM/ 
0.2% non-
DM 
questionnaire on 
CLTI symptoms 
population-
based, 40–69 
years 
Baser et 
al. 2013 
98% US 
population > 65 
years 
0.19% DM/ 
0.04% non -
DM 
CLTI and rest pain, 
inpatient and 
outpatient dg 
any diabetes 
Baser et 
al. 2013 
98% US 
population > 65 
years 
0.84% DM/ 
0.08% non-
DM 
CLTI and ulcer or 
gangrene 
inpatient and 
outpatient dg 
any diabetes 
Morgan 
et al. 
2010 
439 000 local 
population, Wales 
DM 17 100  
9% diabetic foot and 
LEAD 
register-based 
diagnosis 
Tapp et 
al. 2003 
11 247 random 
cohort of Australian 
population, 853 DM2 
14% known 
DM, 7% new 
DM 
ABI, claudication ≥ 25 years, mean 
LEAD 72 years, no 
LEAD 62 years 
Leese et 
al. 2011 
Scottish diabetes 
register 3 719 
patients 
17.2% pulse palpation, 
both pulses 
absent 
population-based 
GP general practitioner, DM diabetes mellitus, LEAD lower extremity arterial disease, 
CLTI chronic limb threatening ischaemia, US United States. 
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Table 3. Incidence of LEAD in diabetic patients 
Study patients incidenc
e 
method characteristics 
Baser et 
al. 2013 
98% US 
population > 65 
years 
0.17% CLTI and rest pain 
inpatient and outpatient 
dg 
any diabetes 
Baser et 
al. 2013 
98% US 
population > 65 
years 
0.69% CLTI and ulcer or 
gangrene, inpatient and 
outpatient dg 
any diabetes 
Shah et 
al. 2015 
1.9 million UK 
population-
based cohort 
610/ 
100 000 
person 
years 
LEAD, register-based 
diagnosis, primary care, 
hospital discharge, death 
registration, myocardial 
ischaemia register 
> 30 years, no
previous
cardiovascular
disease
US United States, CLTI chronic limb-threatening ischaemia, LEAD lower extremity 
arterial disease, UK United Kingdom. 
2.2.3 DM AS A RISK FACTOR FOR LEAD AND THE PROGRESSION OF THE 
DISEASE 
Diabetes is a strong risk factor for asymptomatic and symptomatic LEAD and its 
progression. The prevalence of LEAD is estimated to be from 3 to 4 times higher in the 
diabetic than the non-diabetic population (Norgren et al. 2007). In a meta-analysis 
including community-based studies in high-income countries from 1997 onwards, 
diabetes was a risk factor (OR 1.88) for LEAD, as defined by an ABI ≤ 0.9, in people over 
25 year of age. The other risk factors included in the study were smoking, hypertension 
and hyperlipidaemia. (Fowkes et al. 2013.)  
Diabetes predicts the progression of LEAD. A meta-analysis showed a progression from 
claudication to CLTI during five-year follow- up in 21% of the patients. Diabetes (OR 
2.33), stroke (OR 1.22) and heart failure (OR 1.36) increase the risk of LEAD progressing 
to CLTI. (Sigvant et al. 2016.) However, claudication does not necessarily precede critical 
limb ischaemia. This is typical in patients with diabetes, heart failure, renal failure and 
stroke. In an extensive register-based study in the US, 11% of the general population 
with claudication developed CLTI annually. The risk of CLTI without prior LEAD was high 
in diabetes (OR 7.45). (Nehler et al. 2014.)  
A French population-based study showed that patients who became diabetic developed 
LEAD (ABI and claudication questionnaire) twice as often as patients who remained 
normoglycaemic (Tapp et al. 2007). In an American study with over 3 million 
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participants, diabetic patients had an increased risk of LEAD when compared to non-
diabetic individuals, with an odds ratio of 1.96. When adjusted for age, sex, ethnicity, 
hypertension, hyperlipidaemia, smoking status, BMI (body mass index), coronary artery 
disease and transient ischaemic attack (TIA or stroke), the odds ratio was 1.42. The odds 
ratio for mild LEAD (based on ABI measurements) was 1.37, for moderate LEAD 1.77, 
and for severe LEAD 2.16 after adjustment. (Shah et al. 2015)  
In a study based on US Medicare Data, the annual incidence and prevalence of CLTI was 
roughly nine times higher in diabetic compared to non-diabetic patients. In diabetic and 
non-diabetic patients, the prevalence of CLTI and rest pain was 0.19% and 0.04%, 
respectively, whereas the prevalence of CLTI and tissue lesions was 0.84% and 0.08%, 
respectively. In patients with CLTI, the incidence of amputation was 31% among diabetic 
and 17% among non-diabetic patients. The incidence of revascularisation was 29% 
among diabetic and 31% among non-diabetic patients with CLTI during the first year. 
(Baser et al. 2013.) The OXVASC study from the UK reports vascular events prospectively 
in a population of roughly 92 000 subjects during a ten-year period in 2002–2012. An 
incident CLTI event (rest pain or ulcer for more than 2 weeks needing hospital admission) 
during the 10-year follow-up was observed in 89/3,125 (2.8%) among diabetics, 
compared to the 112/89,603 (0.1%) among non-diabetics (RR 5.96 3.15–11.26, p <0.001) 
(Howard 2015). 
2.2.4 ANGIOSOMES 
An angiosome is an anatomical three-dimensional area vascularised by one source 
artery. Three main arteries supply the foot and the leg: the arteria tibialis anterior (ATA), 
the arteria tibialis posterior (ATP) and the fibular artery. They give altogeather six source 
arteries which feed the six angiosomes of the foot. The ATA extends to periphery via the 
ADP and supplies the anterolateral leg, the anterior ankle and the dorsal foot and the 
toes. The ATP has three main branches: the medial calcaneal branch supplies the medial 
and plantar heel, the lateral plantar artery the lateral plantar area and the toes and the 
medial plantar artery the medial plantar surface and the first toe. The fibular artery 
divides into two main branches: the lateral calcaneal branch supplies the plantar and 
lateral heel and the lateral ankle and the anterior perforating branch the anterior ankle. 
The angiosomes overlap especially in the toes and in the heel. (Figure 2), (Attinger et al. 
2006, Taylor and Palmer 1987). Remarkably, anatomical variations in arterial tree are 
common. Furthermore, collaterals and the pedal arch make the system more complex. 
Revascularisation has been classified as direct, direct through collaterals and 
indirect. However, agreement on the criteria for these groups is lacking. In one study, 
the pedal arch was complete in 31 and occluded in 32 out of 167 feet undergoing bypass 
surgery (Rashid et al. 2013)In another study, in 33% of 106 limbs had an open pedal arch 
(Kret et al. 2014). 
In a study conducted in Helsinki, ulcers were limited to one angiosome in only 24% of 
the lower extremities, while 47% of the ulcers involved two, 26% three and 3% four or 
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five angiosomes (Spillerova 2016). The feasibility of angiosome-targeted endovascular 
revascularisation was considered to increase when the ulcer affected more than one 
angiosome (Spillerova et al. 2016). In another study, 31% of the ulcers were clearly 
limited to a single angiosome, 56% were located within two angiosomes, and 7.5 % 
involved three angiosomes (Kret et al. 2014). 
In a further study (Aerden et al. 2014), the location of 345 ulcers in 185 diabetic feet was 
studied in relation to the angiosomes. Forty-six percent had toe ulcers only, 18% had 
both toe and more proximal ulcers, and 36% had only proximal ulcers. In 77% of the 
ulcers, the location in relation to the angiosomes remained ambiguous. Toe ulcers, 
lateral foot ulcers and heel ulcers were located at the junction of two angiosomes. In 
some patients, the more proximal ulcer made the selection between the ATA and ATP 
more obvious. According to Aerden et al., at least 8.6% of patients with diabetic foot 
ulcers would need revascularisation of two vessels if all ulcer angiosomes in the foot and 
lower leg were to be revascularised. (Aerden et al. 2014.) 
Figure 2. Angiosomes ot the foot and the lower leg. Overlapping areas locate in 
the toes and in the heel. 
ATP arteria tibialis posterior, ATA arteria tibialis anterior. 
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2.2.5 CLASSIFICATION  
 
The most common clinical classifications of ischaemia are the Fontaine and the 
Rutherford classification. The Fontaine classification of LEAD was presented in 1952 
(Becker et al. 2011) (Table 4). The Rutherford classification of LEAD was created in 1986 
and revised 1997 (Rutherford et al. 1997) (Table 5). It first included ankle pressure, toe 
pressure and pulse volume recording (PVR) criteria in addition to clinical criteria, but 
these have been later abandoned (Becker et al. 2011). The WIfI classification grades 
ischaemia based on ABI values and is recommended to be used in all diabetic patients 
with a foot ulcer (Mills et al. 2014). It is presented among the ulcer classifications later 
in this dissertation.  
 
Table 4. Fontaine classification. 
Grade Description 
1 asymptomatic 
2 intermittent claudication 
3 ischaemic rest pain 
4 ulcer or gangrene 
 
 
Table 5. Rutherford classification (Reproduced with permission from Rutherford et al. 
1997). 
0 Asymptomatic Normal treadmill/stress test 
1 Mild claudication Completes treadmill exercise, ankle 
pressure after exercise < 50 mmHg but > 25 
mmHg lower than blood pressure 
2 Moderate claudication Between classes 1 and 3 
3 Severe claudication Cannot complete treadmill exercise and 
ankle pressure after exercise < 50 mmHg 
4 Ischaemic rest pain Resting ankle pressure < 40 mmHg, flat or 
barely pulsatile ankle, 
or metatarsal PVR; toe pressure < 30 mmHg 
5 Small tissue defect Resting ankle pressure < 60 mmHg, ankle or 
metatarsal PVR flat or barely pulsatile; toe 
pressure < 40 mm Hg 
6 Large tissue defect reaching 
proximal to tarso-metatarsal 
joints, functionality of the foot 
not salvageable 
Same as 5 
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2.2.5.1 Glass 
The Global Limb Anatomic Staging System (GLASS) classification considers multilevel 
disease and combines the femoropopliteal and infrapopliteal distribution of disease into 
three stages based on the estimated immediate technical failure rate and the leg-based 
patency at one year. In femoro-popliteal and infrapopliteal segments, the length of the 
diseased and occluded arterial segments and the severity of stenosis are graded. The 
inflow and inframalleolar disease are evaluated separately. (Conte et al 2019.) 
2.2.6 DIAGNOSIS OF LEAD IN DIABETIC PATIENTS 
2.2.6.1 NONINVASIVE METHODS 
Simple and reliable bedside diagnostic methods for LEAD among diabetic patients are 
still required. Approximately 50% of diabetic ulcers are of ischeamic aetiology. 
Therefore, it is not effective to screen ischaemia with very ponderous protocols. Pulse 
palpation is a clinical basic examination of every patient, but the repeatability and 
reliability of pulse palpation have been questioned (Brownrigg et al.  2016). Up to 20% 
of arterial disease confirmed by colour duplex imaging were missed with pulse palpation 
(Williams et al. 2006). While the palpation of pulses in screening for LEAD is not an 
optimal method, it does predict the ulcer risk. A meta-analysis of individual patient data 
of 16 000 subjects worldwide showed that monofilament testing and pulse palpation 
are effective methods for screening diabetic feet at risk of ulceration (Crawford et al. 
2015). Furthermore, in a Scottish population-based study, absent foot pulses and 
neuropathy assessed by means of monofilament testing, among other factors, predicted 
ulceration in diabetic patients with no previous ulcers. Absent pulses also predicted 
amputation as well (Leese et al. 2011). 
ABI is the basic method to diagnose lower extremity arterial disease, and values < 0.9 
have good sensitivity and specificity to detect LEAD in the general population. Ankle 
pressure or ABI never exclude significant LEAD in diabetic patients. Medial sclerosis 
makes the artery walls stiff and poorly compressible in 30%–50% of diabetes with foot 
lesions (Lepäntalo et al. 2011, Faglia et al. 2010, Acin et al. 2014, Prompers et al. 2007). 
Thus, circulation may be poor when the ABI is 1.0–1.4 (Conte et al. 2019).  
In the Eurodiale study, the ABI was over 1.2 in 32% of the patients (Prompers et al. 2007). 
Toe pressure measurement and tcOp2 have been suggested as alternative noninvasive 
methods to detect LEAD in diabetic patients. Medial sclerosis is rare in the digital arteries 
(Williams et al. 2006). Nevertheless, necrosis or a previous amputation of toes prevents 
the measurement of toe pressure in many patients – in an Italian material, in 16% of the 
patients (Faglia et al. 2009). User-friendly equipment is available, but the quality control 
and interpretation of the results require some expertise. Furthermore, the repeatability 
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of toe pressure measurements with the most affordable devices is compromised 
(Widmer et al. 2013). TcpO2 measurement is useful in capable hands. In an Italian 
specialist clinic, tcpO2 was measurable in all 261 diabetic patients, whereas ankle 
pressure could be measured in 58% and toe pressure in 72% of the patients. All patients 
had > 50% stenosis in angiography (Faglia et al. 2010). However, the examination is time-
consuming and requires equipment and expertise, making it non-optimal for screening 
purposes. Lower tcpO2 values have been shown in diabetic than in non-diabetic patients 
with arterial disease and with similar TBIs, which is most pronounced in the presence of 
neuropathy. Diabetic patients are suggested to have worse perfusion than non-diabetic 
patients in the presence of similar macrovascular disease pattern (Williams et al. 2006). 
Triphasic flow in qualitative visual Doppler waveform analysis has been suggested for 
screening of LEAD in diabetic and nondiabetic patients (Brownrigg et al. 2016). A study 
on the ability of the loss of reverse flow to indicate obstructions in the arterial tree 
showed that the false negative rate regarding triphasic flow was quite low: 15% in non-
diabetic and 6% in diabetic atherosclerotic patients (Williams et al. 2005). 
 
2.2.6.2 IMAGING 
 
Digital subtraction angiography (DSA) is the gold standard in diagnosing significant 
arterial disease. Recently, however, DSA has been used mostly for endovascular 
procedures, whereas magnetic resonance angiography (MRA), computed tomography 
angiography (CTA) as well as ultrasound have replaced it as a first line diagnostic method 
(Conte et al 2019). Nevertheless, DSA generally results in the best-quality images of 
crural and pedal outflow arteries. Furthermore, in patients with severe nephropathy or 
a cardiac pacemaker, angiography may serve as a part of the diagnostics.  Angiography 
has many disadvantages, including its invasiveness, the nephrotoxity of contrast media 
and radiation (van der Molen et al. 2018). Nefrotoxity can be avoided with CO2 as 
contrast medium, and images of reasonable quality can be achieved (Palena et al. 2016). 
In a Swedish study, 99 complications ensued in 72/801 (9%) patients after angiography. 
The most frequent were renal impairment, with in 56 cases, and haemorrhage, which 
occurred in 26 cases. One patient had an occlusion, and the rest were miscellaneous 
complications (Apelqvist et al. 2011). In practice, several imaging modalities may be 
necessary (Conte et al. 2019).  
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2.3 DIABETIC FOOT ULCERS 
Diabetic foot problems are one of the most common and most expensive complications 
of diabetes. As regards the costs of diabetes, 20%–40% are due to diabetic feet 
(Lepäntalo et al 2011). The problems initiate with skin/tissue lesions that progress into 
chronic ulcers and can lead to minor and major amputations. Of major amputations, 
80%–90% are preceded by an ulcer (Lepäntalo et al. 2011). In a multicentre study 
comprising data on a cohort of 1,229 patients from 14 European multidisciplinary clinics, 
the ulcers in diabetic patients with LEAD had more extensive tissue loss, reached the 
bone or joint more often and were larger than the ulcers in patients without LEAD 
(Schaper 2012). 
2.3.1 EPIDEMIOLOGY 
The estimation of the lifetime risk of ulceration in diabetic patients is 15%–25% (Singh 
et al. 2005, Schaper 2012). Incidence and prevalence numbers vary in relation to the 
population under study and the reference population. Furthermore, the method of data 
collection affects the numbers (Forssgren and Nelzen 2015, Hopkins et al 2015). 
Typically, cohorts retrieved from specialist clinics or hospitals have a higher incidence 
and prevalence and they are not representative regarding population based 
epidemiological data. 
The point prevalence of diabetic foot ulcers in different studies varies between 1.5% and 
10% of diabetic patients(Singh et al. 2005, Forssgren and Nelzen 2012). In a register 
study consisting of the whole type 2 diabetic population of the Basque Country, the 
prevalence of foot ulcers was 1.93% in 2011 (Alonso-Morán et al. 2014). The point 
prevalence of DFU in 2011 was 0.13 per a general population of 1,000 in Leeds, UK (Hall 
et al. 2014). 
In Sweden, an epidemiologic study of foot and leg ulcers was repeated in the same 
geographical area with 250 000 inhabitants in 1988 and 2002. In 1988, 3.5% of diabetic 
patients had a foot or leg ulcer, compared to 2.2% in 2002. Of all patients with foot 
ulcers, 32% had both ischaemia and DM, and 24% of the ulcers were non-ischaemic 
diabetic ulcers. (Forssgren and Nelzen 2012.) In another study, a questionnaire was sent 
to a randomly selected sample of inhabitants in the same area in 2005. Ulcers were 
verified by clinical examination. The prevalence expected based on the preceding 
questionnaire sent to professionals was 0.23, whereas the prevalence obtained with the 
questionnaire to the inhabitants was 0.52 (Forssgren and Nelzen 2015). 
The mean annual incidence of new and recurrent ulcers was 6.1 and 7.1/1,000 diabetic 
patients, respectively, in a NHS (National Health Service) area in the UK during 2013-
2017 (Paisey et al. 2019). In Scotland, 1.93% of consecutive ambulant diabetic patients 
over 18 years of age with intact skin visiting a community-based primary care podiatric 
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clinic developed an ulceration during 1-year follow-up (Crawford et al. 2011). Based on 
register data in Canada, the incidence of diabetic foot ulcers in 2011 was 42.4/a general 
population of 100 000. A 7.4% yearly increase in the incidence of diabetic foot ulcers 
was observed over the 5 preceding years (Hopkins et al. 2015). In a Japanese special 
diabetic clinic, the foot ulcer incidence was 2.9/1,000 patient years (Iwase et al. 2018). 
In a Danish specialist diabetes centre, the incidence of foot ulcers among type 1 diabetic 
patients was 8.1/1,000 patient years in 2002 and 2.6/1,000 patient years in 2014. The 
study population was representative of the Danish type 1 diabetic population. During 
2002–2014, the incidence of neuropathic ulcers was 2.57/1,000 patient years, of 
neuroischaemic ulcers 2.19/1,000 patient years and of critically ischaemic ulcers 
0.47/1,000 patient years. Of the type 1 diabetic patients included in the cohort, 47% 
were under 40 years of age. (Rasmussen et al. 2017.) In a Swedish cohort study, 18% of 
the patients with diabetic foot ulcers had type 1 diabetes (Gershater et al. 2009).  
In an Australian population-based study of persons over 25 years of age, 2.1% of 
diabetics reported a previous foot ulceration; 3% of patients with known diabetes and 
1.2% of patients with newly diagnosed diabetes (Tapp et al. 2003). A hospital-discharge-
register-based survey from 1996–2000 covering the US showed that diabetic patients 
over 80 years of age had more foot complications than non-diabetic patients. Foot ulcers 
were present in 1.7% of the diabetic and 0.6% of the nondiabetic patients(Reed 2004). 
The main aetiologic factor was diabetes without LEAD in 132 000 patients, LEAD without 
diabetes in 36 000 patients and both LEAD and diabetes on in 52 000 patients in a 
Californian register-based study of patients with a total of 220 000 incident ischaemic or 
diabetic lower extremity ulcers during 2005–2013 (Humphries et al. 2016). 
2.3.2 AETIOLOGY 
Ischaemia and neuropathy are the most important aetiological factors of diabetic foot 
ulcers. Decreased resistance to infections, , is rather one of factors predicting the 
outcome of diabetic ulcers. (Lepäntalo et al. 2011)Traditionally, ulcers have been 
categorised into aetiological subgroups, but in clinical practice, multiaetiological ulcers 
are common. Forty-three percent of the below-knee ulcers in a population-based study 
were multiaetiolgical based on a clinical examination (Forssgren and Nelzen 2012). A 
diabetic patients probability of developing an ulcer on intact skin can be predicted by 
three variables: reduced sensation in monofilament testing, the absence of at least one 
pedal pulse and a previous history of an ulcer or an amputation (Crawford et al. 2015). 
In specialised diabetic foot clinics in Europe, approximately half of the ulcers are 
neuroischaemic and another half neuropathic. Ischaemia was defined according to ABI 
and toe pressure values and/or absent pulses (Prompers et al. 2007, Gershater et al. 
2009). The absence of both ischaemia and neuropathy is rare in diabetic foot ulcers. In 
Scotland, 70% of 221 consecutive patients visiting a regional specialist foot clinic had 
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absent foot pulses and 82% an absence of sensation in monofilament testing. Only 2% 
of the ulcers that were referred to a specialist foot clinic were in low-risk feet with pulses 
and no neuropathy (Leese et al. 2007). Among 194 patients with diabetic foot ulcers 
evaluated at a specialist clinic, 11 (5.6%) had neither ischaemia nor moderate to severe 
neuropathy (Oyibo et al. 2001). In an English diabetic foot centre, 80% of the patients 
with an ulcer had neuropathy (Jeffcoate et al. 2006). 
Typically, multiple factors influence the causal pathway leading to a non-healing ulcer 
(Reiber 1999). Several different factors, such as foot deformities, external pressure or 
trauma, can initiate ulcers, as can some diseases. Often the cause of an ulcer remains 
unknown. Table 6 is summarises factors causing an ulcer.  
The most common pathway to ulceration has been reported to be the combination of 
neuropathy, minor trauma and foot deformity, which was present in > 63% of the ulcers 
in a study conducted at diabetic foot clinics in Seattle and Manchester. Out of the 
individual factors, oedema, ischaemia and callus formation were present in 37%, 35% 
and 30% of the pathways, respectively. Notably, the frequency of single factors at the 
two centres was different (Reiber et al. 1999). 
Table 6. Examples of factors initiating ulceration 
Causative factors for 
DFU 
specific conditions/incidents causing ulcers 
foot deformation hammer toes, mallet toes, claw toes, prominent metatarsal 
heads charcot, hallux valgus, callosities 
other foot problems paronychia, skin cracks 
external pressure footwear, compression stockings and bandages, plaster 
cast, madrass, bed rails and ends 
trauma abrasion, blisters, insect bites, fractures, luxations, crush 
injuries, wounds, foreign bodies, haematoma, burn, cold, 
chemicals, lacerations, fractures. 
iatrogenic trauma surgical wound, amputation wound, revision wound, 
corrective surgery, arthroplasties, biopsies, foot care, self-
induced ulcers 
diseases erysipelas, fascitis, gout, eczema, malignancy, rare 
ulcerative infections 
2.3.3 CLASSIFICATION 
Several classification methods have been introduced to describe diabetic foot ulcers. 
Many aspects should be considered regarding an ulcer scoring system, such as the field 
of use, i.e. clinical or research, and the characteristics of the patient cohort. Few ulcer 
classifications have been validated or their inter-observer variation assessed 
(Karthikesalingam et al. 2016). The most common classifications are the Meggit-Wagner 
(MW), University of Texas (UT), and WIfI classifications.  
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Table 7. Meggit-Wagner classification. Reproduced with permission from Wagner 
1981. 
0 Pre- or post-ulcerative lesion, completely epithelialised 
1 Superficial full-thickness ulcer limited to the dermis, not extending to the 
subcutis 
2 Ulcer of skin extending through the subcutis with exposed tendon or 
bone  
3 Deep ulcer with abscess or osteomyelitis 
4 Localised gangrene of the toes or the forefoot 
5 Foot with extensive gangrene 
Table 8. The University of Texas wound classification system. Reproduced with 
permission from Armstrong et al. 1998. 
Stage Grade 0 Grade 1 Grade 2 Grade 3 
A 
No 
infection 
or 
ischaemia 
Pre- or post-
ulcerative lesion, 
completely 
epithelialised 
Superficial ulcer, 
not involving 
tendon, capsule 
or bone 
Wound 
penetrating to 
ulcer or tendon 
or capsule 
Wound 
penetrating 
to bone or 
joint 
B 
Infection 
Pre- or post-
ulcerative lesion, 
completely 
epithelialised 
with infection 
Superficial ulcer, 
not involving 
tendon, capsule 
or bone with 
infection 
Wound 
penetrating to 
ulcer or tendon 
or capsule, with 
infection 
Wound 
penetrating 
to bone or 
joint with 
infection 
C 
Ischaemia 
Pre- or post-
ulcerative lesion, 
completely 
epithelialised 
with ischaemia 
Superficial ulcer, 
not involving 
tendon, capsule 
or bone with 
ischaemia 
Wound 
penetrating to 
ulcer or tendon 
or capsule, with 
ischaemia 
Wound 
penetrating 
to bone or 
joint with 
ischaemia 
D 
Infection 
and 
ischaemia 
Pre- or post-
ulcerative lesion, 
completely 
epithelialised 
with infection 
and ischaemia 
Superficial ulcer, 
not involving 
tendon, capsule 
or bone with 
infection and 
ischaemia 
Wound 
penetrating to 
ulcer or tendon 
or capsule, with 
infection and 
ischaemia 
Wound 
penetrating 
to bone or 
joint with 
infection 
and 
ischaemia 
The MW classification was generally used clinically and in research before the University 
of Texas (UT) classification sgained popularity (Wagner 1981) (Table 7). It has not been 
validated, and the description of an ulcer is quite poor in its nuances. 
The UT classification systematically combines ulcer depth with infection and ischaemia 
(Lavery et al. 1997) (Table 8). Increasing grade and stage were associated with midfoot 
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and more proximal lower leg amputations. (Armstrong et al. 1998). The UT and MW 
classifications were compared in a cohort of 197 small ulcers dominated by neuropathy. 
Sixty-seven percent of the ulcers were neuropathic and 26% neuroischaemic. The 
association with lower extremity amputation and ulcer healing was assessed. Lower 
extremity amputation was not defined, but as the amputation rate was 15%, it can be 
concluded that all amputations including toe amputations are probably included. 
Increasing grade in the MW and UT classifications was associated with lower extremity 
amputation, whereas the UT classification stage was also associated with ulcer healing 
(Oyibo et al. 2001). 
As a development to earlier classifications, the WIfI classification quantifies infection 
and ischaemia, in addition to defining the depth of the ulcer and its location in the heel. 
The “W” refers to wound, “I” to ischaemia and the final “fI” to foot infection. Different 
combinations of grades were assessed by experts, and each was evaluated into the 
stages of very low, low, moderate or high risk of amputation (Mills et al. 2014) (Table 
9a-d). A review based on 12 retrospective studies published before the era of the WIfI 
classification concludes that the risk of amputation increases with the higher WIfI stages 
(Van Reijen et al. 2019). The identification of patients who would probably benefit from 
revascularisation was studied with clusters of WIfI combinations formed based on the 
difference in predicted and observed lower extremity amputation rates among patients 
who underwent revascularisation. After revascularisation, the wound characteristics 
were associated with lower extremity amputation (Mayor et al. 2019). 
 
Table 9a. Wound grades in the WIfI classification. Reproduced with permission from 
Mills et al. 2014.  
Grade Ulcer Gangrene 
0 No ulcer No gangrene 
1 Small, shallow ulcer(s) on distal leg or 
foot 
No exposed bone, unless limited to 
distal phalanx 
No gangrene 
2 Deeper ulcer with exposed bone, joint 
or tendon 
Shallow heel ulcer, without calcaneal 
involvement 
Gangrene in toes 
3 Extensive, deep ulcer involving forefoot 
and/or midfoot 
Deep, full thickness heel ulcer 6 
calcaneal involvement 
Extensive gangrene involving 
forefoot and/or midfoot  
Full-thickness heel necrosis ± 
calcaneal involvement 
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Table 9b. Ischaemia grades in WIfI classification. 
Grade ABI ankle mmHg toe pressure mmHg 
0 > 0.8 > 100 > 60
1 0.6–0.79 70–100 40–59 
2 0.4–0.59 50–70 30–39 
3 < 0.39 < 50 < 30 
Table 9c. Infection grades in the WIfI classification. Reproduced with permission from 
Mills et al. 2014 and Lipsky et al. 2012.  
Clinical manifestation of infection Grade IDSA/Pedis 
infection 
severity 
No symptoms or signs of infection 0 no infection 
Local infection (No systemic signs) involving only the skin 
and the subcutaneous tissue, at least 2 of the following:  
Local swelling or induration, 
Erythema > 0.5 to 2 cm around the ulcer, 
Local tenderness or pain,  
Local warmth,  
Purulent discharge, 
Exclude other causes of an inflammatory response (e.g., 
trauma, gout, acute Charcot neuro-osteoarthropathy, 
fracture, thrombosis, venous stasis) 
1 mild 
Local infection (No systemic signs) with erythema >2 cm,  
or involving structures deeper than skin and 
subcutaneous tissues (e.g., abscess, osteomyelitis, septic 
arthritis, fasciitis) 
2 moderate 
Local infection with the signs of SIRS, as manifested by 
two or more of the following: 
Temperature > 38 
> 90 beats/min
Respiratory rate > 20 breaths/min
Elevated infection markers
3 severe 
SIRS systemic inflammatory response syndrome. 
Table 9d. WIfI classification clinical stages based on expert consensus. 
ischaemia 0 ischaemia 1 ischaemia 2 ischaemia 3 
W0 VL VL L M VL L M H L L M H L M M H 
W1 VL VL L M VL L M H L M H H M M H H 
W2 L L M H M M H H M H H H H H H H 
W3 M M H H H H H H H H H H H H H H 
FI0 FI1 FI2 FI3 FI0 FI1 FI2 FI3 FI0 FI1 FI2 FI3 FI0 FI1 FI2 FI3 
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2.3.3.1 LOCATION 
Common classification of ulcer location is lacking. Foot ulcers but also ulcers in the ankle 
and leg are often included in publications. Often the term ‘leg ulcer’ comprises ulcers in 
the foot as well. Generally, leg is the most common location of chronic lower extremity 
ulcers.  In Swedish population-based study 70% of all ulcers located above the ankle, 
and this proportion was 10-14% in diabetic patients (Forssgren and Nelzen 2012). 
However, in diabetic patients the most frequent location is toes, independent of the 
setting. (Prompers 2007, Apelqvist 2011) In Eurodiale study 55% of the ulcers were in 
the toes, 32% dorsally or interdigitally and 48% were plantar. 23% of the ulcers were on 
the plantar forefoot, 22%in plantar midfoot, and 3% on the plantar hind foot, 10% in the 
heel, and 10% on the dorsal or lateral aspect of the foot. 40.9% of the ischaemic and 
55% of the non-ischemic ulcers were plantar. (Prompers et al. 2007, Prompers et al. 
2008) Frequently more than one ulcer is found. In a cohort from diabetic foot clinic, a 
half of 185 feet had more than one ulcer (Aerden et al. 2014) 
2.3.3.2 DEPTH OF THE TISSUE LESION 
The classification of depth is typically reported based on the Texas or Wagner 
classifications, but population-based data on ulcer depth is non-existent. In studies from 
specialist foot clinics and surgical series, 15%–55% of the patients have an ulcer 
extending beyond the subcutis. 
In the Eurodiale study, 53% of the ischaemic ulcers and 36% of the non-ischaemic ulcers 
extended beyond the subcutis and were classified as deep. Sixty-four percent of the UT 
stage D ulcers were deep, whereas 20% of stage A ulcers were deep. (Prompers et al. 
2007, Prompers et al. 2008) In a series from a multidisciplinary clinic, 10% of the ulcers 
were MWgrade 3 and 6% grades 4–5, including both purely neuropathic and 
neuroischaemic ulcers (Gershater et al. 2009). In Scotland, 44% of the ulcers of 221 
consecutive patients visiting a regional specialist foot clinic were superficial, 18% were 
deep and 38% reached bone (Leese et al. 2007). In Helsinki, among 113 patients who 
underwent infrainguinal bypasses for CLTI and foot ulcers, 41% had UT 1C lesions, 19% 
had 1D lesions, 10% had 2C, 2D and 3C lesions each, and 23% had 3D lesions. Fifty 
percent of the patients were diabetics (Söderström et al. 2009). 
The depth in the same material varies at different points in time, as shown by a Swedish 
study: of 475 diabetic patients with a foot ulcer and LEAD, 21% had a Wagner grade 3 or 
higher at inclusion. During the study, a total of 55% reached Wagner grade 3 or higher 
at some stage (Elgzyri et al. 2014). 
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2.3.4 ULCERS AND INFECTION 
 
Infection is defined in IWGDF as invasion and multiplication of microorganisms in host 
tissues that induces a host inflammatory response, usually followed by tissue 
destruction. Diabetic patients have decreased resistance to infections, which correlates 
with glucose balance. A known deficit is the impairment of the bactericidal activity of 
polymorphonuclear cells. Furthermore, the clinical signs of infection may be attenuated. 
 
Neuropathy may aggravate infection by hiding the signs of infection and by altering the 
microcirculation. Autonomic neuropathy in the form of C-fibre dysfunction may diminish 
the inflammatory reaction. Absent local nerve stimulus results in a deficient release of 
inflammatory cytokines. The opening of arteriovenous shunts leads to an increase in 
intravenous and tissue pressure and deep tissue ischaemia. The loss of protective 
sensation leads to the aggravation of the infection before it is noticed. (Richard et al. 
2012.)  
Bacterial biofilms seem to act in most chronic diabetic foot ulcers (James et al. 2008). 
Biofilms may prevent antibiotics from reaching the bacteria. The resistance to antibiotics 
may increase as great numbers of bacteria exchange information during the 
colonisation. In the polymicrobial circumstances of biofilms, one antibiotic is not 
necessarily effective against all pathogens (Mottola et al. 2016). 
 
In clinical practice, a diagnosis is based on a clinical decision, basic laboratory tests, 
radiologic imaging, and close follow-up. For research purposes, the definition of 
infection remains equivocal  (Lipsky et al. 2019). 
The identification of a severe limb-threatening infection needing surgical revision may 
be difficult (Clerici and Faglia 2014, Lipsky et al. 2019). The clinical signs are numerous 
but not specific to infection. In diabetic patients, they are frequently absent or 
diminished (Lipsky et al. 2019). Furthermore, in ischaemic ulcers before and after 
revascularisation, redness, swelling and pain are often present. Patients with a deep foot 
infection may have undiagnosed diabetes in the background. 
 
2.3.4.1 EPIDEMIOLOGY OF DIABETIC FOOT INFECTIONS 
 
Recent epidemiological data on diabetic foot infections is scarce. However, the 
incidence of infections seems to be decreasing, at least in the US. In a US discharge 
register, 1 059 552 diabetic foot infections were identified between 1996 and 2010. The 
total number of diabetic foot infections decreased by 11% and the incidence per 100 
diabetic admissions by 52% within this period. (Duhon et al.2015.) 
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In another American study of 1,666 consecutive diabetics enrolled in a diabetic foot 
prevention and treatment programme in the US, 9% developed a foot infection during 
the mean 27 month follow-up (Lavery et al. 2007). In the Eurodiale study, 591 (58%) of 
the 1,033 patients who completed the study had an infection when seen at a foot clinic 
in 2003–2004. Of the 575 patients with complete data, 199 (35%) patients had a grade 
2 (mild) , 338 (59%) a grade 3 (moderate), and 38 (7%) a grade 4 (severe) infection 
(Prompers et al. 2007, Pickwell et al. 2015). 
Remarkably, diabetic foot infections are usually preceded by a foot ulcer. In the 
aforementioned American cohort of 1,666 diabetics, there was only one case  among 
the 199 foot infections that appeared in which no foot ulcer was present. At enrolment, 
247 patients had an ulcer, and 61% of the patients developed an infection (Lavery et al. 
2006). Most frequently, the infection originates in the forefoot. In a French study, 45% 
of the infected ulcers were in the toes and 34% in the forefoot. Protective sensation, as 
assessed in 278 patients by the 10-g monofilament test, was lost in 252 patients (87%), 
and Charcot foot deformity was present in 39 (13%) (Richard et al. 2011). 
Concomitant ischaemia and infection are common in feet with DFU.  Accordingly, 65% 
of the patients operated on because of an acute infection and osteomyelitis had LEAD 
based on pulse palpation, ABI and tcpO2 (Aragon-Sanchez et al. 2008). In a French Opidia 
study 50-62% of diabetic patients clinical examination revealed LEAD (Richard et al 
2011).On the contrary, of the patients with a diabetic foot infection,16.4% had a 
diagnosis of LEAD in a large material from an American discharge register (Duhon et al. 
2015). Probably register based data ignored comorbidities. The risk of infection has been 
reported to be 2- to 5.5-fold in patients with LEAD compared to those with no LEAD 
(Peters et al. 2015, Lavery et al. 2006, Duhon et al. 2015). 
2.3.4.2 OSTEOMYELITIS 
Osteomyelitis is present in roughly 50%–60% of acute infections requiring in-hospital 
treatment and in approximately 10%–20 % of more chronic infections treated in an 
outpatient setting (Lavery et al. 2007, Richard et al. 2011).  
Osteomyelitis is an infection of the bone, which leads to structural changes and lysis of 
the bone, but regeneration of the bone also occurs. Interestingly, even total 
regeneration of bone that is revealed to be widely lysed in x-ray imaging during 
antibiotic treatment is possible (Jeppesen et al 2015). Osteomyelitis can perform as an 
acute or as a chronic infection.  
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The diagnosis of osteomyelitis is based on the probe-to-bone test, serum infection 
markers (e.g. CRP, procalcitonin, ESR) and plain x-ray imaging. In chronic osteomyelitis, 
leukocyte counts are not necessarily elevated, but CRP and the sediment elevation rate 
are more sensitive. In ambiguous cases, advanced imaging, such as MRI, PET-CT or 
scintigraphy, is recommended. If necessary, to confirm the diagnosis and to direct the 
antibiotic regimen, bone biopsy as well as a microbiological culture and histological 
examinations are useful. The typical culprit bacteria are the same as in soft tissue 
infections and other types of chronic ulcers, the most frequent being staphylococcus 
aureus and beta-haemolytic streptococci. (Lipsky et al.2019.) 
 
2.3.4.3 TREATMENT OF INFECTION 
 
DNA analysis of the bacterial composition of 2,936 chronic wounds revealed that the 
general pathogens in diabetic foot infections are the same as in other chronic ulcers. 
The most abundant bacterial species was staphylococci, followed by pseudomonas, 
corynebacteria and streptococci (Wolcott et al. 2015). 
 
The IWGDF guidelines advocate covering gram-positive cocci such as staphylococcus 
aureus and beta haemolytic streptococcus. The treatment of common gram-negative 
bacteria and possibly obligate anaerobes is suggested in chronic ulcers with a moderate 
or severe infection, with severe ischaemia or a history of treatment with antibiotics 
(Lipsky et al. 2019). Worldwide, multiresistant bacteria have become more common. 
However, when appropriately treated, the clinical infection seems not to differ from 
other bacteria (Uckay et al. 2015). 
Revision surgery is often mandatory in an acute infection because of soft tissue 
destruction, but in the chronic form, conservative long antibiotic therapy may achieve 
results comparable to those of revision surgery combined with shorter antibiotic 
therapy after clinical selection of patients to each treatment (Aragon-Sanchez et al. 
2008, Lazaro-Martinez et al. 2014, Tone et al. 2015). The IWGDF recommends a 1–2-
week and a maximum of 3–4-week antibiotic regimen (Lipsky et al. 2019). The presence 
of LEAD may both prolong the antibiotic regimen and cause the failure of conservative 
treatment (Zeun et al. 2015, Aragon-Sanchez et al. 2008). After surgery, only a short 
antibiotic regimen is recommended (Lipsky et al.2019). 
 
Regarding osteomyelitis, conservative treatment can be considered in cases with no 
sepsis and no considerable soft tissue destruction, if the patient prefers nonsurgical 
treatment and tolerates a long-lasting antibiotic regimen. The high risks of surgery also 
favour conservative treatment (Lipsky et al. 2019). 
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Surgical intervention should be considered if osteomyelitis or an accompanying soft 
tissue infection is progressive, the bone is no longer covered by soft tissue or is severely 
destructed, long antibiotic treatment is not feasible, or the patient prefers 
interventional treatment and a shorter antibiotic regimen (Lipsky et al. 2019). Surgery 
aims at removing the infected bone. Minor amputations are frequently performed. In 
the absence of acute infection, some specialists prefer “conservative” surgery: 
arthroplasties, sesamoidectomies, bone curettages and metatarsal head resections. 
Corrective foot surgery, such as resection of bony prominences and tenotomies, can be 
performed at the same time (Aragon-Sanchez et al. 2015). 
2.3.4.4 OUTCOME OF DIABETIC FOOT INFECTION 
Severe infections are seldom cured without surgery (Tan et al. 1996). Delayed surgery 
may result in more proximal amputations (Faglia et al. 2006). Repeated operations are 
typical for infections, and the numbers of minor and major amputations are high (Nehler 
et al. 1999, Commons et al. 2015, Pickwell et al. 2015, Clerici and Faglia 2014). Severe 
infections frequently result in transmetatarsal (TMT), Lisfranc and Chopart amputations 
(Clerici and Faglia 2014, Troisi et al. 2016). However, at least in the US, the number of 
diabetic foot infections requiring in-hospital care has decreased. In 1996, 33.2% of 
diabetic foot infections resulted in a minor or major amputation, whereas the 
corresponding in 2010 was 17.1% (Duhon et al. 2015). 
The incidence of amputation is related to the severity of infection (Lavery et al. 2007, 
Pickwell et al. 2015). Indeed, of 27 patients with a severe infection, 30% underwent a 
major (leg) amputation and 40% a foot-level amputation, whereas the respective figures 
for the 52 patients with 52 a moderate infection were 23% and 23% and for the 71 
patients with mild infections 2.8% and 0% (Lavery et al. 2007). The combination of 
infection and ischaemia, in particular, predicts poor wound healing and an increased 
number of major amputations (Prompers et al. 2008, Cull et al. 2014, Armstrong et al. 
1998, Spillerova et al. 2015).  
Revascularisations are infrequently reported in patients with a diabetic foot infection. 
In a French multicentre survey, only 9% of the patients underwent revascularisation, 
even though roughly 50% of the patients had signs of LEAD (Richard et al. 2012). In 
contrast, a study from an Italian specialised centre reported 64 revascularisations on 65 
patients with absent distal pulses out of a total 106 diabetic patients with deep 
infections and abscesses. One patient with no pulses underwent emergency above-the-
knee amputation because of sepsis (Faglia et al. 2006). Later, the same centre reported 
83 Chopart amputations, 31 because of an abscess and 32 due to wet gangrene. Of the 
total 83 limbs, 64 were ischaemic and underwent revascularisation. Of patients with and 
without CLTI, 28% and 26%, respectively, underwent a major amputation (Clerici and 
Faglia 2014). 
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2.4 TREATMENT OF SEVERE TISSUE DEFECTS 
 
The incidence of severe DFU is not exactly known, but in survey covering all of the US 
from 2001–2010, 2.5 million hospital admissions for DFU were observed, which 
represented 0.6% of all hospital admissions. Of the DFU admissions, 16.5% were for 
amputations, 35% of which were major and 65% minor amputations. In 8.5% of the 
cases, the admissions were for revascularisation, 43.5% of which were open, 51.1% 
endovascular and 5.4% hybrid (Skrepnek et al. 2014). In another nation-wide American 
survey of 625.2 million emergency unit admissions during 2006–2010, 10 19 861 
admissions were for diabetic foot ulcers (Skrepnek et al. 2015).  
A remarkable number of ulcers, seen at specialised multidisciplinary diabetic foot 
centres and vascular surgical centres are deep and infected. In a Swedish cohort from a 
multidisciplinary diabetic foot clinic, 21% of the ulcers were grade Wagner 3, deep and 
infected at inclusion. Furthermore, 55% of the ulcers fulfilled Wagner 3 criteria at some 
point (Elgzyri et al. 2014). In the Eurodiale study, 35% of the non-ischaemic and 63% of 
the ischaemic diabetic ulcers reached beyond the subcutis. Moreover, 58% of the 
Eurodiale patients had an infection (Prompers et al. 2007). 
Large tissue defects are due to osteomyelitis, an abscess or gangrene, which often lead 
to proximal foot amputations if not severe enough to necessitate a major amputation 
(Clerici and Faglia 2014). In a study of 210 diabetic foot infections with an abscess, 45% 
of the patients underwent TMT, Chopart or Lisfranc amputation. A further 8.5% 
underwent a major amputation (Faglia et al. 2012). In an American study, 16% of the 
minor amputations related to vascular reconstruction were ray amputations and 21% 
TMT amputations (Sheahan et al. 2005). In the Eurodiale study, 34% were ray 
amputations and 11% midfoot amputations (Van Battum et al. 2011). 
In and Italian study, diabetic patients had a 19-fold risk of minor amputation compared 
to the general population (Lombardo et al. 2014). Diabetic patients with LEAD had a 3.4-
fold risk of minor amputation compared to nondiabetic patients who had been admitted 
to hospital due to LEAD (Hong et al. 2011).  
 
2.4.1 REVISIONS AND MINOR AMPUTATIONS 
 
Surgical debridement or wound revision comprises operations in which dead tissue, 
including bone, scar and debris, is removed with instruments, leaving vital tissue intact. 
Depending on the extent of the procedure, it can be performed at the bedside or in a 
surgical theatre. Amputations and corrective resections are usually reported separately 
from debridements and revisions.  
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In an Italian single-surgeon material of 1,407 infra-inguinal vascular reconstructions, 
14% and 17.6% of the feet of a total of 705 diabetic patients and 10.1% and 12.9% of 
the feet of a total of 702 nondiabetic patients were preoperatively drained or debrided, 
respectively. Within a 30-day recovery period, diabetic patients underwent 
debridement significantly more often than non-diabetic patients: 5.1% of the diabetic 
patients needed drainage and 21.4% debridement, whereas the respective rates were 
3.4% and 9.5% for nondiabetic patients. (Ballotta et al. 2014). The indication for 
revascularisation was ulcer in 41% of the diabetic patients and in 35% of the non-
diabetic patients, while gangrene was the indication in 39% and 34% and rest pain in 
19.1% and 31.5% of the diabetic and non-diabetic patients, respectively (Ballotta et al. 
2014). In a cohort of 701 plantar forefoot ulcers, 558 healed without amputation below 
or above the ankle. Foot surgery was performed on 172 (30%) of the patients whose 
ulcers healed. Revision was enough in 70% of the patients, and 30% needed resection . 
Only one patient out of 172 received a skin graft (Örneholm et al. 2015). 
Minor amputations of the foot include toe, ray and TMT amputations as well as Lisfranc 
amputation between the tarsal and metatarsal bones, and Chopart amputation in which 
the calcaneus and talus remain after removal of tarsal bones. Amputations in emergency 
situations may be performed with a freestyle approach – in other words, removing all 
non-vital tissue and leaving only viable tissue not adhering to the classical amputation 
levels.  
In non-infectious circumstances, the aim is usually primary closure, but in infectious 
circumstances, the foot or toe amputation wound is commonly left open. It may be 
either closed later or left open to heal with conservative means (Berceli et al. 2006). 
Repeated debridement procedures and foot-level reamputations are frequently needed 
(Berceli et al. 2006, Beaulieu et al. 2015, Kono and Muder 2012, Blume et al. 2007). 
Negative wound pressure therapy probably promotes healing of open surgical wounds 
after partial foot amputations (Armstrong and Lavery 2005). 
Following revascularisation on 554 patients for CLTI, the ulcers healed in 440 patients. 
Ninety-three out of 440 diabetic patients had toe or ray amputations and 254 a TMT 
amputation. Neither minor nor major amputation was necessary in 93 of the 440 
patients: 35 healed with dressing changes, 30 needed split thickness skin graft (STSG), 
16 had ulcerectomies and 12 had bone removals (Faglia et al. 2009).  
In another study a toe amputation rate of 19.8%, a TMT amputation rate of 7.7% and a 
major amputation rate of 2.5% were observed after revascularisation among diabetic 
patients and the corresponding rates of 16.2%, 6.3% and 1.3%, respectively, among 
nondiabetic patients (Ballotta et al. 2014). 
In the US, mortality has been reported to be 17.0%, 29.1% and 49.0% at 1, 3 and 5 years 
after initial minor amputations, respectively (Glaser et al. 2013). 
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2.4.2 SPLIT THICKNESS SKIN GRAFT 
STSG is placed on granulation tissue or muscle, whereas tendon and bone are an 
unfavourable bed for STSG. 
As a procedure, skin grafting is simple and can often be performed under local 
anaesthesia even in the office. Skin grafting may be advantageous regarding healing 
times and the length of hospital stay. Healing in diabetic patients was achieved in an 
average of 28 days after split-thickness skin grafting compared to 122 days after 
conservative treatment. The mean hospital stay also decreased by 12 days. (Mahmoud 
et al. 2008.) According to a review article, 65%–95% of the DFUs were 90% covered by 
the primary split-thickness skin graft within 2 to 8 weeks, depending on the cohort. The 
surface area of the ulcers varied from  1 cm2 to 600 cm2 (McCartan et Dinh 2012). 
The success rate of STSG in diabetic patients has been reported to be similar compared 
to non-diabetic patients with chronic lower leg ulcers of considerable size (66.3 cm2± 
87.5 cm2 in diabetic and 116.3 ± 216.2 in non-diabetic patients). An endovascular or 
open revascularisation preceded skin grafting in 37 of the 94 patients in the cohort. Of 
ulcers, 67% were plantar. Primary healing succeeded in 44/66 (67%) ulcers among 
diabetic patients and in 21/28 (75%) ulcers among nondiabetic patients during the 
median 6.5-month (0.5-52) follow-up. The mean ulcer healing time in successful cases 
was 7.2 ± 4.7 weeks in diabetic patients and 8.8 ± 6.5 weeks in nondiabetic patients, 
with no significant difference between the groups. (Rose et al. 2014.) In another study, 
in 66 out of 83 consecutive diabetic patients, a foot-level amputation was covered with 
STSG (Ramanujam et al. 2010). All but four had a prior infection. The median time to 
complete epithelisation was 6.9 weeks (1.7–31.5 weeks): 6.4 weeks in patients with 
uneventful healing and 9.5 weeks in 29 patients with complicated healing. Twenty-three 
needed regrafting and 21 another procedure, such as drainage of an abscess or resection 
of bone in addition to regrafting.   
2.4.3 LOCAL FLAPS 
Literature concerning local flaps in ischaemic diabetic feet is scarce. In a systematic 
review, a lack of high-quality evidence on the treatment of diabetic foot tissue defects 
with local flaps was observed (Ramanujam et al. 2018). According to the review, 76% of 
the ulcers healed during an average of 2-year follow-up. However, the material was 
heterogeneous. The publications included in the review were not focused on the role of 
vascular disease or other comorbidities. The largest cohort presented 67 patients with 
a deep ulcer, an ulcer on a bony prominence or recurrent ulcer which was revised and 
covered with a local random flap in a single operation. The ulcers were non-infected and 
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tcpO2 was over 30 mmHg. Nine patients had undergone revascularisation. At 20 weeks, 
96% of the ulcers had healed. The most common postoperative complications were 
wound dehiscence (18%), postoperative infection (12%), slough (9%), fracture and the 
recurrence of Charcot foot (6%). Fifty-four percent of the patients had no complications. 
A history of revascularisation or non-palpable pulses were not associated with healing. 
However, the cohort was small. Only the depth of the ulcer was significantly associated 
with healing and the mean number of bed days (Blume et al. 2002). 
Pedicled perforator flaps and local random flaps alike tend to have a high risk of failure 
in patients with DFU and LEAD (Baumeister et al. 2003, Koh et al. 2018). However, 
distally based musculus peroneus brevis flaps were successfully used for covering heal 
ulcers in diabetic patients with only the fibular artery open in the leg (Nguyen et 
Rodriguez-Collazo 2019). Concentrated bone marrow aspirate, negative pressure 
wound therapy (NPWT), bilayer wound matrix, and external fixation were used as 
adjuvants. STSG was delayed. All flaps survived the 18-month follow-up.  
A study comparing pedicled muscle flaps and FTT found no difference in wound healing, 
flap success or leg salvage between diabetic and non-diabetic patients (Ducic et al. 
2011). On the contrary, healing times were longer and reoperations performed more 
often, and long-term survival was shorter in diabetic patients. However, the report only 
included a cursory examination of vascular disease – adequate vascular supply was 
required, and 9 revascularisations were performed during the study period, but more 
details on the presence of vascular disease in the study population were not given. 
2.4.4 OTHER TREATMENTS 
In complex ulcers, multiple methods and repeated procedures are typically necessary in 
order to achieve healing (Nguyen et Rodriguez-Collazo 2019). In a specialised centre in 
the US, the most frequent methods used for treating ulcers in diabetic Charcot feet were 
skin substitutes (32%) and skin grafts (21%). Primary closure was attempted in 15% and 
delayed closure in 18% of the patients. Furthermore, local flaps were used in 8% and 
free tissue transfer in 7% of the ulcers. Fifty percent of the ulcers healed, and 32% of the 
patients underwent major amputation during follow-up. (Sinkin et al.2015.) 
Many promising methods for the treatment of DFU with or without LEAD have been 
suggested. Yet, little convincing proof of the efficacy of such methods as growth factors, 
skin substitutes, engineered biological wound dressings or HBO treatment has been 
published (Game et al. 2016, Conte et al 2019). According to a systematic review, some 
evidence exists on the benefit of hyperbaric oxygen therapy in healing among diabetic 
patients with ischaemia (Stoekenbroek et al. 2014). A pooled analysis showed that skin 
substitutes may be advantageous in total closure of a DFU. However, the role of 
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ischaemia was not discussed (Santema et al 2016). NPWT may increase the wound 
healing rate and reduce the healing time in postoperative wounds and DFU (Liu et 
al.2018). Intermittent pneumatic compression has been used safely on diabetic and 
ischaemic limbs. Bias in the studies reporting enhanced wound healing and improved 
limb salvage cannot be excluded (Conte et al. 2019). Offloading is an elementary part of 
the treatment of DFUs and should always be applied as appropriate (Bus 2016).  
 
2.5 MAJOR AMPUTATIONS 
 
Lower limb major amputation is usually defined as amputation above the ankle level. 
The established amputation levels are below-knee, through-knee, above-knee and hip 
exarticulation. The most common are below-knee and above-knee amputations. A life-
threatening infection, irreversible acute ischaemia, intolerable rest pain and major 
tissue destruction of the foot due to gangrene, ulceration or osteomyelitis necessitate 
major amputation in a diabetic patient with LEAD. (Gooden et al. 1997.)  
 
2.5.1 EPIDEMIOLOGY  
 
In Finland, the incidence of major amputations has been decreasing according to 
population-based studies, but recent data has not been published (Ikonen et al. 2010, 
Eskelinen et al. 2006, Eskelinen et al. 2001) (Table 10). According to Finnish Institute for 
Health and Welfare statistics, the absolute number of all patients undergoing 
transfemoral amputation is quite stable (734 in 2008 and 783 in 2018), and transtibial 
amputations are slightly decreasing (417 in 2008 and 344 in 2018) In Europe, a major 
trend is decrease in the incidence of major amputations in diabetic patients (Lopez-de-
Andres et al. 2015, Lombardo et al. 2014, Jørgensen et al. 2014). The incidences and 
incidence rates are not directly comparable between the studies. (Table 10). 
The amputation rate in type 1 diabeticpatients seems to be higher than in type 2 diabetic 
patients. Type 1 diabetic patients tend to undergo amputation at a younger age (Lopez-
de-Andres et al. 2015). In a Swedish population-based register study conducted in 
2000–2004, below-knee major amputations were 19.5-fold more frequent and 
above-knee amputations 87-fold more frequent among type 1 diabetic patients than 
among the matched general population (Jonasson et al. 2008). According to a 
Scottish survey, the amputation rate was higher among type 1 than type 2 diabetic 
patients; 1.1% of type 1 s and 0.7% of type 2 diabetic patients had ever undergone a 
major amputation by 2016 (Scottish Diabetes Survey 2016). In Sweden, 11% of the 
women and 21% of men with type 1 diabetes had undergone a minor or major 
amputation by the age of 65 (Jonasson et al. 2008). 
According to register-based population studies, the difference in rates of major 
amputation between diabetic and nondiabetic patients seems not to have changed 
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remarkably with time. Diabetic patients underwent 5,047 of the total 9,481 major 
amputations in Finland during 1997–2007 (Ikonen et al. 2010). In Southern Finland, 48% 
of the patients with a major amputation had diabetes, and 39% had both diabetes and 
CLTI in 2000 (Eskelinen et al. 2004). In a Finnish population-based study, the relative risk 
of major amputation was 7.4-fold (95% CI 7.2–7.7) for diabetic versus nondiabetic 
patients (Ikonen et al. 2010). In an Italian population, the age-, sex- and calendar-year-
adjusted relative risk of major amputation was 6.4 in diabetic compared to nondiabetic 
patients (Lombardo et al. 2014).  
The amputation rate of men with LEAD and diabetes was 1.5 times higher than men with 
LEAD alone and 5 times higher than men with diabetes without LEAD. In women, 
patients with LEAD with or without diabetes had amputation rates 2.5 times higher than 
patients with diabetes alone (Humphries et al. 2016a).  
 
2.5.2 REAMPUTATION  
 
Contra- and ipsilateral minor and major amputations are common (Glaser et al. 2013, 
Izumi et al. 2006). In a single institution, 144 patients who underwent above-knee 
amputation, 431 who underwent below-knee amputation and 1,140 patients who 
underwent a minor amputation were identified between 1998 and 2010. Seventy-seven 
percent of the patients had diabetes. Of those initially undergoing a major amputation, 
8.5% had an ipsilateral major amputation and 11.5% a contralateral amputation by 5 
years. Of those initially undergoing a minor amputation, 14% subsequently had an 
ipsilateral major amputation. Of those undergoing an initial minor amputation, 20% had 
an additional subsequent ipsilateral minor amputation by 5 years (Glaser et al. 2013.) 
In Finland, 10% of 210 patients with major amputation had an ipsilateral above-knee 
reamputation, whereas 24% had a contralateral major amputation during the study 
follow-up period of 1998–2006. Fifty percent of the patients had diabetes (Remes 2010). 
 
2.5.3 MORTALITY AFTER AMPUTATION  
 
Mortality after major amputation is high. The patients are mostly in a poor general 
condition, not tolerating vascular surgery or being candidates for prosthetisation, 
some being bedridden. In a Finnish study, the one-month mortality was 21% and one-
year mortality 52%. The annual risk was 7.4-fold compared to the general population 
in Turku (Remes 2010). In Southern Finland, 39% of patients with below-knee 
amputation and 61% of those with above-knee amputation died during the first year 
after major amputation. Roughly 50% of the patients had diabetes (Eskelinen et al. 
2004). In the US, 19.2%, 48.7% and 61.3% died at 1, 3 and 5 years, respectively, after 
the initial major amputation (Glaser et al. 2013).  
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2.5.4 AMBULATION AFTER MAJOR AMPUTATION 
Prosthetisation is successful only in a minority of patients after major amputation due 
to LEAD and diabetes. In a Finnish study, 119 out of 210 LEAD patients who underwent 
major amputation survived longer than one month and were discharged from the 
hospital, 68 to institutional care and 51 to their home. Thirty-nine (33%) of the 
discharged patients became prosthesis users (Remes et al. 2009). 
Similar percentages were presented one year after major amputation in 2000 in 
Southern Finland. Twenty-two percent of all patients and 43% of those alive at one year 
had received a prosthesis. Of the below knee amputees alive at 2 months, 68% received 
a prosthesis within 1 year, compared to the 19% of above knee amputees. Ischaemia or 
diabetes were the cause in 95% of the amputations. (Eskelinen et al. 2004.) In Sweden, 
among 217 transtibial amputees with LEAD and a mean age of 77 years, 55% were fitted 
with a prosthesis (mean age 75 yrs) and, after a standardised rehabilitation programme, 
64% achieved good function within six months, representing 31% of the original cohort. 
Fifty-one percent of the original cohort and 52% of the prosthetised patients had 
diabetes. (Johannesson et al. 2010.)  
Predictors of prosthesis use after rehabilitation were good ambulation and functional 
independence, good cognition, absence of phantom pain and lower leg amputation. Risk 
factors for institutionalisation were old age, living alone, bilateral amputation or above-
knee amputation. Similar reasons prevented prosthetisation. Furthermore, 
comorbidities such as hemiplegia, paraplegia, uraemia, dementia and alcohol abuse 
prevented prosthetisation. (Van Eijk et al. 2012.) In an American study, age > 60 years, 
bilateral amputation and end-stage renal disease were associated with the failure of 
ambulation in a retrospective review of 627 major amputations in 553 previously not 
completely bedridden diabetic and/or LEAD patients (Taylor et al. 2005). 
49 
Table 10. Incidence of major amputations in diabetic patients, with a comparison to 
non-diabetic patients. 
Study Patients Incidence 
1 
Incidence 
2 
Population Other 
Winell et al. 
2013 
Finnish 
diabetic 
population 
10.2 in 
1997–
2000 
7.3 in 
2004–
2007 
Finnish 
population 
100 000 
person 
years 
First major 
amputation, 
standardised, 
population 
corrected incidence 
Ikonen et 
al. 2010 
Finnish 
diabetic 
population 
94.4 in 
1997 
48.3 in 
2007 
Finnish 
diabetic 
population / 
100 000 
Age and sex 
standardised, first 
major amputation 
Ikonen et 
al. 2010 
Finnish 
nondiabetic 
population 
10.7 in 
1997 
8.0 in 
2007 
Finnish 
nondiabetic 
population 
/100 000 
Age and sex 
standardised, first 
major amputation 
Alonso-
Moran et al. 
2014 
Type 2 
diabetic 
population of 
Basque 
country 
0.1% in 
2007 
0.08% in 
2011 
type 2 
diabetic 
population 
of Basque 
Country 
Any major 
amputation 
Lombardo 
et al. 2014 
Diabetic 
population 
114.5 in 
2003 
79.3 in 
2010 
Italian 
diabetic 
population 
/100 000  
Persons with major 
amputation /year, 
crude rate 
Lombardo 
et al. 2014 
Non-diabetic 
population 
4.8 in 
2003 
4.2 in 
2010 
Italian 
nondiabetic 
population 
/100 000  
Persons with major 
amputation /year, 
crude rate 
Lombardo 
et al. 2014 
Diabetic 
population 
48.4 in 
2003 
36.1 in 
2010 
Italian 
diabetic 
population 
/100 000 
Persons with major 
amputation / year, 
Italian population 
age and sex 
standardised 
Lombardo 
et al. 2014 
Non-diabetic 
population 
5.3 in 
2003 
4.2 in 
2010 
Italian 
nondiabetic 
population 
/100 000 
Persons with major 
amputation /year, 
Italian population 
age and sex 
standardised   
Kennon et 
al. 2012 
Diabetic 
population 
1.87 in 
2004 
1.11 in 
2008 
Diabetic 
population 
of 
Scotland/1,
000 
Kennon et 
al. 2012 
Diabetic 
population 
6.73 in 
2004 
443 in 
2008 
Population 
of Scotland 
/100 000 
Li et al. 
2012 
US diabetic 
population 
11.2 in 
1996  
3.9 in 
2008 
diabetic 
population 
of US/1000 
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Goodney et 
al. 2013 
US diabetic 
medicare 
patients with 
LEAD 
 15.8 
in2007–
2009 
/10 000 
Medicare 
patients 
with LEAD 
 
Goodney et 
al. 2013 
US 
nondiabetic 
medicare 
patients with 
LEAD 
 6.8 in 
2007–
2009 
/10 000 US 
medicare 
patients 
with LEAD 
 
Humphries 
et al. 2016 
Diabetic 
patients with 
LEAD 
41 in 2005 31 in 2008 /1 000 000 
total 
population 
in California 
First major 
amputation 
Humphries 
et al. 2016 
Diabetic 
patients 
without LEAD 
 5 in 2005  6 in 2008 /1 000 000 
total 
population 
in California 
First major 
amputation 
Humphries 
et al. 2016 
Nondiabetic 
patients with 
LEAD 
 32 in 
2005 
 17 in 
2008 
/1 000 000 
total 
population 
in California 
First major 
amputation 
Humphries 
et al. 2016 
Diabetic 
patients with 
LEAD 
31 in 2009 31 in 2011 /1 000 000 
total 
population 
in California 
First major 
amputation 
Humphries 
et al. 2016 
Diabetic 
patients 
without LEAD 
6 in 2009  6 in2011 /1 000 000 
total 
population 
in California 
First major 
amputation 
Humphries 
et al. 2016 
Nondiabetic 
patients with 
LEAD 
17 in 2009 19 in 2011 /1 000 000 
total 
population 
in California 
First major 
amputation 
Jørgensen 
et al. 2014 
Male diabetic 
patients 
0.25 in 
men over 
50 in 2011 
0.56 in 
men over 
70 in 2011 
/1,000 
patient 
years 
First major 
amputation, 
patients followed at 
Steno diabetes 
center 
Jørgensen 
et al. 2014 
Female 
diabetic 
patients 
0.21 in 
women 
over 50 in 
2011 
0.41 in 
women 
over 70 in 
2011 
/1,000 
patient 
years 
First major 
amputation 
patients followed at 
Steno diabetes 
center 
Larsson et 
al. 2008 
Diabetic 
patients  
16  
1982–
1986 
6.8 
1997–
2001 
/100 000 
inhabitants 
Two hospital 
districts, primary 
major amputations 
 
US United States, LEAD lower extremity arterial disease. 
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2.6 REVASCULARISATION FOR CRITICAL LIMB THREATENING ISCHAEMIA 
(CLTI) 
Revascularisation without delay down to an artery feeding the affected area the in a 
severely ischaemic leg with a tissue defect is crucial to prevent amputation in diabetic 
and nondiabetic patients alike (LoGerfo and Coffman 1984, Norgren et al. 2007, 
Noronen et al. 2017, Sheahan et al. 2005, Setacci et al. 2013). In the presence of less 
pronounced ischaemia, revascularisation is often necessary to promote healing, 
especially in diabetic patients with multifactorial aetiology, but little evidence exists on 
the proper timing of revascularisation. However, revascularisation is not always possible 
or advantageous for the patient. (Taylor et al. 2009, Chung et al. 2006, Nicoloff et 
al.1998, Oresanya et al. 2015.) Thus, we need to balance between the optimum of 
aiming at the best possible circulation and the consequences of procedures that are 
needed to reach this aim. Indeed, the recent ESVS guideline emphasises evidence-based 
revascularisation (EBR). The guideline proposal for a practical tool, PLAN, includes 
Patient risk estimation, Limb staging and a consideration of the ANatomic pattern of 
disease (Conte et a. 2019). 
In addition to selecting the treatment path, including conservative treatment and 
amputation, according to the general condition of the patient, what is fundamental is 
that the delay is minimised and that after care and rehabilitation are maximised 
(Noronen et al 2017, Taylor et al. 2009, Nicoloff et al. 1998). The desired outcome and 
the patient’s preference need to be defined: ulcer healing, avoidance of major 
amputation, survival, survival with a healed ulcer, independent living, independent 
mobility, good quality of life, etc. When aiming for one outcome, another can be 
threatened. Extensive procedures to overcome ischaemia or lengthy treatment to close 
a wound may threaten the patients’ general condition or life (Nicoloff et al. 1998, Taylor 
et al. 2009 Seabrook et al. 1999). The characteristics (depth, size, infection) and location 
of the lesion, the technical possibilities to perform revascularisation (inflow, outflow, 
conduit), the patient’s morbidity (general condition and procedure risks, mobility, 
nephropathy, dementia, coagulation disorders, oedema) have to be considered.  
Factors not advocating revascularisation, open or endovascular, include an inability to 
use the leg for standing or moving to a wheelchair, an irreversibly poor general 
condition, a non-salvageable foot and life-threatening sepsis. High anaesthetic risks, 
severe nephropathy and poor technical conditions for revascularisation (inflow, outflow, 
conduit) should be weighed in relation to all risks. (Taylor et al. 2009, Oresanya et al 
2015, Davies and El-Sayed 2015, Vierthaler et al. 2015, Suckow et al. 2012, Conte et al. 
2019.) 
Nehler et al. presented a good scheme to start with. If more than one of three fields – 
patient comorbidity, technical issues regarding revascularisation or ulcer characteristics 
– are compromised, the patient may not be a good candidate for vascular reconstruction
(Nehler et al. 2003). In the end, the decision is individual.
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2.6.1 SURGICAL REVASCULARISATION 
 
Open revascularisation techniques comprise endarterectomy, angioplasty and arterial 
bypass. Endarterectomy, the removal of obstructive material and the inner layer of the 
artery through arteriotomy, is a common procedure on the femoral artery. 
Angioplasties, using a piece of vein or artificial material, are used to close an arteriotomy 
in order to prevent the narrowing of a vessel. Open angioplasty is also used to repair an 
obstruction in a vascular bypass graft. Occlusions throughout the arterial tree are 
suitable for bypass surgery, provided that an outflow artery exists. The TAP (target 
arterial path) concept and GLASS classification of the arterial disease pattern introduced 
by the Global Vascular Guideline (Conte et al. 2019) are practical tools also applicable in 
research for planning the treatment of vascular disease. 
In diabetic patients, multilevel and distal disease are typical. Infrapopliteal and pedal 
reconstructions are usually necessary. Whenever proximal arteries are spared from 
occlusive lesions, inflow can be taken from the popliteal or, more rarely, from the crural 
artery (Saarinen et al. 2016). In a series of 1,032 bypasses to the ADP, inflow was 
achieved from the popliteal artery in 53% of the cases (Pomposelli et al. 2003). For 
a short bypass, a shorter vein is adequate, the operation time is often more limited, and 
graft occlusions may be less frequent than in longer grafts (Saarinen et al. 2016). 
A single-segment great saphenous vein (SSGSV) in the best choice of graft for bypass 
surgery, followed by other autologous veins in the absence of SSGSV (Arvela et al. 2012). 
Autologous vein grafts have a good resistance to infections, which is a considerable risk 
in patients with a tissue lesion. In a consecutive series of bypass operations to treat CLTI 
from our clinic, a SSGSV was used in 74% of the operations (Arvela et al. 2010). Other 
options are the lesser saphenous vein and arm veins. A spliced vein is an alternative in 
the absence of a single-segment vein. In the absence a vein conduit, prosthetic material, 
homografts, umbilical vein or biosynthetic material, for example, are available. 
Prosthetic material should be avoided in the presence of an infection. A prosthetic graft 
infection after bypass has been observed in 6% of patients with claudication, in 15% with 
rest pain, in 13% with an ulcer, and 33% with gangrene (Brothers et al. 2009). In a 
multivariate analysis of 496 prosthetic bypass grafts implanted during 2001–2010, 
female sex, diabetes mellitus, active infection and redo bypass were predictive for graft 
infection, and graft infection predicted major amputation (Siracuse et al. 2013). Foot 
infection was more common in diabetic than in nondiabetic patients undergoing 
vascular reconstruction for CLTI. Infection was associated with major amputation and 
the length of hospital stay (Mayor et al. 2018). 
Poor runoff compromises the outcome. Among patients with poor run-off, 70% had 
graft loss, amputation or death six months after infra-inguinal bypass for ischaemic 
tissue loss (Seeger et al. 1999). In the absence of an outflow artery, a bypass to an FTT 
has been successful, in rare cases, without any other outflow (Tukiainen et al. 2000). 
Non-occlusive, obstructive lesions may not be good candidates for bypass surgery, as 
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the remaining flow steals from the graft, which easily occludes. Endovascular 
procedures are ideal for these lesions.  
According to the national Finnvasc register, the 30-day graft thrombosis rate was 9% 
after vascular surgical revascularisation in diabetic patients and 10% in nondiabetic 
patients with CLTI (75% ulcer or gangrene) during 1990–1999 (Virkkunen et al. 2004). 
Diabetic patients seem to have at least as good an outcome for vascular grafts than 
nondiabetic patients (Wölfle et al. 2003, Ballotta et al.2014, Panneton et al. 2000).  
Over time, more than 20% of bypasses occlude. The graft occlusion rate is lowest after 
bypass with a SSGSV conduit and is higher when arm veins, a spliced vein or prosthetic 
material is used (Conte et al. 2019, Arvela et al. 2012). In a series of 1,100 patients, 818 
SSGSVs had better one- and three-year primary patency (74.4% and 67.1%, respectively) 
and limb salvage (88.9% and 86.9%, respectively) than 291 other vein conduits (53.7% 
and 43%; 83% and 77.2%), including lesser saphenous vein, arm vein and spliced vein 
conduits (Arvela et al. 2012). In infrapopliteal bypasses for CLTI, arm veins were superior 
to prosthetic grafts. The rimary patency at three years was 28.3% in arm veins, and 9.6% 
in prosthetic grafts, and the respective limb salvage 75.0% and 57.1 (Arvela et al. 2010). 
Good long-term results are achievable even after inframalleolar bypasses. In a series of 
352 inframalleolar bypasses for CLTI performed between 2002 and 2013 (prevalence of 
diabetes 69%), primary and secondary clinical patency was 81.0% and patency at 10 
years 68.4%. The popliteal artery as the inflow artery (n = 194) was associated with 
superior patency in comparison to bypasses originating from the femoral artery (n = 
158). The limb salvage rate at 1, 5 and 10 years was 78.6%, 72.0% and 67.2%, 
respectively. Limb salvage was equal in patients with and without diabetes (p =.460). 
The amputation-free survival rates at 1, 5 and 10 years were 58.4%, 29.8% and 12.8%, 
respectively (Saarinen et al. 2016). 
2.6.2 ENDOVASCULAR TREATMENT 
Endovascular treatment is performed through a percutaneous arterial puncture, ante- 
or retrograde to the target segment, usually under local anaesthesia and pain 
medication if necessary. Stenosed or occluded arterial segments are passed with a 
guidewire and dilated with a balloon catheter. Stents are placed to prevent recoil or to 
align the damaged arterial wall after dissection. Subintimal recanalisation, 
recanalisation devices, retrograde access and access via collaterals are methods that are 
evaluated for more successful recanalisation. Stents, drug-eluting stents, drug-coated 
balloons and stent prostheses are suggested to prolong the patency. (Conte et al 2019.) 
In diabetic patients with a tissue lesion, the technical success rate has been 85%–93% 
(Alexandrescu et al. 2009, Faglia et al. 2012, Uccioli et al. 2010, Jämsen et al. 2002, 
Ghoneim et al. 2014, Higashimori et al. 2016).  
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Most iliac artery revascularisation procedures are currently performed by endovascular 
means. The main obstacles for successful endovascular therapy are common femoral 
artery disease and long calcified lesions of the SFA and crural vessels (Gargiulo et al. 
2011, Alexandrescu et al. 2009, Conte et al. 2019).  
Due to long occlusions and heavy calcifications, the recanalisation and patency of the 
SFA still cause challenges (Conte et al 2019, Alexandrescu et al. 2009). Femoral 
bifurcation is not routinely treated by endovascular means, but techniques are evolving 
(Gargiulo et al. 2011, Thiney et al. 2015, Siracuse et al. 2017, Conte et al. 2019, Goueffic 
et al. 2017). 
The popliteal artery is frequently treated with endovascular techniques. In the case of 
dissection or heavy calcification, stents may be considered but, as in the common 
femoral area, the risk of fracture and occlusion is increased by the mechanical stress. 
With the technical development of the equipment, crural and pedal vessels are balloon-
dilated and recanalised routinely. However, the risks of failure increase with a 
decreasing size of the artery. Furthermore, the recanalisation of long calcified lesions in 
crural arteries may be impossible, or the result may be compromised. Bypass surgery 
may result in better flow if the patient tolerates surgery (Gargiulo et al 2011). The GLASS 
classification considers multilevel disease and combines femoropopliteal and 
infrapopliteal distribution of disease into three stages based on the estimated 
immediate technical failure rate and the leg-based patency at one year. In femoro-
popliteal and infrapopliteal segments the length of diseased and occluded arterial 
segments and the severity of stenosis are graded. The inflow and inframalleolar disease 
are evaluated separately. (Conte et al 2019.) 
The technical success rate of endovascular treatment limited to the infrapopliteal level 
was 95% in a series of 201 patients with DFU, (Fossaceca et al. 2013). The non-success 
rate for a below-knee procedure was 4% and for the SFA region 5.9% among 728 limbs 
with CLTI considered suitable for endovascular treatment (71% DM, 66% tissue loss) 
(Davies and El Sayed 2015). In the presence of an acute diabetic foot infection, the 
technical success rate has been somewhat lower, 85% (Setacci et al. 2013).  
Restenoses and reocclusions occur frequently, in 20%–40% of lesions, after 
endovascular treatment. The rate depends on whether only observed symptomatic 
reocclusions or also asymptomatic ones caught in duplex surveillance are considered. 
Despite frequent restenosis, the limb salvage rates are quite good (Hinchliffe et al. 
2016). During one-year follow-up, restenosis was observed in duplex surveillance in 80 
out of 201 (39.8%) patients with DFU after endovascular treatment of infrapopliteal 
vessels. Sixty-six were symptomatic, with a recurrence or deterioration of ulcers 
(Fossaceca et al. 2013). Clinical restenosis (non-healing ulcer or recurrent rest pain) was 
observed in 23% of patients during a median of 6-year follow-up after endovascular 
treatment for CLTI in diabetic patients; 77% of the patients underwent a repeated 
endovascular treatment and 10% bypass surgery (Faglia et al. 2009). Restenosis, verified 
by duplex Doppler, occurred in 66/158 (42%) of the successfully treated lesions at one 
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year after endovascular treatment of below-knee arteries among 94 diabetic patients 
with ischaemic ulcers or gangrene who remained alive with the leg intact. The restenosis 
rate was 35% in stenotic and 53% in occlusive lesions. Two patients died, and 3 
underwent major amputation before the one-year follow-up. In this study, only 3 
patients underwent re-PTA, even though the minor amputation rate was 64% and the 
tissue lesions were evidently not minor ones (Ferraresi et al. 2009.) 
2.6.3 HYBRID PROCEDURES 
Hybrid revascularisation is a term used for a procedure containing both endovascular 
and open surgical elements. The unavoidable surgical part of the procedure is 
performed during the same session with the endovascular part. The advantage is that 
separate procedures are not needed, conversion to open surgery can easily be made, 
ulcerated areas can be treated endovascularly, the graft length can be optimised , and 
open surgery can be replaced by endovascular treatment. The combination of femoral 
endarterectomy and iliac PTA, or recanalisation and stenting is a typical hybrid 
procedure (Chang et al. 2008). A distal bypass or endovascular treatment of infrainguinal 
arteries may be included (Brewster et al. 1989). Infrainguinal bypass and outflow PTA is 
also a common 130620 procedure (Gargiulo et al. 2011). Quite extensive hybrid 
procedures have a long history (Lorenzi et al. 1991). Porter published a case report of 
two patients with combined intraoperative endovascular treatment of iliac lesions and 
a surgical revascularisation for limb salvage as early as in 1973 and Corey a series of 
fifteen patients in 1983 (Porter et al. 1973, Corey et al. 1983). 
In multilevel disease, the proportion of hybrid procedures is higher than in local disease. 
Of 770 consecutive lower limb revascularisations (67% CLTI, 48% DM), 29% were opens, 
57% endovascular and 14% hybrid revascularisations. Of multilevel reconstructions, in 
turn, 20% were open, 38% were endovascular and 43% were hybrid procedures 
(Dosluoglu et al. 2010). 
2.6.4 SELECTION OF REVASCULARISATION MODALITY 
Cautious individual consideration of the treatment of choice for each patient has been 
called for, regarding factors such as the general condition of the patient, the 
atherosclerotic disease pattern, the quality of the run-off vessel, graft material and local 
expertise (Spinelli et al. 2015, Conte et al. 2019). The BASIL trial gave no definitive 
answer to the question of whether an endovascular- or open-surgery-first strategy 
would offer a more favourable outcome (Bradbury et al. 2010). At present, a path 
towards evidence-based revascularisaton (EBR) is being searched (Conte et al. 2019, 
Farber 2019, Popplewell 2016). An endovascular-first strategy is not always feasible or 
optimal. Long calcified occlusions, or severe tissue destruction in the presence of an 
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acceptable outflow, vessel may be effectively treated with open-surgical 
revascularisation (Conte et al. 2019, Gargiulo et al. 2011). In contrast, open surgery 
predisposes the patient to general as well as to wound complications (Adam et al. 2005, 
Conte et al. 2019, Dosluoglu et al. 2012). However, the patency may be more durable 
after open surgery than after endovascular treatment and, on some occasions, the 
haemodynamic result better (Spillerova et al 2015). Consequently, in clinical cohorts, 
patients undergoing endovascular treatment tend to have higher morbidity, whereas 
patients with revascularisation tend to suffer from more extensive vascular disease and 
more severe tissue lesions (Dosluoglu et al. 2012, Taylor 2009). Indeed, revascularisation 
is a dynamic process where procedures are repeated or converted if necessary 
(Bradbury et al. 2010). In Helsinki, 394 consecutive patients with a combined 449 limbs 
with a foot ulcer, referred to the clinic due to a suspicion of CLTI during 2010-2011, were 
studied (Figure 3). Of these patients, 4.8% had type I and 56.6% type II diabetes. 
Revascularisation was scheduled for 233 (59%) patients, with a combined 248 (55%) 
limbs. The number of patients undergoing open surgery as a final treatment increased 
by 74% compared to the original strategy. (Noronen et al. 2017.) 
 
 
Figure 3. Treatment process of patients attending vascular surgical consultation in 
Helsinki. Reproduced with permission from Noronen et al. 2017. * Wound healing 
following secondary open surgery. ** Wound healing following primary open 
surgery. 
 
In the US, endovascular treatment outnumbered open revascularisation in the 
treatment of ulcers in 2005 and of gangrene in 2006 (Hong et al. 2011). In an analysis 
based on the Healthcare Cost and Utilisation Project (HCUP) by the Agency for 
Healthcare Research and Quality in US, a very clear shift from open to endovascular 
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procedures was seen between 2001 and 2010. In diabetic patients, the number of open-
surgical revascularisations was reduced from 11,500 to 6,900, while the number of 
endovascular treatments increased from 4,600 to 15,000. The number of combined 
open and endovascular procedures remained at 1,100-1,200 yearly. (Skrepnek et al. 
2014.) 
Whether a failed endovascular attempt deteriorates the results of open bypass surgery 
performed afterwards has been discussed (Conte et al. 2019). Graft patency and limb 
salvage have been poorer in patients with a prior failed endovascular revascularisation 
attempt before bypass surgery, when compared to patients without a prior 
endovascular attempt (69% DM) (Spinelli et al. 2015). However, confounding factors 
may play a role here, as the disease classification and run-off scores before and after the 
operations have not been adjusted, nor have the proportions of patients with rest pain 
only (Spinelli et al. 2015). However, a similar result was reported by Noronen and 
colleagues: limb salvage after a median of 26 months pf follow-up in patients with an 
initial open-surgical treatment was 96%, compared to the 82% (p=0.045) in patients with 
a failed endovascular treatment (Noronen et al. 2017). 
2.6.4.1 FEASIBILITY OF REVASCULARISATION 
A patient’s feasibility for an operation and the technical feasibility of the procedure are 
perquisites for a successful procedure.  
In Sweden, 801 out of 1,151 consecutive diabetic patients referred to a specialist foot 
clinic for ischaemic foot ulcers underwent angiography, and 345 were not considered 
feasible for revascularisation. Based on angiography, no revascularisation was 
technically feasible for 99 (12%) patientss; 50 (6%) had a poor general condition, and 33 
(4%) had no vein graft available (Apelqvist et al. 2011, Elgzyri et al. 2014).  
In the BASIL trial, 21 out of 228 patients assigned to open surgery underwent 
endovascular treatment and 10 had no intervention. Out of the 224 patients assigned 
to endovascular treatment, 4 were treated by open surgery and 4 had no interventions. 
(Bradbury et al. 2010.) In Helsinki in 2010, for 19% of patients initially scheduled for 
endovascular treatment, the intervention was converted to open surgery (Noronen et 
al. 2017). 
In an American centre, the endovascular-first strategy was adequate in only 42% of the 
cases, with 47% of the patients needing bypass surgery and an additional 11% requiring 
a hybrid procedure. Diabetic patients had a higher probability of open revascularisation 
than nondiabetic patients. Trans-Atlantic Intersociety Consensus (TASC D) lesions 
required open surgery more often than less severe lesions. (Gargiulo et al. 2011.) In 
another American centre, patients who received endovascular treatment had more 
comorbidities, whereas those undergoing open revascularisation had more complex 
lesions (Dosluoglu et al. 2012). 
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Unfortunately, 1%–20% of all attempted revascularisations fail. In Sweden, an 
exploration revealed that open revascularisation was not feasible in 19/163 (15%) 
patients at a diabetic multidisciplinary clinic (Apelqvist et al. 2011). Furthermore, the 
absence of a target vessel prevented 1 and poor general condition 3 revascularisations 
(1%) among 360 consecutive diabetic patients referred for revascularisation (Faglia et 
al. 2012) In the BASIL trial, no functional graft was achieved for 5 (3%) patients when 
surgery was attempted. In one of the patients, the outflow artery was too calcified, 
another had no vein available, and for a further three no flow was achieved. In 20% of 
the 216 patients, endovascular treatment was not successful. In ten, the lesion could 
not be recanalised and in 18 the lesions were recanalised subintimally without re-entry 
to the lumen. Two patients could not tolerate the procedure from the beginning, and 
two vessels were perforated before recanalisation. In ten cases, immediate treatment-
resistant thromboses prevented a successful procedure, and in one patient, stenosis 
detected by ultrasound was absent in angiography. (Bradbury et al. 2010.) Overall 
technical failure of endovascular treatment of below-knee arteries was observed in 
11/201 (5.5%) patients due to long calcifications or a vagal reaction (Fossaceca et al. 
2013). 
2.6.4.2 FEASIBILITY OF REVASCULARISATION ACCORDING TO THE ANGIOSOME MODEL 
Better flow in the ulcer area enhances ulcer healing in an ischaemic limb. Angiosome-
targeted revascularisation is not always possible. Naturally, the vessel of the specific 
angiosome is often severely diseased, as the tissue defect is in that area (Zheng et al. 
2016). In a study from Helsinki, all three arteries of the leg were retrospectively 
considered suitable for endovascular treatment in 12.4%, two in 54.7% and only one in 
32.9% of the cases (Spillerova et al. 2016). 
In another study, 16% of all endovascular attempts of tibial recanalisation were 
unsuccessful (Acin et al. 2014). Furthermore, out of these 101 infrapopliteal 
endovascular procedures in 92 diabetic patients with foot ulcers, 17 interventions 
resulted in indirect revascularisation without collaterals. Direct revascularisation to the 
ulcer angiosome was achieved in 46 procedures and indirect revascularisation through 
collaterals in 22 (Acin et al. 2014). In a further study, 31% of the patients had direct 
revascularisation to an angiosome, 26% were in the “without collateral” group, and an 
additional 43% in “indirect through collaterals” group (Zheng et al. 2016). 
In 98 out of a combined 161 (60.9%) legs of patients (DM 66.5%) with CLTI and foot 
ulcers, angiosome-targeted below knee endovascular revascularisation was performed 
successfully (Spillerova et al. 2016). Angiosome-targeted revascularisation was 
considered possible in 129 out of 161 (80%) cases. However, in 23 cases, angiosome-
targeted revascularisation failed (n=9) or was not attempted (n=14) because of a long 
occlusion, and another vessel was recanalised. In a further 8 cases, angiosome-targeted 
revascularisation was not attempted for an unknown reason. Only legs with successful 
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endovascular treatment for ischaemic tissue defects were included. (Spillerova et al. 
2016.)  
 
2.6.5 TIMING OF REVASCULARISATION 
 
Delayed revascularisation deteriorates the outcome especially in diabetic patients 
(Noronen et al. 2017, Elgzyri et al. 2014, Sheahan et al. 2005). In a Finnish study, 394 
consecutive patients with foot ulcers and a suspicion of ischaemia were referred to a 
vascular surgical consultation. Of these, 242 patients (61%) had diabetes. The limb 
salvage rate was significantly poorer in diabetic patients whose revascularisation took 
place later than two weeks after the referral, when compared to nondiabetic patients. 
Diabetic patients with a more than 2-week delay in treatment also had an increased risk 
of major amputation in a multivariate analysis on diabetic patients (Noronen et al. 2017). 
Similarly, in a Swedish study, diabetic patients with foot ulcers with a less than 8-week 
waiting time to revascularisation after evaluation at a multidisciplinary clinic had a 
better probability of healing without major amputation than patients with a waiting time 
exceeding8 weeks (Elgzyri et al. 2014). In urgent situations with a diabetic foot infection 
and ischaemia, rapid treatment has been favourable in terms of the outcome. In Italy, a 
protocol with urgent debridement and revascularisation within 24 hours was 
implemented. In the traditional group (n = 192), revascularisation was performed within 
a mean of 3 days (range 1–7 days) after debridement, whereas in the new protocol 
group (n = 183), revascularisation was always accomplished within 24 hours after 
debridement. The differences between the groups in six-month mortality, 11% vs 4%, 
and major amputations, 40% vs 25%, were statistically significant. The ulcer healing rate 
was low at six months: 8% and 21 %, respectively, with no significant difference. (Setacci 
et al. 2013.)  
 
2.6.6 INCREASING REVASCULARISATION RATE – DECREASING AMPUTATION 
RATE 
 
In the 1980s, a rapid increase in revascularisations for CLTI, including diabetic patients, 
took place in many countries. In population-based studies from Europe, Northern 
America and Australia, a decrease in major amputations has been observed 
concurrently with the increase in revascularisations (Luther et al. 2000, Lindholt et al. 
1994, Gregg et al. 2014). 
 
In Finland, an inverse correlation of increasing revascularisation rates, with infrainguinal 
or infrapopliteal reconstructions in particular, and decreasing amputation rates has 
been reported repeatedly as regards the general population (Luther et al. 1994, Luther 
et al. 2000, Eskelinen et al. 2004, Winell et al. 2006). 
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In a Finnish population-based register study on diabetic patients, the age- and sex-
adjusted incidence of first major amputations and first vascular reconstructions were 
inversely correlated during 1997–2002 among the 14 largest hospital districts 
considering the number of diabetic patients. The inverse correlation was even stronger 
in infrapopliteal reconstructions. (Winell et al. 2006.)  
In the American population during 1996–2011, the total number of revascularisations 
increased along with an increase in endovascular procedures from 138 to 584/100 000 
Medicare patients, even though the number of surgical revascularisations decreased 
from 201 to 83 revascularisations /100 000 Medicare patients. Concurrently, the 
number of both above-knee and below-knee amputations decreased from 91 to 47 /100 
000 and from 82 to 50 /100 000, respectively. (Goodney et al. 2015.) 
2.6.7 PATENCY 
Primary patency and assisted primary patency describe which proportion of bypasses or 
lesions treated with endovascular methods stay open without and with further assisting 
procedures (Table 11). Secondary patency includes bypasses that stay open with or 
without interventions for thrombosis (Table 12) (Rutherford et al. 1997). LBP (limb-
based patency), a concept introduced by the Global Vascular Guideline, defines the 
patency of an arterial line down to the lesion independently of the method of 
revascualrisation (Conte et al. 2019). Graft material affects graft patency: single-
segment vena saphena magna has the best primary patency, arm veins a less optimal 
patency, and prosthetic material the worst primary patency (Arvela et al. 2010, Arvela 
et al. 2012). No significant differences between diabetic and nondiabetic patients were 
observed in the rates of primary (65% and 46% vs 70% and 57%; log-rank test, P = .09) 
or secondary patency (76% and 60% vs 80% and 68%; log-rank test, p = 0.20) at 5 and 10 
years of follow-up after vascular reconstruction for CLTI (Ballotta et al. 2014). Poor 
glycaemic control may decrease the patency (Singh et al. 2014). 
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Table 11. Primary patency (PP) of revascularisations in diabetic patients 
Study patients/ % 
DM 
% tissue 
defect 
1-yr PP 5-yr PP 10-yr PP
Berceli 1999; heel 
ulcers, 96 pedal 
bypasses 
91% 100% 80% 62% 
Berceli 1999; forefoot 
ulcers, 336 pedal 
bypasses 
96% 100% 81% 57% 
Pomposelli et al. 
2003; 1,032 pedal 
bypasses 
92% 57% 38% 
Alexandrescu 2009; 
endovascular 
176/100% 100% 62% 
Ballotta 2014 705/100% 80% 65% 46% 
Ballotta 2014 702/0% 69% 70% 57% 
Wölfle 2003; CLTI, 
femoro-distal bypass, 
35% PTFE 
94/100% 81% 66% 
Wölfle 2003; CLTI, 
femoro-distal bypass, 
31% PTFE 
117/0% 56% 56% 
Faglia et al. 2005; 
endovascular 
CLTI 
993/100% 
87% 88% 
symptomless 
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Table 12. Secondary patency of revascularisation in diabetic patients 
Study patients% 
DM 
tissue 
defect 
% 
1-yr 
secondary 
patency 
5-yr 
secondary 
patency 
10-yr 
secondary 
patency 
limb 
salvage 
Berceli et al. 
1999; heel ulcers 
96 pedal 
bypasses 
91% 100% 85% 60%  94% 1 yr, 
5 yrs 89% 
Berceli et al. 
1999; forefoot 
ulcers 336 pedal 
bypasses 
96% 100% 85% 67%  94% 1 yr, 
5 yrs 87% 
Pomposelli et al. 
2003; pedal 
bypasses 
92%   63% 42% 78% 5 
yrs, 58% 
10 yrs 
Alexandrescu et 
al. 2009; 
endovascular 
176/100% 100% 80%   89% 
Ballotta et al. 
2014; bypass 
705/100% 80%  76% 60% 5 yrs 88% 
10 yrs 
76% 
Ballotta et al. 
2014; bypass 
702/0% 69%  80% 68% 5 yrs 91% 
10 yrs 
83% 
Wölfle et al. 
2003;  CLTI , 
femoro-distal 
bypass, 35% PTFE 
94/100% 81% 72%   1 yr 85% 
Luther et al. 
1997; CLTI, 
autologous vein 
86/100%  61% 
in all 
187  
69%  53% 1 yr 69%, 
5 yrs 51% 
Luther et al. 
1997; CLTI, 
autologous vein 
101/0%  61% 
in 187  
80%  69% 1 yr 81%, 
5 yrs 81% 
 
 
 
63 
2.6.8 COMPLICATIONS 
Since patients with CLTI have severe co-morbidities and often also severe coronary 
artery disease or cerebrovascular disease, the risk of death is increased compared to 
patients treated due to claudication. According to a systematic review, 30-day mortality 
after surgical and endovascular treatment in diabetic patients with tissue lesions was 
0.5% (IQR 0%–4.3%) and 1.4% (IQR 0.8%–3.7%), respectively (Hinchliffe et al. 2016). 
In a Swedish population-based register study, amputation-free survival was poorer 
among diabetic than in non-diabetic patients. Diabetic patients had an increased risk of 
both major amputation and death. Adjustment for demographic and risk factors had no 
significant effect on the result. Type 1 and type 2 diabetes were not reported separately 
(Malmstedt et al. 2008). Diabetic patients had significantly more major (death, systemic 
complications, graft thrombosis, major amputation; 16.7% vs 11.8%, p = .02) and minor 
complications (haematoma, infection, inguinal lymphocele; 9.7% vs 6.5%, p = .02) than 
nondiabetic patients after surgical revascularisation for CLTI. Regarding specific 
complications, the difference was not significant. The rate of wound infections was 0.8% 
in diabetic and 0.2% in nondiabetic patients. Dehiscence under haematomas and 
lymphoceles was classified separately. (Ballotta 2014.) Similarly, diabetes was 
associated with major adverse events following bypass surgery (Wallaert et al 2012). 
In Finnish national register data, 30-day mortality after open surgical revascularisation 
among diabetic patients with CLTI was 4.5%, compared to the 3.4% among non-diabetic 
patients. Seventy-seven percent of the diabetic and 53% of the nondiabetic patients 
presented with tissue loss. Diabetic patients also had significantly more postoperative 
wound infections (15.7% vs 10.5%), below knee amputations (6.5% vs 3.3%), cardiac 
complications (8.8% vs 5.6%), cerebrovascular complications (2.1% vs 1.3%), and renal 
complications (1.6% vs 0.9%) than nondiabetic patients. (Virkkunen et al. 2004.) 
2.6.9 NO REVASCULARISATION 
The outcome of ischaemic ulcers without revascularisation is poor (Lepäntalo and 
Mätzke 1996). However, a tendency towards a better outcome in recent years has been 
observed (Abu Dabrh et al. 2015). Conservative care may preserve the functionality in 
the presence of an unhealing ulcer, when no immediate threat to the limb nor severe 
rest pain exists (Barshes et al. 2014). On the other hand, the benefit of revascularisation 
is not self-evident, as many studies report healing of ischaemic ulcers without 
revascularisation (Marston et al. 2006, Elgzyri et al. 2013, Apelqvist et al.2011). 
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Studying the effect of revascularisation on the outcome of patients with ischaemic ulcers 
is challenging (Bradbury et al. 2010). A trial comparing ulcer outcome after treatment 
for ischaemia to the outcome of leaving ischaemia untreated would be unethical. A 
comparison with historical series is impossible, as the setting was different compared to 
the present era. For instance, the general morbidity, medications and diagnostic 
modalities have evolved. 
The Proportion of patients with an ischaemic foot ulcer who remain without 
revascularisation varies from 1% to 50% (Faglia et al. 2009, Elgzyri et al. 2013, Bradbury 
et al. 2010, Noronen et al. 2017). Frequently mentioned reasons for refraining from 
revascularisation are technical feasibility and poor general condition (Table 13). In a 
cohort of 544 patients with CLTI, 3.5% (n=20) possessed no outflow vessels for either 
endovascular or surgical revascularisation, whereas the general condition of seven 
patients (1.3%) prevented any invasive procedures (Faglia et al. 2009). In the BASIL trial, 
386 out of 456 patients with severe ischaemia (rest pain or tissue loss) due to infra-
inguinal disease were not randomised for the trial. The reason for not randomising were 
as follows: in 34% of the 456 cases, neither endovascular nor surgical treatment was 
considered a possible alternative, in 7% comorbidity precluded open surgery, in 3% the 
clinical situation had improved with medical therapy, and 4% were unable to give 
informed consent. Moreover, 16% were technically unsuitable for endovascular 
treatment and 20% for open surgical treatment. (Bradbury et al. 2010.) In a study 
conducted in Helsinki, 120/273 (44%) limbs of diabetic patients with CLTI (no limit 
values) and tissue loss and 75/176 (43%) limbs of nondiabetic patients were not 
revascularised at baseline, the major reasons being a poor general condition or 
bedridden status, and the assumption that the wound would heal without 
revascularisation. However, 17.5% and 13.3% of these, respectively, were revascularised 
later. In consequence, 37% of the patients had no revascularisation in the end (Noronen 
et al. 2017). 
Not all patients who could benefit from revascularisation are probably offered one 
(Richard et al. 2011, Luther et al. 2000). In the 1990s, 20-fold variation was observed in 
infrapopliteal reconstructions and 30-fold variation in infrapopliteal endovascular 
treatment between different regions of Finland. Both diabetic and non-diabetic patients 
were included (Luther et al. 2000). A systematic stratification of patients (91% diabetes) 
in four treatment groups – revascularisation, primary amputation, palliative care, and 
conservative management without revascularisation – resulted in complete wound 
healing in 73% of the conservatively treated cases within a mean of 4.1 months. A 
revascularisation more than six months from enrolment was performed on 12% of the 
patients. The leg was preserved in 90% of these at four years. (Possagnoli et al. 2017.) 
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Table 13. Reasons for not revascularising, % of not revascularised patients. 
Spontaneous 
healing 
Major 
amputation 
Poor 
condition 
Technically 
impossible 
Lack of 
consent 
Elgzyri et 
al.2013 
16% 4% 28% 10% 17% 
Noronen et al. 
2017 nonDM 
71% 7.5% 13% 6.7% 1.7% 
Noronen et al. 
2017 DM 
47% 4% 47% 2.7% 0% 
Apelqvist et al. 
2011 no angio 
13% 5% 41% 13% 
Apelqvist et al. 
2011 no revasc 
7% 1% 17% 44% 10% 
Bradbury et al. 
2010 
3% 7% 34% 4% 
Faglia et al. 
2009 
1% 3,6% 
Marston et al. 
2006 
78% 14% 8% 
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2.7 FREE TISSUE TRANSFER (FTT) IN THE DIABETIC FOOT 
2.7.1 HISTORY 
The microvascular FTT technique was introduced in the 1970s along with the fast 
development of microsurgical techniques: microscopes, instruments and suture 
materials. Previously, in the 1960s, transfers of bowel segments and 
autotransplantations of the extremities and digits had been performed successfully 
(Seidenberg et al. 1959, Kleinert et al. 1963). The tissue lesions of the first human FTT 
patients were mostly caused by trauma or cancer. The first successful case was probably 
published in 1972. An omentum was used to cover a traumatic lesion on the scalp 
(McLean and Bunke 1972). Free skin flaps such as a groin flap, deltopectoral flap and 
dorsalis pedis flap soon became popular (Taylor and Daniel 1973, Harii et al. 1974). The 
free musculocutaneous flap was introduced in the late 1970s (Harii et al. 1976, Hill et al. 
1978). In the mid-1980s, the technique was successfully applied to ischaemic and 
diabetic foot lesions (Briggs et al. 1985). Since then, dedicated centres in Europe, the US 
and Asia have published several series on the treatment of diabetic and ischaemic 
lesions with FTTs.  
2.7.2 INDICATIONS 
Generally, in large series of microvascular flaps, the most common indication in the 
lower extremities has been trauma. In a series of 231 microvascular flaps, the indications 
were acute (n = 105) or chronic (> 30 days) trauma (n = 59) and postoperative 
complication (n = 26), while 18 (8%) patients had a chronic wound and 15 (6%) had 
undergone oncologic resection. Thirty-five (15%) of the patients had diabetes, and 7 
patients (3%) underwent revascularisation. (Cho et al. 2016.) Almost without exception, 
preventing major amputation has been the indication for FTT in the published series of 
patients with diabetes or LEAD (Moran et al. 2002, Tukiainen et al. 2000, Randon et al. 
2010, Huang et al. 2014, Oh et al. 2013, Briggs et al. 1985, Oishi et al. 1993, Czerny et al. 
2004, Karp et al. 1994, Gooden et al 1997, Hong et al. 2017, McCarthy et al. 1999, 
Shestak et al. 1990, Cronenwett et al. 1989) (Table 14). The distribution of tissue defect 
locations vary between the studies. Notably, in many studies, the proportion of heel 
ulcers is high (Table 15). No specific criteria for the threat of amputation – such as size, 
toe or ABI measurements – are given, but the decision to operate has relied on clinical 
judgement, individually for each patient.  
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Table 14. Patient and FTT a revascularisation operation details. 
Author, 
year/ N 
Age Ma
le 
Smoki
ng 
DM Flap Revasc. urae-
mia/RT 
McCarthy 
1999/ 21 
59  
(40-73)  
95
% 
48% 86% LD 5, RA 5, 
omentum 5, 
gracilis 2, RFA 
3, scapular 1 
21 open  
Tukiainen 
2000/29 
62  
(43-85)  
69
% 
7% 83% LD 20, 7 RA, 
RFA 1, TFL 1, 
gracilis 1  
29 open 28%/1
4% 
Moran 
2002/ 75 
60   76% RA 35, LD 15, 
RFA 24, 
scapular 3, 
omentum 2 
61open 
(81%) 
27%*/
X 
Randon 
2010/ 55 
64  
(42-80) 
76
% 
36% 100
% 
RA 44, LD 5, 
ALT 3, serratus 
anterior, lateral 
arm 
55 open X/5% 
Gooden 
1997/ 26 
60 
(24-76) 
62
% 
50% 90% RA 9, RFA 8, LD 
7, scapular 3 
17 open 
(65%) 
33%/X 
Huang 
2014/ 24 
71 42
% 
 100
% 
LD and RA 24 (endo) 25%/X 
Oh 
2012/121 
55  
(26-78) 
 35% 100
% 
ALT 90, SCIP 
20, AMT 5, 
UMT 3 
9 open+5 
endo 
(11,5%) 
35%/8
% 
Lee 
2014/33 
60 91
% 
45% 100
% 
ALT 19, TAP 9, 
gracilis 5 
33 open 
or endo 
 
 
age mean (range), * renal insufficiency and uraemia, RT renal transplant, open: open 
revascularisation, endo: endovascular revascularisation 
LD, latissimus dorsi muscle flap; RA, rectus abdominis muscle flap; RFA, radial forearm 
fasciocutaneous flap; TFL, tensor fasciae latae muscle flap; ALT, anterolateral thigh 
perforator flap; SCIP, superficial circumflex iliac perforator flap; AMT, anteromedial 
thigh perforator flap; UMT, upper medial thigh perforator flap; TAP, thoracodorsal 
artery perforator flap 
 
As a more specific indication, tissue lesions with the joint, bone or tendon visible are 
often mentioned (Randon et al. 2009, Gooden et al. 1997, Tukiainen et al. 2000, Lee et 
al. 2014, Karp et al. 1994, MCCarthy et al. 1999). The background factors often include 
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osteomyelitis (Hong et al. 2017, Gooden et al.1997, Moran et al. 2002, Cronenwett et 
al. 1989), a plantar defect (Cronenwett et al. 1989, McCarthy et al. 1999, Gooden et al. 
1997, Randon et al. 2010, Vermassen and van Landuyt 2000), infection (Hong et al. 
2017), foreign material (Tukiainen et al. 2000), or wound healing problems after an open 
fracture (Tukiainen et al. 2000). An attempt with an STSG or local flap has often been 
made previously (Cronenwett et al. 1989, Gooden et al. 1997). As regards a previous or 
present revascularisation, flaps have been used to cover distal anastomosis in the tissue 
defect area (Gooden et al. 1997, Tukiainen et al. 2000), necrotic defects in the distal 
anastomosis site due to vascular graft infection (McCarthy et al. 1999, Tukiainen et al. 
1998), ischaemic muscle necrosis after vascular reconstruction and fasciotomy 
(Tukiainen et al. 2000), and necrotic vein harvesting wounds (Gooden et al 1997). FTTs 
have been shown to increase flow in the vascular graft (Lorenzetti et al.  2001). They 
have been used as a sole outflow for a graft in the absence of local outflow artery 
(Shestak et al. 1990, Tukiainen et al. 2000, Moran et al. 2002, Mimoun et al. 1989, 
McCarthy et al.1999 ). Even neovascularisation in the native tissue via the FTT has been 
suggested (Mimoun et al. 1989, Randon et al. 2010, Mätzke et al. 1998). The locations 
of the tissue defect in various series is presented in Table 15. 
To qualify as a candidate for FTT, the patient should be ambulatory, at least being able 
to step on the foot when moving into a wheelchair (Gooden et al. 1997, Tukiainen et al. 
2000, Oishi et al. 1993). Some studies report many patients with a previous major 
contra-lateral amputation (Gooden et al. 1997, Moran et al. 2002, Tukiainen et al. 2000, 
Serletti et al. 1993). Cultural reasons may favour FTT over amputation, not necessarily 
even for the sake of mobility but simply to preserve the leg (Huang et al. 2014). Good 
cooperation by the patient is required for the procedure. A general condition allowing 
an operation that lasts several hours and involves substantial bleeding, as well as a 
lengthy recovery period, is obligatory (Oishi et al. 1993). Along with the experience 
accumulated from many centres, patients with severe nephropathy have often been 
excluded from this kind of treatment at present. Furthermore, in bedridden patients, as 
well as patients with a poor prognosis of survival, poor predicted outcome or severe 
neurologic impairment, major amputation is indicated in lieu of FTT and vascular 
reconstruction (Randon et al. 2009). 
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Table 15. Location of the tissue defect in patients with FTT. An ulcer may involve more 
than one location. 
Author N flaps forefoot heel plantar leg dorsum, 
ankle 
McCarthy et 
al. 1999 
21 - 52% (or 
plantar) 
52% (or 
heel) 
- - 
Tukiainen et 
al.  2000 
29 40% 43% - 3% - 
Illig et al. 
2001, Moran 
et al. 2002 
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(2001) 
79 
(2002) 
13% 
(2002) 
19% 
(or plantar, 
2002) 
37% (2001) 
19% (or 
heel 2002) 
17% 
(2001) 
22% 
(2002) 
46% 
(2002) 
Randon et al. 
2009, Randon 
et al. 2010, 
76 
(2009) 
55 
(2010) 
44% 
(2009) 
51% 
(2010) 
29% (or 
plantar 
2009) 40% 
(2010) 
29% (or 
heel 2009) 
9% (2010) 
12% 
(2009) 
15% 
(2009) 
Gooden et al. 
1997 
26 - 44% 11% 30% 15% 
Huang et al. 
2014 
24 27% 19% 27% 23% 
Lee et al. 
2014 
33 - 12% 9% - d:55%, 
a:24% 
Fitzgerald 
O'Connor 
2011 (review) 
399 30% 24% 10% 24% 12% 
2.7.3 FTT AND CLTI 
In CLTI, the proportion patients who undergo FTT surgery varies between 0% and 10% 
at specialised clinics. A survey from an amputation prevention clinic describes the 
podiatric as well as vascular procedures performed in 89 patients to save a limb 
threatened with amputation due to neuroischaemic ulcers. Of the patients, 68% had 
diabetes. A total of 151 podiatric, 86 vascular and 8 plastic surgical interventions were 
performed. Two (2.4%) of them were FTTs. (Vartanian et al. 2015.) In another study, 585 
procedures for tissue defects on 544 patients with lower extremity ischaemia in 1992–
1996 included 266 infra-inguinal bypasses, 66 major amputations, 226 minor 
amputations or operative debridements, and 27 (5%) myofasciocutaneous FTTs. 
(Gooden et al. 1997). Furthermore, 55 diabetic patients underwent FTT during same 
time period, as infrapopliteal vascular reconstructions were performed on 248 diabetic 
patients and major amputations on 295 patients (Randon et al. 2010). In Seoul, Korea, 
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71 out of 287 (25%) diabetic patients who were evaluated for limb salvage underwent 
perforator flap reconstruction. Of these, 216 were considered unsalvageable (Hong 
2006). In Helsinki University Hospital, the treatment for 733 patients with CLTI was 
vascular reconstruction in 66%, primary amputation in 19% and conservative treatment 
in 15% of the cases. FTT was applied in 15 cases (Lepäntalo and Mätzke 1996).
2.7.4 FLAPS 
Evidence on the applicability of different free flaps in the diabetic foot is lacking. The 
current practice leans on case series and expert experience. An almost endless choice of 
flaps is available. While selecting the flap for a diabetic foot, the size, depth and location 
of the defect and the presence of atherosclerosis are evaluated. The size and volume of 
the flap, the flow in the flap, the length and atherosclerosis of the pedicle, the 
tolerability to pressure and shear stress, as well as donor site morbidity and the 
complexity of the elevation of the flap are considered. According to published series, 
most centres use a variety of flaps that are appropriate for individual cases of diabetic 
and ischaemic foot defects (Table 16). Microvascular muscle flaps (latissimus dorsi, 
serratus, rectus abdominis) and microvascular fasciocutaneous radial forearm flaps have 
been popular in treating DFU (Tukiainen et al. 2000, Moran et al. 2002, McCarthy et al. 
1999, Randon et al. 2009, Fitzgerald O’Connor et al. 2011). Muscle is well vascularised 
and optimal for filling in cavities, and the pedicle size is moderate. High flow is 
considered advantageous for vascular bypass graft patency (Lorenzetti et al. 2001). 
However, a muscle flap can be bulky and cause donor site problems (Knott et al. 2015).  
More recently, good results have been reported with microvascular perforator flaps 
(Hong 2006, Randon et al. 2010, Oh et al. 2013, Fitzgerald O’Connor et al. 2011). The 
advantages of perforator flaps are the good cosmetic fit, an abundance of different flap 
options and the fact that, in the case of failure, the underlying muscle is often usable 
(Koh et al. 2018, Goh et al. 2015). The disadvantages of microvascular perforator flaps 
are the time-consuming elevation and small size of the pedicle. The flow in the flap is 
low and tissue needed to fill cavities is meagre compared to muscle flaps. Large series 
on the lower leg include ALT (anterolateral thigh perforator) and SCIP (superficial 
circumflex iliac artery perforator flap), which have been used for ischaemic and diabetic 
foot defects, among other purposes (Koh et al. 2018, Goh et al. 2015). In a series of 
anterolateral thigh perforator flaps, sensate flaps were used in diabetic feet, in which 
preserved sensation was confirmed by filament testing preoperatively (Hong 2006). The 
sensation returned in four months.  
The omentum has been used occasionally, especially in extensive defects (McCarthy et 
al. 1999, Mazzaferro et al. 2018).  
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Table 16. Characteristic of different types of FTT. Reproduced with permission from 
Lepäntalo et al. 2004. 
Flap Outflow 
ml/min 
Athero- 
sclerotic 
pedicle 
Harvest 
compli 
cations 
Anaesthetic 
considera 
tions 
Patient 
position 
Size 
latissimus 
dorsi 
20–50 
ml/min 
+ + +++ lateral/ 
dorsal+upper 
body twist 
+++ 
rectus 
abdominis 
10–20 
ml/min 
++ ++ ++ dorsal ++ 
gracilis 5–15 
ml/min 
+++ - - lateral + 
serratus 5–15 
ml/min 
+ - +++ lateral + 
radial 
forearm 
4–10 
ml/min 
+ ++ ± dorsal + 
anterior 
thigh 
10–20 
ml/min 
++ + - dorsal ++ 
omentum 20–30 
ml/min 
+ ++ +++ dorsal ++ 
2.7.5 FTT TECHNIQUE IN THE ISCHAEMIC DIABETIC FOOT 
FTT and vascular reconstruction are possible to perform with simultaneous or staged 
operations. Two teams working at the same time reduce the operating time (Randon et 
al. 2009). The absence of scarring in a simultaneous operation facilitates dissection and 
performing venous and arterial anastomoses (Moran et al. 2002, Randon et al. 2009). A 
staged operation may ensue when the severity of the defect is revealed after 
revascularisation and debridement, often multiple. However, a staged operation may 
be preferred, as small deep veins tend to dilate after revascularisation, which is 
advantageous for the microvascular venous anastomosis.  
Debridement and the final evaluation of the defect initiate the operation. In a large 
series from Belgium, 64% of the patients needed minor revision or amputation (Randon 
et al. 2009). 
Subsequently, flap elevation and vascular reconstruction may be performed 
simultaneously in clean fields. The ipsi- or contralateral vena saphena magna is the 
preferred vascular graft  (McCarthy et al. 1999, Tukiainen et al. 2000). Good-quality 
arm veins (McCarthy et al. 1999, Tukiainen et al. 2000), the vena saphena parva 
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(McCarthy et al. 1999), and very seldom a composite graft (McCarthy et al. 1999, 
Tukiainen et al. 2000) are secondary options. In the absence of a vein graft, PTFE or 
cryopreserved allografts have been used (Tukiainen et al. 2000, Randon et al. 2009). 
The thoracodorsal artery may sometimes replace a venous graft (Malikov et al. 2009). 
Inflow to the flap is obtained via the vascular graft or tibial vessel closest to the defect 
site (Moran et al. 2002). Venous drainage is anastomosed to the tibial vein (McCarthy 
et al. 1999). The anastomosis of the flap artery is made end-to-side to the vein graft 
(McCarthy et al. 1999, Moran et al. 2002, Oh et al. 2013, Tukiainen et al. 2000), directly 
to the flap (McCarthy et al. 1999, Tukiainen et al. 2000) or to a native artery (Moran et 
al. 2002, Tukiainen et al. 2000). The anastomosis can be made end-to-end to a native 
artery branch (Oh et al. 2013), end-to-end to a native artery stump (Oh et al. 2013), or 
side-to-side to a GSV bypass or distal native artery (Randon et al. 2009). Especially 
large muscle flaps enhance flow (Randon et al. 2009, Lorenzetti et al. 2001) (Table 16). 
Muscle and omentum flaps need coverage with a skin graft, whereas myocutaneous 
and fasciocutaneous flaps include the skin. The mean duration of a simultaneous 
operation has varied between 5 and 7 hours, range 4–13 h (McCarthy et al. 1999, 
Tukiainen et al. 2000, Moran et al. 2002, Randon et al. 2010, Malikov et al. 2009). 
A combined endovascular revascularisation and FTT is described in a series of 26 flaps 
in 24 patients with diabetic Wagner 3 and 4 lesions. The patients were treated with 
PTA of infrapopliteal lesions and revision. A week later, a free vastus lateralis or rectus 
femoris free muscle transfer and STSG was performed. One perioperative death 
occurred. Two major amputations were observed at 6 and 21 months, respectively. 
(Huang et al. 2014.)  
2.7.6 POSTOPERATIVE SURVEILLANCE AND AMBULATION 
Intensive postoperative surveillance of the flap by means of hourly clinical assessment 
(inspection, temperature, bleeding) (Gooden et al. 1997, Randon et al. 2009) and 
Doppler auscultation (Randon et al. 2009) ensures the early detection and removal of 
vascular thrombosis, enabling flap salvage. The median hospital stay is long, in two large 
studies 32 and 48 days (6–113 days), respectively (Moran 2002, Randon 2009). Duplex 
Doppler surveillance of the vascular graft every three months has been standard during 
the first year after the operation (Randon et al. 2009, Tukiainen et al. 2000, McCarthy et 
al. 1999, Illig et al. 2001).  
Bed rest is advocated for the first postoperative week (Tukiainen et al. 2000). Weight 
bearing is allowed 3–6 weeks postoperatively (Illig et al. 2001, Randon et al. 2009, 
Tukiainen et al. 2000, Hong 2006). Achieving bipedal ambulation takes from three weeks 
in the case of the most favourable non-plantar ulcers to up to twelve weeks in plantar 
ulcers (Czerny et al. 2004, Gooden et al.1997, Randon et al. 2009, Hong 2006, Illig et 
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al.2001). Independent ambulation was achieved by 65%–76% of patients  at some point 
(Illig et al. 2001).  Swelling needs to be avoided by light elevation of the extremity. After 
wound healing, compression stockings have been used for six months for remodelling 
(Randon et al. 2009, Hong 2006). 
 
2.8 OUTCOME 
  
2.8.1 ULCER HEALING 
 
In chronic ulcers, the process of healing is disturbed. Wound healing consists of four 
phases: haemostasis, inflammation, proliferation and remodelling. Excessive 
inflammation, a decreasing division of fibroblasts, and alterations in bacterial flora are 
suggested factors in the background of impaired healing (Bosanquet et al. 2014). The 
healing of ulcers remains consistently undefined in clinical studies, and the frequency of 
control visits is seldom reported. Small epithelial defects may not be detected with the 
naked eye, or an unremoved eschar may cover them. Furthermore, ulcers may 
reulcerate soon after they have been assessed to be healed. Consequently, a Swedish 
study group considered ulcers healed after the skin has been intact for 6 months 
(Gershater et al.2009).  
Series mostly from multidisciplinary diabetic foot clinics describe a worse outcome for 
neuroischaemic and ischaemic ulcers than for neuropathic ulcers. However, the level of 
ischaemia, revascularisation and the outcome of revascularisation remain ambiguous in 
many reports (Prompers et al. 2008, Jeffcoate et al. 2006). 
In clinical work, no method is available for ensuring adequate circulation as regards 
healing. A small stabile ulcer rarely deteriorates acutely (Barshes et al. 2014). Indeed, 
spontaneous healing of ulcers in ischaemic feet is also known to occur (Marston et al. 
2006). Revascularisation is probably not always necessary for the healing of small non-
infected ulcers (Cull et al. 2014), but the probability of amputation increases with the 
depth and level of infection of the ulcers (Lepäntalo and Mätzke 1996, Cull et al. 2014). 
The proportion of healed ulcers has been noted to decrease along with the severity of 
ulcer scoring performed after revascularisation (Cull et al. 2014). The scoring is based on 
the extent of the ulcer, the severity of ischaemia and infection. Thirty-seven percent of 
WIfI score 4 ulcers healed within 1 year, as opposed to 65.2% of WIfI 3, 78.1% of WIfI 2 
and 92.5% of WIfI 1 ulcers. The limb salvage was 62.5% in WIfI 1, 76.7% in WIfI 2, 88.9% 
in WIfI 3, 97.3% in WIfI 1 ulcers. (Cull et al. 2014.) However, we do not have tools to 
exactly predict which ulcers heal or show no progress. Similarly, the complete healing of 
ulcers in 124 limbs of 98 patients with or without a minor amputation was observed in 
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79% of the limbs following angiosome-oriented endovascular revascularisation. 
Furthermore, 89% of Wagner grade 1–2 ulcers and 67% of Wagner grade 3–4 ulcers 
healed within 3 months. (Alexandrescu et al. 2008.)  
2.8.1.1 ULCER HEALING IN COHORTS WITH DIABETIC ULCERS 
Generally, 60%–75% of neuroischaemic or otherwise complicated ulcers heal, whereas 
the healing rate is over 80% for purely neuropathic ulcers treated in specialised diabetic 
foot centres. In the Eurodiale study, 69% of the ischaemic or neuroischaemic ulcers 
healed within one year, in comparison to the 84% healing rate of purely neuropathic 
ulcers (Prompers et al. 2008). When infection was present in an ischaemic ulceration, 
64% of the wounds healed and 10% of the limbs underwent major amputation during 
one-year follow-up. On the contrary, in non-ischaemic limbs, the healing rate was 85% 
irrespective of infection.  
In a cohort of 2,480 diabetic ulcers that were followed until healing or death in a Swedish 
multidisciplinary foot clinic, 65% healed primarily. The primary healing rate of 
neuropathic ulcers was 79.4%, whereas only 44.4% of neuro-ischaemic ulcers healed 
primarily. In legs with an ankle pressure less than50mmHg, 39% of the ulcers healed 
primarily. Of neuropathic ulcers, 7.1% resulted in minor and 2.4% in major amputation, 
and 11.1%  remained non-healed at death, compared to the corresponding rates of 
14.5% ,15% and 25.5 %, respectively, with neuroischaemic ulcers. (Gershater et al. 
2009.) Other factors associated with ulcer healing are named in Table 17. The outcome 
of a subgroup of 701 consecutive patients with a single plantar forefoot ulcer between 
1984 and 2012 was studied separately. Twenty-six percent had severe LEAD and 14% a 
deep infection of the foot. In 385 (55%) patients, the ulcer healed without surgery, in 
173 (25%) after foot surgery, in 42 (6%) after minor amputation and in18 (3%) after 
major amputation, and 83 (12%) died with the ulcer unhealed. Thirteen percent 
(92/701) of the patients underwent revascularisation during the follow-up. Of these, 39 
(42%) healed without surgery on the ulcer, 22 (24%) healed after ulcer surgery, 10 (11%) 
healed after minor amputation, 6 (7%) underwent a major amputation, and 15 (16%) 
died with the ulcer unhealed. (Örneholm et al. 2015.) A hospital-discharge-register-
based survey from 1996–2000 covering the US showed that diabetic patients over 80 
years had more complications of foot ulcers than nondiabetic patients: a respective 
0.04% and 0.02% had a foot infection, and a respective 0.5% and 0.1% underwent toe 
amputation, a respective 0.2% and 0.01% underwent a foot-level amputation, and 1.2% 
and 0.3%, respectively, underwent a major amputation (Reed 2004). 
In a British study involving 432 diabetic patients, 55% and 65.7% of foot ulcers of mixed 
origin healed by 6 and 12 months, respectively. Of the ulcers 27.8% and 11.6% were 
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unhealed at six and 12 months, 6.2% and 10.9% were unhealed at death, whereas 5.8% 
and 8% of the ulcers resulted in amputation, respectively. At 1 year, 45% of the patients 
were alive, ulcer-free and without amputation. (Jeffcoate et al. 2006.) 
 
 
Table 17. Factors related to primary healing in all surviving neuroischaemic/ischaemic 
patients. (Reproduced with permission from Gershater et al. 2009).  
 
Factor Odds ratio 95% CI p-value 
 
Age 18–60 years 1.80 1.01–3.21 0.045 
 
Age 71–80 years 1.70 1.14–2.52 0.009 
 
Male sex 1.40 1.00–1.93 0.044 
 
Living in own home 2.43 1.58–3.72 <0.005 
 
Nephropathy 1.54 1.03–2.28 0.033 
 
No uraemia 2.45 1.35–4.46 0.003 
 
No previous amputation 2.30 1.23–4.29 0.009 
 
Claudication 1.71 1.17–2.51 0.006 
 
No pain 1.90 1.37–2.63 < 0.005 
 
Single ulcer 2.17 1.44–3.28 < 0.005 
 
Wagner grade 1 and 2 9.76 6.77–14.08 < 0.005 
 
Wagner grade 1, 2 and 3 3.52 2.11–5.88 < 0.005 
 
 
 
 
 
2.8.1.2 IMPACT OF REVASCULARISATION  
 
The ulcer healing rate after revascularisation varies between 60% and 80% (Hinchliffe et 
al. 2016). In one series, complete healing of diabetic foot ulcers was achieved in 83% of 
patients after revascularisation by endovascular or surgical means. In 80% of the 
patients, healing was completed after a minor amputation. (Faglia et al. 2009.) Apelqvist 
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and colleagues describe the outcome of revascularisation in a cohort of 1,046 diabetic 
patients with ischaemic foot ulcers treated and followed up at a multidisciplinary clinic. 
PTA and vascular surgery increased the probability of primary healing in multivariate 
analysis (OR 1.77 and 2.05, respectively). Other factors related to primary healing were 
age, the severity of ischaemia, the extent of tissue destruction and the presence of 
comorbidity, such as heart failure and renal impairment. In 46% of endovascular cases, 
the crural arteries were treated, and 51% of the open-surgical reconstrucions had 
truncal or lower run-off. Healing without major amputation (primary healing and healing 
after minor amputation) occurred in 61% of 190 patients after vascular surgery, in 58% 
of 314 patients after PTA, in 46% of 297 patients after angiography without PTA, and in 
47% of 345 patients without angiography. The median healing time was 27 weeks (1–
292 weeks). The median follow-up time was 2 years (0.5–5) (Apelqvist et al. 2011) (Table 
18). 
Table 18. Outcome of diabetic patients with neuroischaemic diabetic foot ulcers. 
Reproduced with permission from Apelqvist et al. 2011. 
No angiography 
n=345 
Medical 
treatment 
n=297 
PTA n=314 Vascular 
surgery 
n=190 
n n % n % n % n % 
primary 
healing 
415 127 37 96 32 121 39 71 37 
minor 
amputation 
184 36 10 43 14 60 19 45 24 
major 
amputation 
143 33 10 45 15 34 11 31 16 
deceased 310 128 37 84 28 63 20 35 18 
dropouts 60 14 4 21 7 21 7 4 2 
unhealed 34 7 2 8 3 15 4 4 2 
Even though a review by Hinchliffe et al. (2016) concludes that one method of 
revascularisation is not superior over another regarding outcome, a study from our clinic 
in Helsinki indicated that bypass surgery may have a better haemodynamic effect than 
endovascular surgery. In a retrospective cohort of 545 diabetic patients with CLTI and 
tissue loss (Rutherford 5and 6), who underwent infrapopliteal endovascular (PTA) or 
open surgical revascularisation between January 2008 and December 2013, 60.3% of the 
ischaemic wounds healed during 1 year of follow-up. The highest wound healing rate 
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was achieved after angiosome-targeted bypass (77%) and the worst after non-
angiosome-targeted endovascular revascularisation (52%). When Cox proportional 
hazard analysis was adjusted for the number of affected angiosomes, direct bypass 
yielded the best wound healing (p = 0.003). (Spillerova et al. 2017.) Indeed, earlier 
studies report a similar outcome of bypass surgery regardless of the angiosome in 
relation to the location of the ulcer (Bergamini et al. 1994, Berceli et al. 1999).  
 
2.8.1.3 ANGIOSOMES 
 
Four recent meta-analyses reported better wound healing and limb salvage after 
angiosome-targeted versus non-angiosome-targeted revascularisation. One concerned 
endovascular treatment in diabetic patients, the others endovascular and open 
revascularisation of either infrapopliteal or any lower limb arteries (Jongsma et al. 2017, 
Chae et al. 2016, Bosanquet et al. 2014, Biancari and Juvonen 2014). One of the meta-
analyses entailed a discussion on the limited benefit of angiosome-targeted open 
surgical revascularisation, as the least affected outflow vessel, irrespective of the 
angiosome, is usually selected (Jongsma et al. 2017). 
A better ulcer healing rate of 75% among diabetic patients who underwent a combined 
121 angiosome-targeted revascularisations compared to the rate of 45% among patients 
who underwent a combined 129 non-angiosome-targeted revascularisations was 
observed in a Finnish study. The result was confirmed by propensity score analysis. In 
the case of an ulcer involving multiple angiosomes, direct revascularisation was defined 
as one opened angiosome specific artery (Söderström et al. 2013.)  
In another Finnish study including patients with endovascular and open surgical 
revascularisation, an association was observed between ulcer healing and angiosome 
targeted revascularisation only after adjustement for the number of affected 
angiosomes and CRP (Spillerova et al. 2017). 
 
 2.8.1.4 COLLATERALS 
 
Interest has been growing towards the indirect revascularisation of an angiosome 
through collaterals (Varela et al. 2010, Alexandrescu et al. 2019, Acin et al. 2014, Zheng 
et al. 2016). Some studies show that the outcome is similar irrespective of whether the 
angiosome is revascularised by the source artery or the collaterals but that indirect 
revascularisation without collaterals has an inferior outcome.  
In a study from Belgium, the ulcer healing rate within one year was 70%  (79/113) in the 
group with direct angiosome-targeted revascularisation, 54% (15/28) in the group with 
collaterals to the ulcer angiosome, and 20% (7/35) in the group with indirect 
revascularisation. The mean ulcer healing times were 6.8±0.4 months, 7.9±0.6 months, 
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and 9.8±0.7 months, respectively.  The estimated limb salvage at six months was better, 
86%, in the group with direct angiosome-targeted revascularisation, compared to the 
61% in the group with collaterals to angiosome and to the 58% in the group with indirect 
revascularisation. Notably, the mean follow-up time of the study was short (10.9 
months, range 3–12.5), the number of patients in the two latter groups was quite small 
and the definition of collaterals was ambiguous. The revascularisation of 18 patients was 
not successful. (Alexandrescu e al. 2019) 
In a Chinese study, 486 patients undergoing endovascular treatment for infrapopliteal 
CLTI and a tissue lesion were retrospectively divided into three groups: direct 
revascularisation of the angiosome, indirect revascularisation through collaterals and 
indirect revascularisation without collaterals based on postprocedural angiography. The 
direct revascularisation group and the revascularisation through collaterals group had 
similar unhealed ulcer and limb salvage rates, whereas the group without collaterals had 
a significantly higher rate of non-healed ulcers and a lower leg salvage rate. Diabetic 
patients without collaterals had an unhealed ulcer rate of 90% at one year, compared to 
75% in non-diabetic patients. (Zheng et al. 2016.)  
 
The 12-month ulcer healing rate was 55% among 92 diabetic patients with a combined 
101 footulcers after an attempt at infrapopliteal endovascular revascularisation. The 
technical success rate was 86%. Indirect revascularisation with collaterals to the ulcer 
area (n=22) resulted in a 12-month ulcer healing rate of 68%, with no significant 
difference in comparison to the 66% ulcer healing rate after direct revascularisation 
(n = 46). On the contrary, after indirect revascularisation without collaterals, the healing 
rate was only 7%. In the group where no patent tibial arteries were achieved, the ulcer 
healing rate was 14%. (Acin et al. 2014.) 
 
2.8.1.5 PEDAL ARCH 
 
In a series including patients withn open surgical revascularisations, 66/141 patients 
with a tissue defect had no possibility of angiosome-targeted revascularisation. The 
quality of the pedal arch was associated with ulcer healing and leg salvage, whereas the 
revascularisation of the angiosome of the tissue defect was not. Amputation-free 
survival and graft patency were similar in all pedal arch groups. (Rashid et al. 2013.) 
Similarly, in an Italian study, open pedal arch was associated with improved wound 
healing rate, one-year leg salvage rate and one-year survival rate whereas direct 
revascularisation to angiosome had no significant association to outcome. (Troisi et al. 
2017). 
Higashimori et al. observed that the leg salvage was better in patients with open 
connections through the pedal arch after infrapopliteal endovascular treatment of CLTI, 
independent of which artery was recanalised and where the ulcer was located 
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(Higashimori et al. 2016). In contrast, Kret et al. found that, among 97 patients 
undergoing a combined 106 bypass operations for CLTI, the quality of the pedal arch 
was not associated with ulcer healing but that angiosome-targeted revascularisation 
was (Kret et al.2014). 
 
2.8.1.6 HEEL ULCERS 
 
Ischaemic heel ulcers are often regarded as having a poor outcome. Studies report 
varying results, but small superficial ulcers tend to heal well. IIschaemia, nephropathy, 
oedema, osteomyelitis and gangrene are associated with an unsuccessful outcome. 
(Örneholm et al 2017, Bosanquet et al. 2015, Dosluoglu et al. 2007). Indeed, in a study 
from a limb preservation clinic with 68% diabetic patients, hind foot lesions were 
associated with a failure to heal.s. (Vartanian et al. 2015.) Chipchase and colleagues 
studied the healing of 154 heel ulcers among 97 diabetic patients. Surprisingly, only 35% 
of the diabetic patients with heel ulcers had successful healing after revascularisation. 
In contrast, the healing rate was 84% among patients with palpable pulses. Cases with 
osteomyelitis were excluded, one fifth of the ulcers had an area smaller than 3 cm2, and 
86% of the ulcers were superficials. (Chipchase et al. 2005.)  
However, severe ulcers may well heal with active treatment. A cohort study of 768 
patients showed a 65% healing rate of heel ulcers. Paradoxically, however, in addition 
to nephropathy and oedema, vascular surgery was also associated with poor healing 
(Örneholm et al. 2015).In contrast, after bypass to the dorsal pedal artery, the outcome 
of heel lesions was comparable with forefoot lesions. The bypass was performed for 336 
patients with forefoot lesions, 67 with heel lesions and 29 with both heel and forefoot 
lesions; 304 (90.5%) patients with forefoot lesions and 84 (86.5%) of the heel lesions 
healed. The above-knee (0.9% and 1.0%) and below-knee (8.9% and 8.3%) amputation 
rates were similar among the patients with forefoot and heel lesions, respectively. No 
difference was found in the wound healing rates of forefoot and heel lesions – 90.2% 
and 83.7%, respectively – irrespective of whether the pedal arch was complete (48%) or 
not. (Berceli et al. 1999) In another study, 71 legs with ulcers or gangrene of the heel 
and 237 legs with ulcers in other parts of the foot were revascularised either by vascular 
reconstruction or endovascular treatment and debridement, repeatedly if necessary. 
However, 11% of the patients with heel ulcers versus 3% with non-heel ulcers 
underwent primary amputation (p < 0.001). Leg salvage after revascularissation was 
similar in patients with heel ulcers and those with non-heel ulcers, whereas mortality 
was higher among patients with heel ulcers, 63% vs 43% (p < 0.001), respectively. 
Gangrene, dependence on dialysis treatment and low albumin levels were associated 
with major amputation in patients with heel ulcers and gangrene. Diabetes was present 
in 74% of the patients. (Dosluoglu et. al 2007.) 
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In severe tissue defects, the posterior part of the calcaneus can sometimes be removed 
and the defect closed primarily or after local treatment; for example, NPWT and STSG. 
A retrospective survey after partial calcanectomy in 42 patients (80% DM) showed no 
difference in amputation or patient ambulatory status irrespective of whether the 
resection was less or more than 50%. A major amputation was unavoidable in 28% of 
the patients, but the rate in relation to time or the rate of healing was not given. 
Approximately 45% of the patients had some vascular intervention. (Oliver et al. 2015.) 
 
2.8.1.7  HEALING TIME 
 
Median ulcer healing times vary substantially between studies, ranging from 2.5 
months to up to 14 months, probably due to different patient selection. In 
specialised foot clinics, short healing times are probably explained by, in addition to 
specialised care, the small size of ulcers and the exclusion of hospitalised patients. In an 
English cohort of patients with diabetic foot ulcers of both neuropathic and ischaemic 
origin, the median ulcer healing time was 78 days (range 7–364 d). Seventy-eight 
percent of the ulcers were superficial, 61% had an area smaller than 1 cm2, 48% were 
ischaemic and 41% infected. (Jeffcoate et al. 2006.) In another study, the healing of 
mostly superficial ulcers, only 10% UT 3D, took a mean of 165 days (Akturk et al. 2019). 
Yet, the average healing time was as short as 12 weeks in a limb preservation clinic 
where 44% of the ulcers were complex neuroischaemic ones (Vartanian et al. 2015). 
After bypass surgery, median wound healing times were observed to be longer in 74 
diabetic (213 days) than in 76 non-diabetic patients (159 days) (Söderström et.al. 2008). 
After 250 infrainguinal vascular reconstructions (66% DM), ischaemic pedal lesions 
healed in median of 198 days (Chung 2006). In connection with bypass to the dorsal 
pedal artery, the mean healing time of heel ulcers that closed was 200 (24–1,225) days 
(Chipchase et al. 2005). The mean time to complete healing was 139 days (13–16d) for 
96 heel ulcers after a bypass to the ADP (91% DM) (Berceli 1999). 
In one series, sssthe mean healing times after direct revascularisation, revascularisation 
through collaterals and indirect revascularisation were 6.8, 7.8 and 9.8 months, 
respectively (Alexandrescu et al. 2019). The healing times are associated with the tissue 
lesion and extensiveness of surgery. Among 701 patients with a plantar forefoot ulcer, 
the median healing time after inclusion was 17 (range 1–252) weeks, being 36 weeks 
after minor or major amputation (n=60), 21 weeks after debridement (n=173), and 13 
weeks without major debridement (n=385). Eighty-three (12%) patients died with 
unhealed ulcers. (Örneholm et al. 2015.) 
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2.8.1.8 REULCERATION 
The reulceration rate has ranged from 13% to 33% with follow-up periods varying 
between 8 months and 6 years (Faglia et al. 2009, Vartanian et al. 2015, Elgzyri et al. 
2015, Iwase et al. 2018, Akturk et al. 2019). The ulcer recurrence rate at a limb 
preservation centre was as high as 45% during a median follow-up of 395 (80–635) days 
(Ramanan et al. 2017). In a British study consisting of a population with approximately 
60 000 diabetic patients in a defined geographical area, the risk factors for the 
recurrence of first diabetic ulcer in a univariate model were age, type and treatment of 
diabetes, microvascular complications and location of ulcer. In a multivariate model, 
also including smoking status and depression classification, only microvascular 
complications were associated with recurrence. Remarkably, patients with severe 
ischaemia, dementia or rheumatoid arthritis and many more, were excluded from the 
study. (Winkley et al. 2007.) 
2.8.1.9 ULCER-FREE TIME 
Ulcer recurrence is frequent. Thus, the ulcer-free time provides additional outcome data 
compared to ulcer healing only. In one series, the ulcer healing rate over 12 months 
among 158 diabetic patients was 67% and the recurrence rate 31%. The mean ulcer-free 
time for healed ulcers was 212 days within 12 months and 130 days for all patients. 
Diabetes duration, CLTI, coronary artery disease, end stage renal disease (ESRD) and 
infection were independently associated with shorter ulcer-free time. (Akturk et. al 
2019.) 
2.8.2 LIMB SALVAGE 
The limb salvage rate refers to the proportion of patients who have not had a major 
amputation (amputation above ankle level) during follow-up. As deaths do occur in this 
patient population, limb salvage is an estimate usually presented as a percentage of the 
initial population. The time interval from the evaluation of the ulcer to revascularisation 
has a significant influence on limb salvage (Sheahan et al. 2005, Elgzyri et al. 2013, 
Noronen et al. 2017). According to a systematic review including 19 studies, the 1-year 
median limb salvage rate after surgical revascularisation of ulcerated diabetic feet was 
85% (IQR 80%–90%). After pedal bypass, the 1-year and 5-year median limb salvage 
rates were 86% (IQR of 85%–98%) and 78% (IQR 78%–82%), respectively. (Hinchliffe et 
al. 2016.) A meta-analysis of reconstructions with popliteal inflow (86% diabetic 
patients, 88% tissue loss) consisting of 31 studies from 1986–2004 showed a 5-year foot 
preservation rate of 78% of the patients. The 1- and 5-year limb salvage rates after 
popliteal to tibial grafts were 88% and 80 %, respectively, and after popliteal to pedal 
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bypass 88% and 78%, respectively. (Albers et al. 2006.) A systematic review of patients 
with ischaemic diabetic foot ulcers shows that, following endovascular treatment, the 
median 1-year and 3-year limb salvage rate was 78% (IQR 70.5–85.5) and 77% (IQR 63%–
80%), respectively. The 5-year limb salvage was reported in two studies, being 56% and 
77%, respectively (Hinchliffe et al. 2016). 
Four recent meta-analyses that were already mentioned in the context of ulcer healing, 
report a better limb salvage rate after angiosome-targeted than after non-angiosome-
targeted revascularisation. One focussed on endovascular treatment among diabetic 
patients, the other three on the infrapopliteal and any lower limb endovascular and 
open revascularisation (Chae et al. 2016, Bosanquet et al. 2014, Biancari and Juvonen 
2014, Jongsma et al. 2017). In one of the meta-analyses, the pooled limb salvage in 
patients with direct revascularisation after any lower limb endovascular and open 
revascularisation swas 86% at one year and 85% at two years, whereas indirect 
revascularisation resulted in rates of 78% and 70%, respectively. More than 70% of the 
patients had diabetes (Biancari and Juvonen 2014).  
The location of the ulcer was insignificant for limb salvage after bypass to the ADP. The 
1- and 5-year limb salvage rates were 93.5% vs 94.2% and 89.4% vs 87.4% in patients 
with heel or forefoot ulcers, respectively (Berceli et al. 1999). After revascularisation, no 
significant difference seems to exist between diabetic and non-diabetic patients as 
regards long-term limb salvage (Table 19). The 5- and 10-year limb salvage rates 
reported after 352 inframalleolar bypasses for CLTI performed between 2002 and 2013 
in Helsinki were 72.0% and 67.2%, respectively. The majority of the patients had 
diabetes (69%), and limb salvage was equal in patients with and without diabetes (p = 
.460). (Saarinen et al. 2016.) Accordingly, no significant difference between 643 diabetic 
and 667 nondiabetic patients was observed in the rates of limb salvage at 5 and 10 years 
(88% and 76% vs 91% and 83%; log-rank test, P = .12) after bypass with infrainguinal 
outflow. Eighty percent of diabetic patients and 67% of nondiabetic patients had a non-
healing ulcer or gangrene. (Ballotta et al. 2014.) 
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Table 19. limb salvage after revascularisation. 
Author, year Number of 
patients 
(DM) 
Open/ 
endovascular 
Limb salvage Special 
Pomposelli et 
al. 2003 
865 (92%) open 5-year 78%,
10-year 58%
pedal bypass 
Panneton et 
al. 2000 
157 (100%) open 5-year 78% inframalleolar bypass, 
tissue defect 93% 
Panneton et 
al. 2000 
57 (0%) open 5-year 78% inframalleolar bypass, 
tissue defect 79% 
Ballotta et al. 
2014 
643 (100%) open 5-year 88%,
10-year 76%
infrainguinal outflow, 
80% tissue defect 
Ballotta et al. 
2014 
667 (0%) open 5-year 91%,
10-year 83%
infrainguinal outflow, 
67% tissue defect 
Berceli et al. 
1999 
336 open 1-year 94.2%,
5-year 87.4%
pedal bypass, forefoot 
ulcer 
Berceli et al. 
1999 
96 open 1-year 93.5%,
5-year 89.4%
pedal bypass, heel 
ulcer 
Sheahan et al. 
2005 
670 (92%) open 1-year 90%,
5-year 82%
all subsequent or 
previous minor 
amputation 
Hughes et al. 
2004 
98 (84%) open 1-year
75%,5-year
69%
plantar arteries/ 
lateral tarsal artery, 
95% tissue defect 
Azuma et al. 
2012 
228 (81%) open 2-year 93% 100% ulcer or 
gangrene 
Alexandrescu 
et al. 2009 
176 limbs 
(100%) 
endo 1-year 89%,
3-year 80%
100% ulcers 
Acin et al. 
2014 
46 (100%) endo 2-year 89% 100% ulcers, direct to 
angiosome 
Acin et al. 
2014 
22 (100%) endo 2-year 85% 100% ulcers, indirect 
with collaterals to 
angiosome 
Acin et al. 
2014 
17 (100%) endo 2-year 59% 100% ulcers, indirect 
without collaterals 
Söderström et 
al. 2013 
121 (100%) endo 1-year 86% infrapopliteal, direct 
to angiosome, 100% 
ulcer or gangrene 
Söderström et 
al. 2013 
129 (100%) endo 1-year 77% infrapopliteal, indirect 
to angiosome, 100% 
ulcer or gangrene 
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2.8.2.1 RISK FACTORS FOR MAJOR AMPUTATION 
 
Many factors have been associated with poor limb salvage. Diabetes, in addition to the 
degree of ischaemia and infection, was associated with major amputation within one 
year of revascularisation among 139 patients (66% diabetic individuals) with a 
combined 158 ischaemic ulcers scored according to the WIfI classification s(Cull 2014).  
In patients with a DFU an ulcer diameter of over 3 cm, associated osteomyelitis and 
ESRD predicted limb loss after revascularisation (Alexandrescu et al. 2009). The risk 
factors for major amputation in patients with a DFU were bony invasions, dialysis, 
gastrointestinal disorders, hind foot locations, low levels of haemoglobin and elevated 
fasting blood sugar levels (Namgoong et al. 2016). 
A cohort of 2,511 consecutive patients from a multidisciplinary diabetic clinic were 
followed prospectively. Amputation in connection with neuro-ischaemic ulcers was 
related to comorbidity, peripheral vascular disease and the type of ulcer. Age, sex, 
duration of DM, neuropathy, deformity, duration of ulcer or site of ulcer were not 
related to the probability of amputation (Gershater et al. 2009) (Table 20). 
In a multivariate analysis included in one study, any lower-extremity amputation 
(including minor amputations) due to an infected diabetic foot ulcer was associated 
with periwound oedema, foul smell, increased exudate and pus, ulcer depth, pretibial 
oedema, a body temperature of > 38°C, and high CRP. (Pickwell et al. 2015). 
 
Table 20. Factors related to major amputation in connection with neuroischaemic/ 
ischaemic ulcers. Reproduced with permission from Gershater et al. 2009. 
Factor Odds ratio 95% CI p-value 
Duration of diabetes >23 years 1.88 1.15–3.50 0.011 
Uraemia 2.43 1.33–4.45 0.004 
Oedema 2.51 1.79–3.54 0.000 
Foot deformity 1.69 1.08–2.63 0.021 
Toe pressure < 30 mmHg 1.70 1.20–2.40 0.003 
Intermittent claudication 1.88 1.25–2.82 0.002 
Rest pain 2.06 1.45–2.98 0.000 
Multiple ulcers 2.92 1.90–4.49 0.000 
Non-compliant 2.15 1.26–3.66 0.005 
Male sex 1.51 1.06–2.15 0.021 
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2.8.3 AMPUTATION FREE SURVIVAL 
Whether the outcome of diabetic patients after bypass surgery is worse than that of 
nondiabetic patients is controversial and probably depends on the point of view. In a 
registry-based study from the US, CLTI was a more important predictor of low AFS than 
DM in patients with lower extremity ulcers. Patients with LEAD only were 8 years older 
than patients with LEAD and DM. (Humphries et al. 2016.) Furthermore, no significant 
difference between 643 diabetic and 667 nondiabetic patients with CLTI was observed 
in the rates of AFS at 5 and 10 years after infrainguinal vascular reconstruction by a single 
surgeon (45.5% and 27% vs 51% and 29%; log-rank test, P =.19) (Ballotta et al. 2014). 
However, population-based data achieved from a Swedish national register showed 
that, after lower extremity bypass for CLTI, AFS was lower in diabetic than in nondiabetic 
patients. The age-adjusted hazard ratio (HR) for death or ipsilateral major amputation 
was 1.55, and for ipsilateral major amputation 1.67 in diabetic patients. Diabetic 
patients were younger but had more severe tissue defects and more comorbidities. Type 
1 and type 2 diabetes could not be analysed separately. (Malmstedt et al. 2008.)  
2.8.4 SURVIVAL 
Mortality among patients with DFU is high (Armstrong et al. 2020). The ten-year survival 
of diabetic patients under 65 years of age presenting with first foot ulcer was 85%, of 
patients aged 65-74 years the survival was 50% and of patients ovet 74 years it was 25% 
in a NHS area of the UK. In patients with new DFU combined with LEAD 5-year survival 
was 35%. (Paisey et al.2019) Three-year mortality in patients with diabetic foot ulcers 
was 26% in a Canadian register-based study (Hopkins et al. 2015). Five-year mortality in 
a cohort of 185 diabetic patients with new foot ulcers and ischaemia was 56%, whereas 
it was significantly lower, 45%, in patients with neuropathy. However, the only factor 
associated with mortality in the multivariate model was age. Accordingly, patients with 
ischaemic ulcers were older than patients with neuropathic ulcers. Five-year mortality 
was similar in patients with a new diabetic foot ulcer, either neuropathic or ischaemic, 
who underwent minor or major amputation and in patients who had ulcers but no 
amputation: 47% and 43%, respectively. (Moulik et al. 2003.) 
One-year survival after revascularisation for DFU has been approximately 90% and five-
year survival circa 50% (Faglia et al. 2009, Hinchliffe et al. 2016). A Swedish register-
based study showed an increased risk of death (HR 1.49, 95% CI 1.30–1.71) among 
diabetic patients compared to non-diabetic patients after revascualrisation fot CLTI 
(Malmstedt et al. 2009). In contrast, no significant difference between diabetic and 
nondiabetic patients was observed in the rates of survival at 5 and 10 years after 
vascular reconstruction for CLTI (51% and 34% vs 57% and 38%; log-rank test, P = .41) 
(Ballotta et al. 2014). After bypass surgery for patients with Fontaine IV foot lesions (55% 
DM), the survival rates at one, three and five years were 71%, 53% and 38%, respectively 
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(Söderström et al. 2010). The five- and ten-year survival rates after pedal bypass for limb 
salvage (92% DM) were 49% and 24%, respectively (Pomposelli et al. 2003).  
 
2.8.5 CLINICAL/FUNCTIONAL OUTCOME 
 
Taylor et al. studied the clinical outcome of revascularisation in patients with ischaemic 
tissue loss (68% DM) (Taylor et al. 2009). Four criteria needed to be fulfilled in clinically 
successful revascularisation: the treated segment should stay open until wound healing, 
ambulation at 1 year, at least 1-year limb salvage, and 6-month survival. The failure rate 
among diabetic patients was 64%. Among diabetic patients with impaired preoperative 
ambulation, 74% failed to fulfil the criteria. Of diabetic patients with impaired 
ambulation and ESRD, the failure rate was 82%. For diabetic patients with impaired 
ambulation and gangrene, the failure rate was 85% and for diabetic patients with ESRD 
58%. Among diabetic patients with ESRD, impaired ambulation, gangrene and a prior 
revascularisation, the failure rate was 93%. (Taylor et al. 2009.) Iida et al. studied the 
outcome of 662 patients with CLTI who needed assistance in daily living and/or had 
impaired cognitive function. Of these patients, 562 were in the revascularisation group 
and 100 in the non-revascularisation group. Functional ability after one year was similar 
to the baseline functional ability, but the quality of life quality had improved in the 
revascularisation group. (Iida et al. 2017.) 
ESRD is significantly associated with poor outcome. Jones et al. studied the outcome one 
year after revascularisation. Only 40% of patients with ESRD and tissue loss (85% DM) 
remained alive for at least 6 months, had the bypass open until the healing of the tissue 
lesion, remained ambulatory for at least six months and had their limb intact for one 
year after surgical revascularisation (Jones et al. 2007). In another study, 70 patients 
with a technically successful vascular reconstruction for limb-threatening ischaemia 
(open in follow-up) had a decreased walking capacity and were less able to manage 
household tasks and shopping, prepare meals, bathe, drive a car and participate social 
activities when compared to an age- and sex-matched control group . No significant 
difference was observed in dressing and going to the toilet. Despite these functional 
impairments, patients with vascular reconstructions had a similar sense of wellbeing and 
a similar amount of health complaints to the control group. (Seabrook et al. 1999.) 
In order to study ideal recovery from infra-inguinal open revascularisation, data on the 
functional status, wound healing time, the need for repeat operations, recurrent 
ischaemia, postoperative complications, mortality, graft patency and leg salvage were 
analysed among 112 patients (53% DM). Fourteen percent of the cohort reached the 
ideal outcome with prompt healing, long-term disease control and the maintenance of 
functional capacity without postoperative complications, reoperations or relapses. 
(Nicoloff et al. 1998) 
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Of ambulatory, nursing home residents 63% remained nonambulatory or died within 
one-year after open surgical or endovascular revascularisation. Age over 80 years, 
cognitive impairment, congestive heart failure, renal failure, emergent surgery, non-
ambulatory status before surgery, and a decline in daily activities before surgery were 
associated with death or nonambulatory status after revascularisation. (Oresanya et al. 
2015.) 
2.8.6 OUTCOME OF FREE TISSUE TRANSFER 
2.7.6.1 GENERAL POSTOPERATIVE COMPLICATIONS 
The risk of complications after FTT is high, as the overall 30-day complication rate has 
been 30%–50% (Moran et al. 2002, Randon et al. 2010, Fitzgerald O’Connor et al. 2011). 
The most common fatal complication has often been congestive heart failure. In 
Belgium, in addition to three fatal congestive heart failures in 76 patients, three patients 
suffered strokes with a good recovery (Randon et al. 2009). Congestive heart failure was 
also observed in 6 out of 76 patients in Rochester, 4 with a fatal outcome. A further two 
non-fatal AMs (acute myocardial infarctions) were encountered. The one of these two 
patients developed intestinal ischaemia, which was operated on successfully. (Moran et 
al. 2002.) In an earlier series from Helsinki University Hospital, 3 respiratory, 2 cardiac 
and renal complications, 1 cerebrovascular complication, and 1 multiorgan failure 
occurred. Furthermore, 2 cases of sepsis were encountered. The one of these was due 
to sacral decubitus. (Tukiainen et al. 2000.) The 30-day postoperative mortality was 3%–
5% in a large meta-analysis (Fitzgerald O’Connor et al. 2011). The two largest series 
report 30-day postoperative mortality rates of 5% and 3.8%, respectively (Moran et al. 
2002, Randon et al. 2009), and mortality was lower among diabetic patients, only 2%. 
(Randon et al. 2010). Diabetes alone and combined with ESRD were associated with 
mortality (Illig et al. 2001). In the earlier series from Helsinki, one patient with open 
sacral decubitus died of sepsis on the 40th postoperative day, accounting for a 3.4% 
mortality (Tukiainen et al. 2000).  
2.8.6.2 POSTOPERATIVE FLAP AND DONOR SITE COMPLICATIONS 
Minor complications are seen in 30% of the patients and include haematoma, infection 
and flap edge necrosis (Fitzgerald O’Connor et al. 2011, Moran et al. 2002, Randon et al. 
2010, Tukiainen et al. 2000). Reinterventions are frequently necessary after FTT and 
include thrombectomies, reanastomosis of arteries or veins, new free flaps, skin grafts 
and amputations. (Table 21) The postoperative major amputation rate was 6% in two 
large studies (Randon et al. 2009, Moran et al.2002). Flap failure often leads to major 
amputation, while this end result is not as frequent with vascular graft thrombosis. The 
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reported total flap failure rates are 10%–25%. In a large series (433 patients), the overall 
failure rate was 10%; for patients who had free perforator flap (n=152), the rate was 
15% and for patients who had LEAD (n=102) 25%. DM, LEAD, chronic ulcer, nephropathy, 
location in the foot and CHD were risk factors for an unsuccessful flap, whereas trauma 
was associated with better success in univariate analysis (Koh et al. 2018). Among 231 
FTTs due to various reasons, the leading cause being trauma, diabetes was a risk factor 
for flap failure in multivariate analysis (Cho et al. 2016). 
Donor site problems are flap specific. The ALT-flap typically has a low frequency of 
complications (Randon et al 2009, Ren et al. 2015) In the LD flap donor site, a seroma or 
wound healing problems were observed in 5.3% of patients (Kim et al 2015). The 
shoulder extension strength diminished permanently but the subjective morbidity was 
low according to a study focusing on the latissimus dorsi muscle donor site problems 
(Salmi et al. 1995). In one meta-analysis some decrease in the strength and mobility of 
the shoulder region as determined by means of objective measurements and to patient 
questionnaires, as well as impairment of working ability and discomfort were observed 
(Lee et al. 2015). The rectus abdominis flap donor site complications include donor site 
healing problems 18%, mesh-problems and further, the abdominal wall laxity and 
hernias (Mirzabeigi et al. 2014, Randon et al. 2009). In one study, an unhealed donor 
site wound at six months was observed in 18 % of patients. (Mirzabeigi et al. 2014) In 
another study, an abdominal bulge and hernias were observed among 10% of patients 
(Sailon et al. 2009). Delayed healing and a partial loss of skin graft easily result in a 
tendon adhesion and furthermore, an impairment in hand strength and range of 
movement after raising of the radial forearm flap (Suominen et al. 1996). These 
problems are encountered in up to 10% of patients. In one study, dysesthesia was 
observed in half of the patients, but it usually resolved later (Lutz et al 1999). However, 
suprafascial elevation and a sheet skin graft may diminish the donor site problems of 
radial forearm flaps. (Chau et al. 2009, Lutz et al 1999) 
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Table 21. Postoperative outcome after FTT 
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McCarthy 
1999 30-d 
21 LD 5, omentum 
5, RA 5, gracilis 
2, RF 3, 
scapular 1 
21 7 2 3 0 3 0 
Tukiainen 
2000 30-d 
29 LD 20, 7 RA, RF 
1, TFL 1, 
gracilis 1 
29 10 5 4 2 1 0 
Moran 
2002 
75 RA 35, LD 15, 
RF 24, scapular 
3, omentum 2 
61(81%) - 7 6 9 5 4 
Randon 
2010 
55 RA 44, LD 5, 
ALT 3, serratus 
anterior, lateral 
arm 
55 17 ? 5 6 5 1 
Gooden 
1997 
26 RA 9, RF 8, LD 
7, scapular 3 
17 (65%) 9 4 2 2 2 2 
Huang 
2014 
24 LD and RA 24 (endo) 12 3 0 - 0 1 
Oh 2012 121 ALT 90, SCIP 
20, AMT 5, 
UMT 3 
9+endo5 
(11,5%) 
10 14 10 - - - 
Lee 2014 33 ALT 19, TAP 9, 
gracilis 5 
33 open 
or endo 
8 - 10 3 d - - 
revasc (revascularisation), Cl-D (Clavien-Dindo), partial fl (partial flap loss), bypass 
thromb (bypass graft thrombosis) LD (latissimus dorsi), RA (rectus abdominis), RF 
(radial forearm), TFL (tensor fasciae latae), ALT (antero-lateral thigh), SCIP (superficial 
circumflex iliac artery perforator) AMT (anteromedial thigh), UMT (upper medial thigh), 
TAP (thoracodorsal artery perforator) 
a no major amputation b included in Clavien-Dindo classification c not included in 
Clavien-dindo d (included in flap loss) 
2.8.6.3 LONG-TERM OUTCOME 
The complete healing of all wounds in an ischaemic foot takes an average of 4 months 
(range 1–8) after FTT (McCarthy et al. 1999). The reported one-year limb salvage rate 
among diabetic patients after FTT has been 70%–96% (Huang et al. 2014, Moran et al. 
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2002, Randon et al. 2010). The average limb salvage in a meta-analysis on FTT in diabetic 
feet was 83.4% over an average of 28 months (1–68) of follow-up (Fitzgerald O’Connor 
et al. 2011). Amputations mostly occur during the first two years after the operation. In 
an all-diabetic population, the 5-year limb salvage rate was 64% (Randon et al. 2010). 
LEAD and PTA were correlated with flap loss (OR 17.6 and 10.2), in addition to 
immunosuppressive medication related to kidney transplantation (OR 4.9) (Oh et al. 
2013). Atherosclerotic calcifications (p = 0.002) and elevated serum creatinine levels 
(p = 0.04) were associated with partial or total flap loss (Lee et al. 2014). Renal 
insufficiency has also been identified as a risk factor for limb loss after FTT and vascular 
reconstruction, with an HR of 5.6 (95% CI 1.4–22.5) (Randon et al. 2010). However, 
location (foot vs leg), weight bearing flap, hypertension, previous acute myocardial 
infarciotn (AMI), osteomyelitis, inflow vessel, the timing of vascular reconstruction and 
flap type, in turn, have not been established as risk factors for FTT failure (Moran et al. 
2002). 
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3 AIMS OF THE PRESENT STUDY 
1) To evaluate the incidence and risk factors of lower extremity arterial disease in type
2 diabetic patients (Study I).
2) To assess the long-term limb salvage rates and risk factors of amputation after
combined vascular reconstruction and microvascular free-flap transfer in patients with
critically ischaemic large tissue defects (Study II).
3) To analyse the impact of the severity of LEAD and other risk factors on the long-term
outcome after FTT for large diabetic foot lesions (Study III).
4) To prospectively evaluate the long-term survival, limb salvage, ulcer healing and
reulceration rate in nonselective consecutive patients with an ischaemic foot ulcer
visiting a university hospital vascular surgery unit, and to assess the risk factors for
amputation (Study IV).
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4 MATERIAL AND METHODS 
The thesis includes three cohorts of patients. One was a cohort of 130 type 2 diabetic 
patients, the second was a cohort of 96 consecutive patients who underwent free flap 
transfer between in order to treat large tissue defects of the diabetic or ischemic foot, 
and the third was a cohort of 95 consecutive patients who were referred for vascular 
surgical consultation and admitted to the ward for specific investigations. Two 
overlapping subcohorts were formed out of 96 patients who had undergone FTT: a 
cohort of 63 patients with diabetes and a cohort of 79 patients who underwent 
combined FTT and vascular reconstruction. Included in both cohorts were 51 patients 
with DFU who underwent combined FTT and revascularisation. 
Table 22. Demographics of Studies I-IV 
Study 1 Study 2 Study 3 Study 4 
Number of patients 130 79 63 95 
Age, years 58±6 (42-69) 61±12 56 (IQR21) 71±12 (r40-
92) 
Male 51% 65% 70% 55% 
Ever smoking 53% 28% 19% 62% 
Type 1diabetes 0 26% 38% 9,5% 
Type 2 diabetes 100% 47% 62% 46% 
Coronary artery 
disease 
13% 
(AMI+ECG) 
(n=126)
35% 32% 54% (n=91) 
Cerebrovascular 
disease 
2,3% (n=129) 7% 11% 26% (n=91) a 
Renal insufficiency 0 27% 23% 
Uraemia 0 3% 7% 
Renal 
transplantation 
0 9% 13% 4% 
ASA 4 0 25% 22% 
Revascularisation 2,3% 100% 84% 75% 
a (inf tai EA) AMI acute myocardial infarction, ECG electrocardiogram, ASA American 
Society for Anesthesiologists, IQR = interquartile range. 
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4.1 STUDY I 
4.1.1 PATIENTS AND STUDY DESIGN 
In order to conduct a prospective cohort study, 130 type 2 diabetic patients, arbitrarily 
selected from the register of the Helsinki Diabetes Association, were examined at 
baseline in 1983–1985 and at follow-up in 1992–1993, an average of 11 years later 
(Table 22). Ninety-three patients were available for the follow-up study.  
4.1.2 OUTCOME MEASURES 
Study I focused on the risk factors of the presence of LEAD at baseline and on the 
development of new LEAD during follow-up. The primary endpoint was LEAD based on 
the ankle-brachial index, and if it exceeded 1.15, on toe pressure measurement in the 
vascular laboratory. Secondary endpoint data on deaths was obtained from the Digital 
and Population Data Services Agency. Causes of death were ascertained from medical 
records. Risk factor assessment was accomplished at baseline. Blood tests for HBA1c 
percentage, c-peptide, cholesterol and triglyceride concentrations were analysed at 
baseline. Urine albumin excretion rate (UAER) was calculated from 24-hour or overnight 
urine collection. EKG was taken and analysed according to the Minnesota coding. A 
review of medical history was ascertained from medical records. 
4.1.3 STATISTICAL ANALYSIS 
Categorical data were analysed with Fischer’s two-tailed test and continuous data with 
the Mann-Whitney U test. For the identification of risk factors, Cox backward stepwise 
logistic regression analysis was applied. A significance level of p < .05 was used. 
94 
4.2 STUDY II 
4.2.1 PATIENTS AND STUDY DESIGN 
All 79 consecutive patients in Helsinki University Hospital who underwent FTT and 
vascular reconstruction for ischaemic foot defects from 1989 to 2003 were included in 
the retrospective cohort study  (Figure 4. The follow-up data until the end of 2005 were 
retrieved from medical records, and, if necessary, via telephone calls to patients. 
Figure 4. Decision tree for the treatment of ischaemic lower extremity ulcers in Helsinki 
University Hospital. Reproduced with permission from Tukiainen et al. 2003. 
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4.2.2 OUTCOME MEASURES 
The primary endpoint was amputation, and the secondary endpoints were amputation-
free survival and death. Amputation and operation data were available form medical 
records. Amputations were confirmed from HILMO (Care register for health care) and 
deaths from the Digital and Population Data Services Agency. Demographics, medical 
history, the characteristics of the ulcers, noninvasive vascular measurements, 
angiographic findings and operation details were based on medical records. (Tables 22 
and 23.) 
Table 23. Location of tissue defects 
Location Number of defects 
Forefoot 30 
Dorsum of the foot 8 
Heel 18 
Mid-foot plantar 3 
Tarsal 5 
Achilles tendon region 3 
Lower leg 14 
4.2.3 STATISTICAL ANALYSIS 
Categorical data were analysed with Pearson’s X 2 test, and log-rank test was used for 
the comparison of 2 groups. Survival and amputation data were compared with Kaplan-
Meier analysis. Cox backward stepwise logistic regression analysis was applied for the 
identification of factors influencing survival and major amputations. A p-value of < .05 
was considered statistically significant. 
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4.3 STUDY III 
4.3.1 PATIENTS AND STUDY DESIGN 
All 63 consecutive diabetic patients whose tissue defect of the foot due to chronic 
ulceration or gangrene was covered with FTT in Helsinki University Hospital during 
1991–2003 were included. Three groups with different strategies required to overcome 
ischaemia were observed (Figure 5). Patients in group NA (native artery) had patent 
native arteries and no need for vascular reconstruction. Patients in group C (correctable 
ischaemia) underwent vascular reconstruction to overcome ischaemia. Patients in group 
U (uncorrectable ischaemia) were lacking a recipient artery in the ulcer area, making 
vascular reconstruction to overcome ischaemia impossible. The follow-up lasted until 
the end of year 2009 or to the death of the patient. 
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4.3.2 OUTCOME MEASURES  
 
The primary endpoint was a major amputation and secondary endpoints were ulcer 
healing, ulcer healing time, amputation free survival and death. The ulcer was 
considered healed if it persisted fully epithelised at least six months after healing. 
The pre- and perioperative baseline data, demographics, the medical history, 
characteristics of the ulcers, the noninvasive vascular measurements, angiographic 
findings and operation details were retrieved from medical records and partly collected 
prospectively. The follow-up data was retrieved from hospital medical records as well as 
from the primary care centres and home nursing services.  
 
4.3.3 STATISTICAL ANALYSIS  
 
Baseline data were compared between the groups using the chi-squared Pearson’s or , 
Fischer’s exact test or the Mann-Whitney U test, as appropriate. Survival was studied by 
means of Kaplan-Meyer analysis. The estimated median survival was given with a 95% 
CI. Risk factors for endpoints were tested with the log-rank test. A p-value of < .05 was 
considered statistically significant. 
 
4.4 STUDY IV 
 
4.4.1 PATIENTS AND STUDY DESIGN 
 
In 1999, 99 consecutive patients with ischaemic ulcers admitted to the wards for 
angiography by appointment or as emergency cases were interviewed, and the ulcers 
were examined. In 1999, angiography was the primary diagnostic method following 
vascular laboratory measurements and required an inpatient admission. Follow-up data 
were retrieved ten years later from patient records and by means of telephone 
interviews when necessary. Baseline examinations revealed 4 non-ischaemic ulcers, 
which were excluded from the study, leaving 95 patients (Figure 6). 
 
4.4.2 OUTCOME MEASURES  
 
Primary endpoint was amputation and secondary endpoints were postoperative 
mortality and amputations above the ankle level, as well as limb salvage, survival, 
amputation-free survival, ulcer healing, mean ulcer healing time and mobility.  An ulcer 
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was considered healed if it was still fully epithelised after six months. Smoking, ulcer 
duration, mechanism of ulceration and mobility, as well as the diameter, depth, signs of 
infection, location and the number of ulcers were recorded. The medical history was 
ascertained from the medical records. The feeding arteries of angiosomes could be 
ascertained for 91 patients from angiographic findings and operation data. Feeding 
arteries and angiosomes were defined as follows: the ADP and distal ATP for the toes; 
the distal ATP for the plantar surface; the distal ATP and fibularis for the heel; the ADP 
for the dorsal surface of the foot; and all three arteries of the leg for the ankle and leg.  
4.4.3 STATISTICAL ANALYSIS 
In Study IV, factors associated with amputation, death and ulcer healing were analysed. 
Pearson’s chi-squared and Mann-Whitney U tests were used to study univariate 
associations. Independent associations with endpoints were analysed with a COX logistic 
regression model. The Kaplan-Meier test was used for survival analysis. 
Figure 6. Patients and treatments at baseline in Study IV 
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5 RESULTS 
5.1 LEAD IN TYPE II DIABETIC PATIENTS (STUDY I) 
5.1.1 INCIDENCE 
At baseline, 16% of type 2 diabetic patients (mean age 58 years) had LEAD. During a 
mean 11-year follow-up, 24% of the patients developed new LEAD (Figure 7). 
Figure 7. Patients in Study 1. PAD peripheral arterial disease. Reproduced with 
permission from Kallio et al. 2003. 
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5.1.2 RISK FACTORS 
At the baseline, patients with LEAD were older, had a longer duration of diabetes, and 
were more often microalbuminuric than patients without LEAD (Table 24). In 
multivariate logistic regression analysis, LEAD was associated with age, the duration of 
diabetes, smoking and urinary albumin excretion rate (Table 25).  
Table 24. Characteristics of the patients at baseline 
LEAD, 21 patients no LEAD, 
109 patients 
p 
Age (years) 61±0.8 57±0.6 0.01 
Sex (% male) 57 50 
History of smoking (%) 71 50 
BMI (kg/m2) 27±0.5 27±0.4 
Insulin treatment (%) 18 22 
Duration of diabetes (years) 12±1.0 9±0.4 0.01 
HbA1 (%) 10.6±0.4 9.9±0.2 
C-peptide (nmol/l) 0.48±0.06 0.47±0.03 
Systolic BP (mmHg) 156±7 153±2 
Diastolic BP (mmHg) 87±3 88±1 
Hypertension (%) 67 51 
Total cholesterol (mmol/l)* 6.5±0.3 6.3±0.1 
LDL cholesterol (mmol/l)* 4.4±0.3 4.3±0.1 
HDL cholesterol (mmol/l)* 1.3±0.05 1.4±0.04 
Triglycerides (mmol/l)* 2.8±0.5 2.3±0.2 
UAER (mg/24h) 61±19 12±2 0.0003 
Microalbuminuria (%)** 52 11 <0.0001 
ECG changes (%) 5 10 
History of MI (%) 1 8 
History of stroke (%) 2 1 
LEAD lower extremity arterial disease; BMI, body mass index; BP, blood pressure; UAER, 
urine albumin excretion rate; ECG, electrocardiogram; MI, myocardial infarction. HDL 
high density lipoprotein. Data are means ± SE or percentage. LEAD/no LEAD n= *22/104, 
**21/103. 
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Table 25. Factors associated with LEAD at baseline in multivariate analysis. 
Log likelihood ratio Odds ratio (95%CI) 
Age p=0.03 1.15 (1.00–1.32) 
Smoking p=0.04 3.69 (0.98–13.84) 
Duration of diabetes p=0.05 1.13 (1.00–1.27) 
UAER p=0.002 1.02 (1.00–1.04) 
UAER urine albumin excretion rate 
The patients who developed new LEAD had higher lipid levels than patients who 
remained free of LEAD (Table 26). In multivariate logistic regression, age, high LDL 
cholesterol and low HDL cholesterol were associated with the development of new LEAD 
(Table 27).  
Table 26. LEAD at follow-up: baseline characteristics of the 89 patients with no LEAD at 
baseline who participated in the follow-up study 
new LEAD 
(21 patients) 
no LEAD 
(68 patients) 
p 
Age (years) 58.6±1.0 56.6±0.7 
Sex (% male) 38 49 
Smoking history (%) 57 44 
BMI (kg/m2) 27±1 27±1 
Systolic BP (mmHg) 158±5 153±3 
Diastolic BP (mmHg) 88±1 88±2 
Hypertension (%) 48 52 
Insulin treatment (%) 14 24 
Diabetes duration (years) 9.9±0.6 8.5±0.6 
HbA1 (%) 10.3±0.5 9.6±0.2 
C-peptide (mmol/l) 0.49±0.05 0.44±0.05 
Total cholesterol (mmol/l) 7.2±0.4 6.1±0.2 0.002 
LDL cholesterol (mmol/l) 4.8±0.3 4.1±0.1 0.03 
HDL cholesterol (mmol/l) 1.3±0.1 1.5±0.1 0.04 
Triglycerides (mmol/l) 3.5±0.6 1.8±0.2 
UAER (mg/24h) 10±3 10±3 
Microalbuminuria (%) 10 7 
BMI body mass index; BP blood pressure; LDL low density lipoprotein; HDL high density 
lipoprotein; UAER urine albumin excretion rate; LEAD lower extremity arterial disease 
102 
Table 27. Factors associated with development of new LEAD in 89 patients free of 
LEAD at baseline 
p for log likelihood ratio Odds ratio (95%CI) 
Age 0.002 1.25 (1.06–1.48) 
LDL cholesterol 0.002 2.97 (1.33–6.66) 
HDL cholesterol 0.0003 0.009 (0.0003–0.23) 
Follow-up time 0.008 1.62 (1.09-2.41) 
5.1.3 LONG-TERM OUTCOME 
During the follow-up, 29 patients (22%) died, 21 of cardiovascular causes. Mortality in 
patients with LEAD was high compared to patients without LEAD: 58% vs 16% 
(p < 0.001). An ABI of < 0.9 was strongly predictive of death in patients with no other 
sign of cardiovascular disease at baseline (p < 0.001). 
5.2 EFFECT OF REVASCULARISATION ON THE LONG-TERM 
OUTCOME OF DIABETIC PATIENTS WITH ISCHAEMIC ULCERS 
(STUDY IV) 
5.2.1 CHARACTERISATION OF PATIENTS AND ULCERS REFERRED FOR 
VASCULAR CONSULTATION 
The cohort of patients with ischaemic ulcers was heterogeneous. Revascularisation was 
performed on 75% of the patients, whereas 25% received conservative treatment 
(Figure 6). The patient characteristics are presented in Table 28 and ulcer characteristics 
in Table 29. Revascularisation was performed for equally sized groups of type 2 diabetic 
patients and nondiabetic patients. In addition, a small group of seven patients with type 
I DM underwent revascularisation. Significant differences existed in cardiovascular and 
renal morbidity, as well as age and ulcer characteristics between the patient groups. 
Heel ulcers were common in patients with type 1 diabetes and deep ulcers and infection 
in patients remaining without revascularisation.  
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Table 28. Patient characteristics in Study IV 
Variable Revasc Revasc DM2 Revasc NoRevasc sig. 
DM1 n=7 n=33 noDM n=31 n=24 
male sex 4 (57) 22 (67) 13 (42) 13 (54) b 
age 45 (40–55) 74 (48–88) 76 (60–89) 73 (44–92) a,d,e 
no DM 0 0 31 11 
DM 2 0 33 0 11 
uraemia 3 (43) 2 (6) 0 2 (8) a,d,e 
renal transplantation 4 (57) 0 0 0 a,d,e 
CVD 1 (14) 9 (27) 3 (10) 12 (50) b,c 
history of AMI 4 (57) 17 (52) 4 (13) 6 (25) b,e 
coronary bypass 4 (57) 7 (21) 2 (7) 6 (25) a,c,e 
body mass index 23 (18–29) 26 (17–40) 23 (18–34) 21 (15–51) b 
ever smoking 4 (57) 24 (73) 21 (70) 10 (42) f 
current smoking  2 (29) 3 (9) 12 (40) 5 (21) b,c 
contralat. major LEA 2 (29) 4 (12) 2 (7) 4 (17) 
C-reactive protein 13 (4–165) 20 (4–159) 13 (4–114) 60 (4–308) c,f 
leukocytes 11 (3.8–12.4) 8.2 (4.8–11.8) 7.3(3.6–13.9) 8.5 (4–24) 
creatinine 115 (64–999) 110 (67–596) 82 (57–140)n 115 (58–408) b,c 
GFR 57 (8–132) 54 (14–88) 52 (33–108) 42 (16–99) 
toe pressure 21 (0–39) 
n=6 
19 (0–82) 
n=30 
25 (0–63) 
n=28 
0 (0–54) n=18  
ankle brachial index 0.69 (0.39–2) 
n=5 
0.52(0.2–1.95) 
n=31 
0.42 (0–1.67) 
n=29 
0.53 (0.2–
1.82) n=21 
living at home 6 (86) 27 (82) 26 (84) 17 (71) 
walking>100m* 3 (43) 6 (18)  5 (16) 0 d,f 
a: significant difference between revasc DM 1 and revasc DM2  
b: significant difference between revasc DM 2 and Revasc noDM  
c: significant difference between Revasc noDM and Norevasc  
d: significant difference between Norevasc and Revasc DM1  
e: a significant difference between Revasc DM1 and Revasc noDM 
f: a significant difference between Norevasc and Revasc DM2 
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Table 28: LEA lower extremity amputation; CVD cerebrovascular disease; AMI acute 
myocardial infarction; GFR glomerular filtration rate; Revasc revascularisation; sig. 
significance; * without aid 
Table 29. Ulcer characteristics 
Variable Revasc DM1 Revasc DM2 Revasc noDM NoRevasc sig 
n=7 n=33 n=31 n=24 
ulcer in toes 4 (57) 20 (61) 10 (32) 17 (71) b,c 
ulcer in heel 3 (43) 7 (21) 3 (10) 4 (17) a 
ulcer in leg 0 3 (9) 8 (26) 1 (4) c 
ulcer in  ankle 0 0 6 0 
ulcer dorsally 0 1 3 1 
plantar ulcer 0 2 1 0 
UT 3 4 (57) 14 (42) 4 (13) 17 (71) b,c,e,
fUT D 3 (43) 16 (49) 17 (55) 18 (75) e
UT 3D 3 (43) 10 (30) 4 (13) 15 (63) c,e 
number of 
ulcers 
1 (1–3) 1 (1–5) 1 (1–7) 2 (1–6) 
ulcer diameter, 
mm  
26 (5–100) 24 (0.5–163) 29 (2–129) 17 (1–82) 
a: significant difference between revasc DM 1 and revasc DM2  
b: significant difference between revasc DM 2 and Revasc noDM 
c: significant difference between Revasc noDM and Norevasc  
d: significant difference between Norevasc and Revasc DM1  
e: significant difference between Revasc DM1 and Revasc noDM  
f: significant difference between Norevasc and Revasc DM2 
Revasc revascularisation; UT University of Texas classification 
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5.2.2 OUTCOME 
Twenty-eight patients underwent a major amputation, and 83 patients died during the 
follow-up. Seven patients died within 30 days. Two patients had non-salvageable legs 
needing immediate amputation. Amputations were rare after one year. The leg salvage 
rate following revascularisation was similar in type 2 diabetic and nondiabetic patients: 
106 (95% CI 90–123) months and 112 (95% CI 97–127) months, respectively (p = 0.55). 
One-, five-, and ten-year amputation free survival rates in the whole cohort were 59%, 
31% and 11%, respectively (Figure 8). Events during the 10-year follow-up in each group 
are presented in Figure 9. 
Figure 8. A) Leg salvage, B) survival, C) amputation-free survival 
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Figure 9. Outcome of the patients. A) Patients with type 1 diabetes, B) patients with type 
2 diabetes, C) patients without diabetes, D) patients without revascularisation. 
5.2.3 RISK FACTORS FOR AMPUTATION 
In univariate analysis, amputation during the first year of follow-up was significantly 
associated with age (p = 0.007), CRP (p < 0.001), creatinine (p = 0.043), type 1 DM 
(p = 0.003) and uraemia (p = 0.046), as well as UT grade 3 depth (p = 0.001) and UT stage 
D infection (p = 0.038), in addition to being inversely associated with revascularisation 
(p < 0.001). An angiosome-oriented open arterial line was not significantly associated 
with major amputation within one year of follow-up. Table 30 shows the findings of 
multivariate analysis.  
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Table 30. Factors associated with major amputation during the first year of follow-up. 
Cox logistic regression analysis. 
 
 Sig HR 95%CI 
Age 0.002 0.922 0.875–0.972 
CRP 0.009 1.019 1.004–1.034 
Revascularisation 0.003 0.169 0.045–0.636 
 
Other parameters tested in the model were UT (University of Texas), sex, type 2 DM, 
DM, ever smoking, ulcer location in the toes, clinical infection UT D, angiosome oriented 
open arterial line, ulcer diameter 
Sig significance; HR hasard ratio; CI confidence interval; CRP c-reactive protein 
 
5.2.4 RISK FACTORS FOR DEATH 
 
Death was significantly associated with type 2 DM (p = 0.028), CRP (p = 0.003) and 
creatinine (p = 0.043), and inversely associated with type 1 DM (p = 0.049) in univariate 
analysis. Table 31 shows the findings from multivariate analysis. 
 
Table 31. Factors associated with death during the follow-up. Cox logistic regression 
analysis. 
 Sig Exp(B) 95%CI 
Age < 0.001 1.066 1.040–1.094 
UT 3C or 3D 0.026 1.871 1.079–3.243 
Uraemia < 0.001 6.252 2.506–15.597 
Diabetes 0.022 1.799 1.090–2.972 
Revascularisation 0.012 0.497 0.289–0.855 
 
UT (University of Texas) 
 
 5.2.5 ULCER HEALING AND RE-ULCERATION 
 
At one year, 3/24 (13%) ulcers healed in patients who did not undergo revascularisation. 
As regards patients who underwent revascularisation, 2/7 ulcers healed among type I 
diabetic patients, 22/33 (67%) among type 2 patients and 20/31 (65%) among 
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nondiabetic patients. Out of the 54 patients whose ulcers healed during the follow-up, 
43% developed a reulceration. The median healing times were 3.5 months (95% CI 
0.7;6.3)in type 2 diabetic patients and 2.8 (95% CI 1.4;4.1) months in nondiabetic 
patients. The difference is not statistically significant. 
An angiosome-targeted open arterial line was significantly associated with ulcer healing 
rate (p < 0.001), as was revascularisation as such (p < 0.001).  
Walking capacity at six months and at one year was recorded in patients without 
amputation. Two of the 7 patients without revascularisation were able to walk more 
than a few steps. Of patients with revascularisation, both two with type 1 diabetes, 
16/21 with type 2 diabetes and all 21 without diabetes were able to walk more than few 
steps.  
5.3 FREE TISSUE TRANSFER WITH OR WITHOUT VASCULAR 
RECONSTRUCTION IN THE TREATMENT OF LARGE TISSUE 
DEFECTS (STUDY II AND III) 
5.3.1 CHARACTERISTICS OF PATIENTS 
The characteristics of patients are presented in Table 32 and Table 33 a-c. In Study II, 
73% of the patients had diabetes. Type 1 diabetes was present in 26% of all patients and 
in 36% of the diabetic patients in Study II and 38% of the diabetic patients in Study III. In 
Study III, a significant difference between the groups related to the treatment of 
ischaemia was observed in creatinine values, toe pressures, ABI values, lesion locations 
and CRP-values. 
109 
Table 32. The characteristics of 81 lower extremieties of 79 patients with FTT and 
revascularisation in Study II. 73% of patients have DM. 
Patient and lesion 
characteristics  
DM 1 DM 2 no DM sig 
DM1 vs 
DM2 
sig DM1 
vs no 
DM 
sig DM2 
vs no 
DM 
n 21 38 22 
Median age, years 
(range) 
47 (39-
73) 
65.5 (37-
84) 
68.5 (48-
85) 
p<0.001 p<0.001 NS 
Male 57.1% 76% 54.5% NS NS NS 
History of smoking 33.3% 15.8% 45.5% NS NS p=0.012 
ASA 4 23.8% 31.6.% 13.6.% NS NS NS 
Elevated creatinine 57.1% 23.7% 4.7% n=21 p<0.01 p<0.001 NS 
Renal 
transplantation  
28.6% 2.6% 0 p=0.03 p=0.007 NS 
CAD 42.9% 34.2% 27.3.% NS NS NS 
History of MI 23.8% 15.8% 4.5% NS NS NS 
CVD 4.8% 7.9% 9.1% NS NS NS 
Median BMI (range) 24 (18-
31) 
26 (19-
36) 
23 (16-32) p=0.016 NS p=0.002 
History of BKA/AKA 28.6% 28.9% 9.1% NS NS NS 
Lesion in the leg 4.8% 7.9% 45.5% NS p=0.002 p=0.001 
Lesion in the 
achilleus region 
0 5.3% 4.5% NS NS NS 
Lesion in the 
forefoot 
47.6% 39.5% 22.7% NS NS NS 
Lesion in the heel 33.3% 23.7% 9.1% NS p=0.051 NS 
Plantar involvement 81% 54%, 
N=37 
18.2% p=0.041 p<0.001 p=0.007 
Ulcer 
diameter > 10 cm 
33.3% 51.3%, 
n=37 
90%, n=20 NS p=0.001 p=0.004 
Pre-operative 
infection 
57.1% 60.5% 40.9% NS NS NS 
Median pre-
operative CRP 
(range) 
38 (5-
152) 
39 (0-
181) 
38 (5-132) NS NS NS 
preceding revision 89% 81.6% 52% NS p=0.004 p=0.009 
Bypass to flap 23.8% 18.4% 4.5% NS NS NS 
Pedal bypass 52.4% 47.4% 45.5.% NS NS NS 
Crural bypass 19% 21% 36% NS NS NS 
Popliteal bypass 4.8% 2.6% 4.5% NS NS NS 
PTA 0 7.9% 9.1% NS NS NS 
LD flap 66.7% 57.9% 36.4% NS p=0.047 NS 
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Table 32.  
ASA = American Society of Anesthesiologists; CAD = coronary artery disease; 
MI = myocardial infarction; CVD = cerebrovascular disease; BMI = body mass index; 
BKA = below knee amputation; AKA = above knee amputation; CRP=C-reactive protein; 
PTA = percutaneous transluminal angioplasty; LD = latissimus dorsi; sig=significance; 
NS = not significant. 
Nephropathy was defined as plasma or serum creatinine level exceeding the reference 
values of uraemia treated with dialysis. *Smoking during 5 preceding years was 
recorded. 
 
 
Table 33 a. The characteristics of patients with DM in relation to the treatment of ischaemia in 
Study III.  
P
atien
t 
ch
aracteristics 
A
ll 
N
ative artery 
(N
A
) 
C
o
rrectab
le 
isch
aem
ia (C
) 
U
n
co
rrectab
le 
isch
aem
ia (U
) 
p
 (N
A
 vs C
) 
p
 (C
 vs U
) 
p
 (N
A
 vs U
) 
n 63 19 32 12 
   
Median age, years  56 (21) 55 (17) 63 (24) 56 (19) NS NS NS 
Male 44 (70) 11 23 10 NS NS NS 
Type 1 diabetes 24 (38) 8 12 4 NS NS NS 
History of smoking 12 (19) 1 8 3 NS NS NS 
ASA 4 14 (22) 2 8 4 NS NS NS 
Elevated creatinine a 13 (21) 1 6 6 NS .05 .01 
Renal transplantation b 8 (13) 3 5 4 NS NS NS 
Retinopathy 43 (81)c 14 21 8 NS NS NS 
CAD 20 (32) 3 13 4 NS NS NS 
History of MI 12 (19) 2 7 3 NS NS NS 
CVD 7 (11) 1 4 2 NS NS NS 
Median BMI (IQR) 24.5 (6.0) 24.5 (5.5) 25.0 
(6.0) 
23.0 (6.0) NS NS NS 
History of BKA/AKA 14 (22) 1 11 2 .02 NS NS 
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Table 33 b. The characteristics of lesions in relation to the treatment of ischaemia in 
Study III.  
P
atien
t 
ch
aracteristics 
A
ll 
N
ative artery 
(N
A
) 
C
o
rrectab
le 
isch
aem
ia (C
) 
U
n
co
rrectab
le 
isch
aem
ia (U
) 
p
 (N
A
 vs C
) 
p
 (C
 vs U
) 
p
 (N
A
 vs U
) 
Median pre-operative TP d 35 (33) 60 (43) e 30 (21) f 34 (45) g .001 NS .01 
Median pre-operative ABI 
h 
.99 
(.78) 
1.19 (.42) 
i 
.71 (.84) j .86 (.98) k .01 NS NS 
Lesion in the ankle 7 (11) 5 2 0 NS NS NS 
Lesion in the forefoot 30 (48) 7 14 9 NS NS .04 
Lesion in the heel 18 (29) 4 13 1 NS .04 NS 
Plantar involvement 44 (70) 11 24 9 NS NS NS 
Heel lesion > 10 cm 10 (16) 2 8 0 NS NS NS 
Ulcer diameter > 10 cm 28 (44) 9 13 6 NS NS NS 
Pre-operative infection 41 (65) 14 21 6 NS NS NS 
Median pre-operative CRP 38 (46) 28 (5–38) 48 (53)l 37.5 
(63.5) 
.002 NS NS 
Table 33 c. The operation details of patients with DM in relation to the treatment of 
ischaemia in Study III.  
P
atien
t 
ch
aracteristics 
A
ll 
N
ative artery 
(N
A
) 
C
o
rrectab
le 
isch
aem
ia (C
) 
U
n
co
rrectab
le 
isch
aem
ia (U
) 
p
 (N
A
 vs C
) 
p
 (C
 vs U
) 
p
 (N
A
 vs U
) 
Bypass to flap 11 (17) 5 6 
Pedal bypass 23 (37) 23 
Crural bypass 13 (21) 8 5 
Popliteal bypass 1 (2) 1 
PTA 3 (5) 3 
LD flap 38 (60) 12 20 6 NS NS NS 
Median flap OT, min  276 
(53)m,n 
280 (48)o 323 
(60)p 
Median vascular OT, min 177 (61)q 197r 
Median combined OT, 
min  
354 (154)s 387 (80)t 356 
(104)u 
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Tables 33a-c: 
Note. Data are given as n (%) or median (IQR). 
IQR = interquartile range; ASA = American Society of Anesthesiologists; CAD = coronary 
artery disease; MI = myocardial infarction; CVD = cerebrovascular disease; BMI = body 
mass index; BKA = below knee amputation; AKA = above knee amputation; TP = toe 
pressure; ABI = ankle brachial index; CRP=C-reactive protein; PTA = percutaneous 
transluminal angioplasty; LD = latissimus dorsi; OT = operation time; NS = not significant. 
aTwo patients were uraemic. 
bNormal serum creatinine, four of 12 of patients with renal transplant had elevated 
creatinine. 
cn = 53; .dn = 41; .en = 11;  fn = 23; gn = 7; hn = 50; in = 13; jn = 26: kn = 11;ln = 31; m 
Including PTA. 
nn = 14; on = 11; pn = 2; qn = 11; rn = 1; sn = 5; tn = 21; .un = 10. 
5.3.2 COMPLICATIONS 
Healing after the 98 FTT was uneventful in only 17% of the operations when 
postoperative 30-day amputations, flap losses and other local complications, as well as 
donor site complications, general complications and mortality were considered. The 
most common 30-day postoperative complications after the 98 FTT operations were 
minor flap edge necrosis and an infection (Table 34). Major postoperative complications 
such as death, amputation, flap loss, flap or vascular salvage operation and general 
complication were avoided in 49% of the flap operations. For the patients included in 
Study II with combined FTT and vascular reconstruction, the mean hospital stay was 70 
days.  
During the 30-day postoperative period, 1-4 reoperations were required in 58% 
percentof the 98 FTT operatons (Clavien-Dindo grade III) (Table 35 and Table 36). Fifteen 
legs were amputated within 3 postoperative months and 13 legs thereafter. Persisting 
tissue destruction and vascular problems were the most frequent causes (Table 36 and 
Table 37). 
Seroma of the donor site was observed 21 cases and infection, bleeding and failure to 
heal in four cases. In addition, three hernias and two hypertrophic scars were 
encountered. Tight scar, chronic pain, unsuccesfull flap elevation and local necrosis of 
the rectus fascia were reported once each. Seroma was mostly encountered after 
latissimus dorsi muscle elevation, hernias after rectus abdominis muscle elevation and 
slow healing after forearm flap elevation. 
 The most frequent general complications were cardiac insufficiency and acute 
myocardial infarction. The three-month postoperative mortality was 4.9%. 
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Table 34. Local complications of the 98 flaps. No more than two complications per 
operation were recorded here. 
Complication 
none 29 
flap vein thrombosis 6 
flap edge necrosis 32 
vascular reconstruction failure 4 
new ulcer 2 
wound infection 15 
osteitis 1 
haematoma 6 
partial necrosis of the flap 7 
toe amputation 3 
fistula problem 1 
arterial anastomosis problem 5 
venous anastomosis to artery 1 
seroma 1 
venous congestion 1 
Table 35. Postoperative complications related to microvascular FTT within the first 30 
days in 98 FTTs in Studies II and III. 
n local 
compl. 
general 
compl. 
Clavien-
Dindo 
III 
partial 
flap 
loss 
postop. 
flap 
loss 
postop. 
amputation 
postop 
death 
DM I 27 21 6 14 1 6 3 0 
DM II 49 35 14 27 3 8 5 2 
no DM 22 13 4 15 2 4 2 1 
total 98 69 24 56 7 17 10 3 
compl. =complication, postop=postoperative 
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Table 36. Lower extremity major complications related to combined vascular 
reconstruction and microvascular FTT for CLTI within the first 3 months in Study II 
C
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licatio
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n
 
Salvage 
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n
 
Flap
 lo
ss after 
salvage 
o
p
eratio
n
 
A
m
p
u
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after salvage 
o
p
eratio
n
 
A
ll 3
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n
th
 
flap
 lo
ss 
A
ll 3
-m
o
n
th
 
am
p
u
tatio
n
 
Bypass occlusion 5 3 0 2 1 3 
Flap artery thrombosis  2 2 0 1 0 1 
Flap vein thrombosis 11 8 1 3 4 3 
Flap vein and artery 
Thrombosis  
3 2 1 0 1 1 
Persisting infection or 
gangrene of the foot 
7 0 0 0 0 7 
Total 28 15 2 6 6 15 
 
 
 
Table 37. The reasons for late major amputations after 3 postoperative months in Study 
II 
 Number of legs 
Vascular graft thrombosis 4 
Early flap loss, no healing 3 
No healing despite a vital flap 2 
Ischaemic tissue defect in locations remote from the flap 2 
Late flap Necrosis  1 
Vascular prosthesis infection after multiple reconstructions 
during 7 years 
1 
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5.3.3. OUTCOME 
In Study II, the one- and 5-year limb salvage rates were 73% and 66%, survival rates 91% 
and 63%, and amputation-free survival rates 70% and 41%, respectively (Figure 10).  
Figure 10. Limb salvage (A) and amputation-free survival (B) of 79 patients in Study II. 
(Reproduced with permission from Tukiainen et al. 2003) 
In Study III, the leg salvage rates at 1, 5 and 10 years were 94%, 94% and 87%, 
respectively, in group NA; 71%, 65% and 65%, respectively, in group C; and 50%, 50% 
and 50%, respectively, in group U. The amputation-free survival rates at 1, 5 and 10 years 
were 90%, 79% and 63%, respectively, in group NA; 66%, 25% and 18%, respectively, in 
group C; and 50%, 42% and 17%, respectively, in group U. (Figures 11 and 12.) 
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Figure 11. Leg salvage. Differences between the groups A and B as well as between A 
and C were significant (p<0.001 and p=0.01). Reproduced with permission from Kallio 
et al. 2003. 
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Figure 12. Amputation-free survival. The diggerence between the groups A and each of 
B and C were significant (p<0.001 and p=0.01) Reproduced with permission from Kallio 
et al. 2003. 
 
In Study II, 52% of the patients were able to ambulate in the community and in the 
household with the preserved leg at two years (Figure 13). In Study III, healing within 1 
year, with full epithelisation for at least 6 months, was achieved by 43%, 45% and 18% 
of the patients in groups NA, C and U, respectively.  
Minor ulcer recurrence was observed in 54% of patients with primary skin healing for at 
least six months in Study II. 
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Figure 13. Outcome of the 79 patients at two years. Reproduced with permission from 
Tukiainen et al. 2003. 
 
5.3.4 PREDICTORS OF OUTCOME  
 
In Study II, male sex and an American Society of Anesthesiologists (ASA) score of 4 were 
associated with an increased risk of death, whereas diabetes was not. The involvement 
of the heel, mostly with calcaneal osteomyelitis and a large defect size, predicted major 
amputation (Table 38). 
In Study III, major amputation was associated with smoking (risk ratio [RR] 3.09, 95% CI 
1.8–5.3), heel ulceration (RR 2.25, 95% CI 1.1–4.7), nephropathy (RR 2.24, 95% CI 1.04–
4.82), and an ulcer diameter of > 10 cm (RR 2.08, 95% CI 1.03–4.48)  (Figure 14). 
The most morbid patients, with an ASA score of 4, in Study III had complications 
frequently, and their 5-year survival was 45%. A learning curve was seen, and fewer 
ASA 4 patients were operated on during the later years, resulting in lower mortality 
(Figure 15). 
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Table 38. Cox regression analysis: variables associated with death and amputation 
during the follow-up 
Variable Hazard ratio 95% confidence 
interval 
p 
Association with death 
Male sex 2.2 1.1–4.4 0.03 
ASA 4 vs  ASA < 4 2.6 1.4–5.0 0.003 
Coronary artery disease 2.2 1.2–4.2 0.01 
Contralateral amputation 2.5 1.3–4.9 0.006 
Association with amputation 
Location in the heel 2.5 1.2–5.5 0.02 
Diameter exceeding 10 cm 2.5 1.0–5.9 0.04 
Other variables tested in the analysis: age(years), type 1 DM vs type 2 DM, previous 
coronary artery bypass grafting, cerebrovascular disease, nephropathy, previous renal 
transplantation, smoking during 5 preceding years, BMI, preoperative CRP, forefoot as a 
specific location, leg as a specific location, plantar involvement, chronic wound as a 
specific indication, graft infection as a specific indication, latissimus dorsi flap, forearm 
flap, and availability of recipient artery for bypass. 
Figure 14. Leg salvage in smokers and non-smokers (p=0.01). Reproduced with 
permission from Kallio et al. 2003. 
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Figure 15. ASA 4 patients in Study II. Reproduced with permission from Tukiainen et al. 
2003. 
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6 DISCUSSION 
6.1 LIMITATIONS OF THE STUDY 
The cohorts were quite small for generalisable conclusions on outcomes or for running 
multivariate analyses in Studies I–IV. Indeed, the multitude of variables affecting the 
outcome causes challenges for implementing studies investigating ulcers (Gershater 
2009). Ulcer characteristics (depth, size, location), the side and number of ulcers, 
additional aetiologies (type 1 and type 2 diabetes, LEAD, neuropathy, nephropathy, 
infection, oedema, rheumatoid diseases, gout, etc.), as well as patient demographics 
and characteristics (age, sex, weight, smoking) vary. Furthermore, the small number of 
patients made type 2 error probable. Long-term comparative survival data was 
statistically insignificant in many subgroups due to high mortality and amputation rates, 
leaving  a small number of patients for the analysis. To form a uniform group for studying 
the effect of factors or interventions in patients with ulcers, considerable effort and very 
large groups of patients would be needed.  
In Study IV, a thorough clinical examination was performed at baseline, but ABI and TP 
measurements were not always available due to frequent admittance out of office 
hours. Since the implementation of our study, the classification and treatment of 
ischaemic ulcers have taken many steps of development. However, the ulcer 
characteristics were carefully recorded prospectively. Basic findings, such as the severity 
of infection and ischaemia and the anatomical depth and location of the ulcer, are still 
regarded important elements in defining the outcome of an ulcer (Mills et al. 2014).  
All the studies included herein are clinical cohort studies, as the available resources were 
insufficient for running randomised studies. Furthermore, the number of FTT operations 
is limited and randomisation would have necessitated a multicentre study. In Studies I 
and IV, the baseline data was collected prospectively, but the follow-up was 
retrospective in all studies. In Study IV, only 30% of the patients attended a planned 
control visit. Therefore, follow-up data in Studies II, III and IV were checked from the 
patient records from all health care levels. All data were based on active recordings. For 
example, an ulcer was not regarded as healed if it was not mentioned or there were no 
more visits. In contrast, a recording of healing was required.  
In Study I, the Helsinki Diabetes Association register may not have contained a fully 
representative population from the region. On the national level, 62% of type II diabetic 
patients in 1988 were women. In thebaseline cohort of our study, 43% of the patients 
without LEAD and 50% of those with LEAD were women. The median age of Finnish 
diabetic men in 1988 was 66 years and of diabetic women 73 years. (Niemi and Winell 
2005.) The patients in the current study were younger. The ABI values between 0.9 and 
1.15 might have included falsely elevated values.  
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Due to the retrospective and descriptive nature of Studies II and III, generalisation of the 
results requires caution. However, the outcome estimates are similar when compared 
to other large series of diabetic patients (Randon et al. 2010, Oh et al. 2012). A study 
arm for collecting a control group of patients with lower extremity major amputations 
was initiated. However, it proved difficult to find patients in a similar general condition 
compared to patients undergoing FTT. In another Finnish study, 57% of the patients 
survived longer than one month after major amputation (Remes et al. 2008). 
6.2 DEVELOPMENT AND RISK FACTORS OF LEAD IN TYPE 2 
DIABETIC PATIENTS  
In Study I, a long follow-up and wide package of investigations enabled us to show the 
development of LEAD and other cardiovascular complications and weigh different risk 
factors. Half the patients with LEAD died during the follow-up. Concurrently, the 
proportion of patients with LEAD increased further from 16% to at least 31% at follow-
up. Decreased ABI values predicted death in diabetic patients with no other signs of 
cardiovascular disease concordantly with earlier studies among the general population 
(Leng et al. 1996).  The risk factors for LEAD were different at baseline and at follow-up. 
LDL cholesterol and HDL cholesterol were significant predictors of developing LEAD, 
especially in patients with less fatal cardiovascular complications. At baseline in 1984, 
LDL cholesterol levels were high compared to modern standards, ranging from 2.11 to 
7.62 mmol/l. The medications as well as operative care have developed since then. 
Secondary prevention was already suggested for patients with asymptomatic LEAD in 
the 1990s. (Leng et al 1996). Nevertheless, until recently, asymptomatic LEAD and 
claudication were considered relatively benign complications of cardiovascular disease, 
with a 1% major amputation risk in patients with claudication (Norgren 2007). Currently, 
the high morbidity of patients with LEAD has gradually been fully recognised, and the 
treatment of risk factors is emphasised (Ögren et al. 2005, Diehm et al. 2009, Aboyans 
et al. 2018). Indeed, in the Fourier study, LDL cholesterol lowering from a median of 2.4 
mmol/l to a median of 0.8 mmol/l with evolocumad, an effective cholesterol-lowering 
medication, induced a significant risk reduction in MALEs (major adverse limb event) 
and major adverse cardiovascular events (MACE)s among patients with LEAD, with and 
without previous cardio- or cerebrovascular disease. The event-reducing effect was 
almost linearly related to LDL cholesterol levels down to 0.26 mmol/l. (Bonaca et al. 
2017.) 
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6.3 ISCHAEMIC ULCERS 
 
People and their needs are different. A small superficial ulcer in a person with a poor 
general condition needs a different approach than an infected large tissue defect of a 
person with an active life. For one person, a stump or a foot with a quiet ulcer and ability 
take a few steps is an optimal solution, while for somebody else, this would entail 
amputation and a functional prosthesis, allowing active mobility. An increasing group of 
patients are not able to weigh risks and benefits of treatment or the desired aims of 
treatment themselves because of dementia. More data is needed to find the best 
solution for individual patients but also for directing the resources effectively. 
Selecting a clinically significant outcome, such as ulcer healing, leg salvage, reulceration 
or AFS, is crucial. At present, MALEs and MACEs are widely used end points. Some 
outcomes may be useful for other study purposes, such as patency for the development 
of revascularisation techniques and a diminishing wound surface for the testing of new 
local treatment methods. Whether the outcome is determined for the ulcer, for the leg 
or for the patient needs to be considered. Ulcer healing and reulceration requires long 
and strict follow-up and consistent criteria. 
The cohort in Study IV contained consecutive patients referred for vascular consultation. 
The long-term outcome of patients with ischaemic ulcers was poor. A total of 11% of the 
original cohort was alive with the leg intact after 10-year follow-up. Type 1 diabetes was 
associated with major amputation within 1 year of follow-up, whereas type 2 diabetes 
was associated with death during the follow-up. Leg salvage was similar among type 2 
diabetic patients and nondiabetic patients after revascularisation. Patients without 
revascularisation had a very poor outcome. This finding is similar to that of Lepäntalo 
and Mätzke (1996). Type 1 diabetic patients with cardiac and renal complications were 
at a very high risk of amputation due to ischaemic ulcers.  
Ulcer healing at one year was similar in nondiabetic (65%) and type 2 diabetic patients 
(67%) with revascularisation. A later cohort from our clinic showed 63% and 87% healing 
of the lesions after bypass surgery in diabetic and nondiabetic patients, respectively. 
However, incisional wounds and type 1 diabetic patients were also included. 
(Söderström et al. 2008.) A systematic review reported an ulcer healing rate of 60% in 
diabetic patients at one year after endovascular revascularisation but observed 
substantial variation in figures, probably mostly due to heterogeneous material and 
differences in reporting (Hinchliffe et al. 2016). Indeed, a surprise in our projects was 
that ulcer healing was poorly recorded. The data was tracked all the way down to hand-
written home care notes until a specific positive or negative recording was found. 
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6.4 REVASCULARISATION 
A more favourable outcome in terms of both leg salvage and ulcer healing among 
patients who underwent revascularisation than those remaining without 
revascularisation was observed in this thesis. Angiosome-oriented revascularisation was 
not associated with amputation. In contrasrt, angiosome-oriented was associated with 
ulcer healing. Notably, the division into angiosomes was performed post hoc. Better 
healing and leg salvage rates in patients with more direct revascularisation, especially 
endovascular, to the ulcer area have been reported in many studies (Spillerova et al. 
2016, Zheng et al. 2016, Alexandrescu et al. 2019, Jongsma et al 2017). However, the 
actual circulation in the angiosome and its effect on ulcer healing is challenging to 
evaluate. Endovascular treatment and open surgery may have different haemodynamic 
effects (Spillerova et al. 2016). Anatomic variations in the calf and foot arteries exist, and 
the collateral network is individual. Moreover, angiography ignores haemodynamic 
circumstances. No general validated definition or classification exists for the quality of 
collaterals. Furthermore, ulcers can involve more than one angiosome, and, on the other 
hand, the feeding areas of arteries overlap. (Attinger et al. 2006, Spillerova et al. 2016.) 
Therefore, identifying the angiosome requiring revascularisation is often ambiguous 
(Aerden et al. 2014). Furthermore, the endless variation in the characteristics of ulcers 
and patients easily make comparisons biased (Conte et al. 2019).   
A small stable ulcer rarely deteriorates acutely (Barshes et al. 2014), and spontaneous 
healing of ulcers in ischaemic foot also does occur (Marston et al. 2006). 
Revascularisation is not always necessary for the healing of small non-infected ulcers 
(Cull 2014, Conte et al 2019). However, vascular supply and infection seem to be the 
main factors influencing the healing of ischaemic diabetic foot ulcers, and the UT and 
WIFI classifications can be used to predict major amputations (Cull et al. 2014, 
Armstrong et al. 1998). 
Methods for evaluating the haemodynamic conditions necessary for ulcer healing are 
incomplete. Optimally, perfusion would be investigated during the revascularisation 
procedure, and further revascularisation should be attempted if low-perfusion areas 
remain. Transcutaneous oxygen pressure (tcpO2) measurements and Indocyanine green 
fluorescence imaging (ICG-FI), noninvasive methods for studying the oxygenation of 
tissue and the distribution of arterial circulation, have their limitations. They are time-
consuming and especially ICG-FI is subject to wide interpersonal variety, with no 
universal reference values (Hinchliffe et al. 2016, Conte et al. 2019, Antonopoulos et al. 
2019). 
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6.5 TREATMENT OF LARGE TISSUE DEFECTS  
 
Deep infections, ischaemic ulcers and gangrene, which often necessitate revisions and 
foot-level amputations, result in large tissue defects in diabetic patients (Lombardo et 
al 2014, Hong et al. 2011). Deep infections are typically encountered in diabetic patients, 
and roughly half of the patients with ischaemic ulcers have diabetes (Prompers et al 
2007, Söderström et al. 2008). Combined ischaemia and infection pose a great risk on 
leg salvage (Cull et al. 2014, Armstrong et al 1998). In the present thesis, a third of all 
tissue lesions in diabetic patients who were referred to a vascular surgeon were deep 
and infected.  Revascularisation and CRP were associated with major amputation and 
ulcer healing time. Furthermore, 84% of the diabetic patients who underwent FTT had 
undergone preceding revisions or minor amputations, and roughly 60% had a foot 
infection in the background. 
Many alternatives for closing the defects and enhancing healing are available: NPWT, 
skin grafting, skin and dermal substitutes and local flaps. These methods are sometimes 
insufficient for covering large defects that expose bones and tendons or are located on 
weight-bearing surfaces. Moreover, in the presence of LEAD and diabetes, local flaps 
tend to have a high failure rate (Baumeister et al. 2003). Occasionally, a major 
amputation is inevitable. However, amputation may also be the best treatment option. 
If the capacity for rehabilitation is good, ambulation with a prosthesis may offer better 
functional ability than a deformed, easily ulcerating foot. Comorbidities, such as 
coronary artery disease, nephropathy and obesity, are common in diabetic patients and 
may be an impediment to major surgery (Krempf et al. 2010). Sometimes comorbidities 
cause special challenges. For a patient removed from the waiting list for renal 
transplantation or cardiac procedure because of an ulcer, the time-consuming effort 
required to get a severe ulcer to heal can be a catastrophe. According to Attinger and 
Brown, “function and quality of life are the outcomes of interest and may be maximised 
through either limb salvage or amputation” (Attinger et al. 2012). 
Below-knee amputation gives a reasonable opportunity for ambulation with a 
prosthesis. Still, elderly and multimorbid patients often lack the capacity for 
rehabilitation required for becoming successful users of prosthesis.Above-knee 
amputation is a simple and quick procedure, and the healing is less complicated than 
after below-knee amputation. Therefore, it is frequently chosen for patients with a 
greatly reduced general condition and limited mobility. The functional aim is often 
independent or assisted mobilisation with a wheelchair. Palliative care without 
amputation may be considered in patients with a very poor general condition. 
Complicated tissue defects in the diabetic foot can be overcome with vascular and 
plastic surgeon teamwork in selected cases. 
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6.6 FTT 
 
Sustaining teamwork between vascular and plastic surgeons resulted in the thus far 
largest cohort of patients with combined FTT and vascular reconstruction for limb-
threatening tissue defects and ischaemia. The amputation-free survival rate was 41% at 
five years. Excellent amputation-free survival at five years can be expected in diabetic 
patients with a native artery open to the foot. At ten years, amputation-free survival 
was still 63%. In comparison, amputation-free survival was 51% at five years in patients 
with ischaemic lesions treated with a similar technique (Randon et al. 2009). In the US, 
a limb salvage rate of 65% and a survival rate of 67% at 5 years were observed (Moran 
et al. 2002). The three-year amputation-free survival was 56% in a cohort of diabetic 
patients (Randon et al. 2010). According to our findings, even in the absence of options 
for revascularisation, moderate AFS can be reached by careful individual assessment.  
Diabetes was not associated with amputation or death after FTT in our study. Large 
defects with a diameter exceeding 10 cm and heel ulcers in ischaemic extremities, and 
in diabetic patients, smoking and nephropathy, were associated with amputation. 
Severe morbidity, coronary artery disease, male sex and age were associated with death. 
In Belgium, renal insufficiency and earlier contralateral limb amputation were risk 
factors for amputation and in the US, diabetes combined with renal insufficiency and 
diabetes alone. (Randon et al. 2009, Randon et al. 2010, Illig et al. 2001.) The risk factors 
for death were previous foot surgery in the Belgian study and diabetes and diabetes 
combined with ESRD in the American study. 
Careful patient selection and planning are crucial. A multidisciplinary team with a 
vascular surgeon, plastic surgeon, anaesthesiologist, internist and infection specialist is 
invaluable in the planning. The cardiovascular risks should be investigated and a 
cardiologist consulted, as necessary. Uraemic and ASA 4 patients are usually no longer 
considered for FTT in our clinic. Smoking is also a strong argument against the operation, 
and  every effort should thus be taken to support the patient in stopping smoking. It is 
important that all aspects of major surgery and long rehabilitation are discussed 
thoroughly with the patient before the decision to operate. It should be noted that the 
achievable walking distance can be limited and that ulcer healing is often time-
consuming and reulcerations occur. 
In patients with a successful outcome, a good level of ambulation was achieved. Fifty-
nine percent of patients who survived and 89% of patients with limb salvage were 
ambulant at two years. All surviving patients returned home. Especially patients whose 
independent living is depending on the few steps taken with their own limb benefit from 
this operation. The mobility after FTT might be compared to the mobility of patients 
returning home after major amputation. Of patients who underwent major amputation 
due to ischaemic or diabetic complications, 22%–45% gained community or household 
ambulation. (Kanellopoulos et al. 1996, , Remes et al. 2009.) In a Finnish study, 43% of 
patients surviving after major amputation returned home. However, 72% of the patients 
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who were discharged and returned home gained ambulation, with only 33% being able 
to ambulate outdoors. (Remes 2009.)  Diabetes was associated with successful 
prosthesis usage. A high rate of diabetes in younger age groups may explain this. Of 
patients under 65 years, 72% had DM (Remes et al. 2009).  
The rehabilitation aiming at walking ability with a prosthesis requires good physical and 
mental capacity from the patient. Wearing prosthesis at nighttime is burdensome. Such 
diseases as rheumatoid diseases and arthrosis may hinder prosthetisation.  In diabetic 
patients, visual impairment is frequent, as is a history of stroke with reduced strength 
and coordination. In elderly individuals, atrophy and contractions in the hand 
musculature and arthropathies can make the wearing a prosthesis or the utilisation of 
devices difficult. Moreover, balance can be insufficient. These conditions may favor FTT 
over a major amputation in patients with adequate general condition. 
However, the groups of patients with FTT and major amputation are not comparable. 
The general condition of patients undergoing major amputation is, on average, 
considerably poorer than that of patients undergoing profound evaluation before FTT 
reconstruction (Elgzyri et al 2013, Noronen et al. 2017). Moreover, many amputations 
are performed as a last option when revascularisation is considered too risky.   
In the studies included in this thesis , recovery from the FTT operation was uneventful 
in only 17% of the patients. Fifty-eight percent of the legs required reoperations. After 
below-knee amputation, stump problems delaying rehabilitation are also common. 
Problems in healing easily lead to femoral amputation, which is rarely a realistic premise 
for ambulation with a prosthesis.  
In consequence, the choice of treatment is based on individual assessment: the patient’s 
needs as regards ambulation, the severity of the tissue defect, general condition and the 
patient’s cooperation and motivation are important aspects to be considered. 
Teamwork and experience are essential for the successful treatment of large ischaemic 
diabetic foot defects. 
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6.7 FUTURE PERSPECTIVES 
A multitude of variables affecting the outcome cause challenges for implementing 
studies on ulcer healing. Therefore, large cohorts comprising all care levels are needed 
(Gershater et al. 2009). Ulcer healing and reulceration require long and strict follow-up 
and consistent criteria. Prospective register-based data is invaluable (Öien et al. 2016). 
In the future, separate analyses of type 1 and type 2 diabetic patients may offer more 
accurate outcome data. 
With modern technologies, limb salvage can often be achieved despite a complicated 
situation. More sophisticated endovascular techniques – also combined with FTT, 
perforator flaps, bio-engineered skin substitutes, negative pressure devices and 
compression pumps – have become additional options in everyday practice since the 
studies included herein were conducted (Oh et al. 2012, Huang et al. 2014, Game et al. 
2016, Liu et al. 2018, Conte et al 2019). The potential of stem cells and growth factors 
to enhance ulcer healing in diabetic patients is being studied actively (Gorecka et al. 
2020, Lopes et al. 2018). However, the current situation is not yet acceptable: an 
immense amount of resources are spent on unhealed ulcers, and ulcers continue to 
cause suffering and a reduced quality of life for patients. Indeed, 783 transfemoral and 
344 transtibial amputations were still performed in Finland in 2018. The overall duration 
of diabetes will increase due to the growing incidence, the onset of type2 diabetes at a 
young age, and decreased mortality. This might affect the future incidence of diabetic 
complications in the general population. (Gregg et al. 2016.) Great future potential lies 
in prevention: the prevention of diabetes, LEAD, conditions predisposing to ulcers, as 
well as of delays in proper treatment and of reulceration. 
Tools to prevent type 1 diabetes are yet to make a breakthrough. In the meantime, the 
outcome of type 1 diabetics with ulcers emerges as a meaningful field of research. In 
contrast, the prevention of type 2 diabetes is often possible by increasing mobility and 
by weight control, and the risk factors of LEAD are well known. However, changing 
people’s lifestyle and habits has proven difficult. (Fogelholm et al. 2017.)  
Effective ways to influence people lifestyle remain to be discovered. Obviously, 
interdisciplinary collaboration is necessary, as is changing behaviour in the entire 
society. 
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7 CONCLUSIONS 
1) One in five patients aged 60 years with type 2 diabetes develop new peripheral
arterial occlusive disease (LEAD) during 11-year follow-up. High serum LDL and low
serum HDL cholesterol are risk factors for incident LEAD.
2) Vascular reconstruction combined with microvascular free-tissue transfer (FTT) offers
an option for advanced limb salvage in a selected group of patients with a critically
ischaemic large tissue defect. Risk factors for a modest outcome are poor general
condition, the involvement of the heel frequently complicated by osteomyelitis and an
extensive defect. In these circumstances, primary amputation might be suggested
instead of extensive reconstructive surgery.
3) In diabetic patients who have a native in-line artery to the ulcer area, extensive
complicated foot defects may be covered by FTT, with excellent long-term amputation-
free survival despite diabetic comorbidities. In the presence of occlusive disease and
ischaemia, limbs may also be salvaged with combined FTT and vascular reconstruction
in non-smokers and in the absence of a very extensive heel ulcer. Occasionally, even
without the possibility of direct revascularisation, amputation is avoidable with FTT.
4) The ten-year amputation-free survival rate is approximately 10% in patients with
ischaemic ulcers attending a vascular surgical consultation. The long-term amputation-
free survival of patients who are not candidates for vascular reconstruction is
dismal. The risk factors for amputation include unreconstructable vascular disease, high
CRP and uraemia whereas type 2 diabetes remains insignificant. Instead, type 2 diabetes
is associated with mortality. The role of type I diabetes is ambiguous. A substantial
proportion of the patients whose ulcers heal during the follow-up develop a
reulceration.
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